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1. Definition, clinical relevance and current treatment of atherosclerosis 
 
Atherosclerosis is the many years ongoing process of thickening of the 
vascular wall of medium to large sized arteries and often leads to ischemia in 
tissues located distally from the atherosclerotic lesion. This lack of perfusion 
and subsequent lack of oxygen and nutrient supply can be the direct 
consequence of the arterial stenosis induced by atherosclerosis. However, 
the majority of the clinical consequences of atherosclerosis are based on 
acute thrombus formation on a ruptured atherosclerotic lesion with 
subsequent sudden arterial occlusion either at the site of the atherosclerotic 
lesion or more distally in the case of release of parts of the thrombus.1  
Depending on the artery that is affected by atherosclerosis, the resulting 
ischemia may induce myocardial infarction, cerebral stroke, or peripheral 
artery diseases such as intermittent claudication. Atherosclerosis is thought 
to start already in childhood. However, the clinical consequences of 
atherosclerosis are usually observed in the middle aged to elderly population. 
Recently, coronary heart disease (CHD), which is mostly due to 
atherosclerotic lesion formation, became the primary cause of death world-
wide, killing 7.2 million people per year globally (World Health Organization 
2002).2 After cancer, cerebral stroke, which is mostly due to atheroclerosis, 
occupies the third place in global causes of death. The fact that ischemic 
heart disease and cerebrovascular disease can be found among the top 4 
leading causes of global disease burden further illustrates the enormous 
impact of atherosclerosis on global health and encourages the development 
of novel treatments against atherosclerosis.2  
Several risk factors for atherosclerosis have been identified, such as 
hyperlipidemia, hypertension, smoking, physical inactivity, obesity, diabetes 
mellitus, male sex, and age.3 Current treatment of atherosclerosis is based 
on these classical risk factors. Medication that lowers circulating levels of 
total cholesterol or reduces hypertension and thrombosis in combination with 
life style advices has restricted the development of atherosclerosis and its 
sequelae. If atherosclerosis leads to infarction, but is not followed by death, 
the affected artery can be reopened by percutaneous transluminal 
angioplasty (with or without stent placement), or can be circumvented by 
means of by-pass grafting. However, despite these attempts to prevent or 
treat atherosclerosis, this process remains the leading cause of death 
globally indicating the need for novel therapies. 
Recently, atherosclerosis has been identified as an inflammatory process.4 
Since this novel insight many scientists have contributed to the elucidation of 
the inflammatory mechanisms that modulate atherosclerosis. Interference in 
the inflammatory mechanisms in atherosclerosis or identification and 
targeting of factors that stimulate inflammation, such as infectious agents 
may contribute to novel therapies against atherosclerosis. This thesis focuses 
on Chlamydia pneumoniae, interleukin 17, and interleukin 12 as inflammatory 
regulators of atherosclerosis. Furthermore, we evaluated the effect of a cell 
based therapy on atherosclerosis. In this approach, VEGFR2 or TIE2 positive 
cells were targeted. The general introduction will provide an overview of the 
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pathogenesis of atherosclerosis, with emphasis on the factors that were 
studied in this thesis.  
 
2. Pathogenesis of atherosclerosis 
 
Atherosclerosis has been widely accepted to develop according to the 
hypothesis of the “response to injury”, which is thought to be initiated with a 
dysfunctional endothelium at predisposed sites, such as arterial branches or 
bifurcations.5 Many factors have been described that can induce this initial 
injury of the vessel wall, including oxidized low density lipoprotein (oxLDL), 
free radicals caused by cigarette smoking, homocysteine, oscillatory and 
turbulent shear forces, hypertension, and infectious agents, such as 
Chlamydia pneumoniae.6 Exposure of the endothelium, which normally 
regulates the homeostasis of the artery, to these factors induces increased 
permeability to lipoproteins7 and elevated expression levels of adhesion 
molecules, such as E-selectin, P-selectin, vascular cell adhesion molecule 1 
(VCAM-1), and intercellular adhesion molecule 1 (ICAM-1), causing rolling 
and adhesion of circulating leukocytes to the dysfunctional endothelium.3,4 
Subsequently, the adhered leukocytes (monocytes and T lymphocytes) 
migrate through the endothelial layer into the subendothelial space, the 
intima, where a variety of cytokines, such as macrophage colony stimulating 
factor (M-CSF) and interferon-γ (IFN-γ), contribute to the differentiation of 
infiltrated monocytes into tissue macrophages.8 While residing in the intima 
these macrophages start to accumulate lipids from modified lipoproteins via 
scavenger receptors, resulting in the formation of lipid rich foam cells.9,4 
Accumulation of these foam cells forms the early atherosclerotic lesion, also 
called a fatty streak, which remains asymptomatic.10 Progression of 
atherosclerosis after this stage includes migration of vascular smooth muscle 
cells (VSMCs) from the media into the atherosclerotic lesion where these 
cells start to cover the perpetual accumulation of lipids, macrophages, T 
lymphocytes and a poorly developed matrix of connective tissue.3,4 A fibrous 
cap, developed by migration and proliferation of smooth muscle cells and 
production of extracellular matrix components such as collagen, covers a 
necrotic core which is now composed of cell-free lipid pools with cholesterol 
crystals. This fibrous cap and lipid core mark the next stage in lesion 
development, which  is also called an advanced atherosclerotic lesion.3,4,11 
Occasionally, extension of these atherosclerotic lesions induces the growth of 
intra-plaque capillaries that are thought to originate from the vasa vasorum, 
located in the media and adventitia of the arterial wall.12 These lesions can 
become increasingly complex when calcification at the luminal surface and 
haemorrhage from the intra-plaque capillaries occurs.13 Advanced 
atherosclerotic lesions may become clinically symptomatic when rupture of 
the fibrous cap takes place and the necrotic core is directly exposed to the 
blood stream, which immediately induces thrombus formation, potentially 
leading to occlusion of the artery.14,15  
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3. Vulnerability of atherosclerotic lesions 
 
Initially, the growth of the atherosclerotic lesion is directed towards the 
adventitia and causes outward remodeling of the artery without affecting the 
lumen size.16,17 At a critical moment this mechanism which prevents luminal 
stenosis can not compensate anymore and the atherosclerotic lesion starts to 
grow into the lumen. Apart from the potential unwelcome consequences of 
the disturbed perfusion due to the increased stenosis, the atherosclerotic 
lesion now becomes exposed to the mechanical forces of the blood stream, 
which may cause rupture of the lesion leading to thrombus formation with its 
potential ischemic consequences. The chance of rupture, in which there is a 
discontinuity in the fibrous cap and the thrombogenic lipid core is directly 
exposed to the blood stream, is largely reflected by the composition of the 
atherosclerotic lesion. A thin fibrous cap with little smooth muscle cells and 
collagen overlying a large amorphous lipid core and a high inflammatory cell 
content are characteristics of an unstable lesion, which is prone to rupture. A 
stable lesion is characterized by a thick smooth muscle cell and collagen rich 
cap covering a small lipid core.14,15 Since the composition of the 
atherosclerotic lesion has been considered at least as important for inducing 
ischemic events as the actual size of the lesion, much research focuses on 
improvement of the stability of atherosclerotic lesions.  
 
4. Inflammation in atherosclerosis 
 
The process of inflammation is induced as a reaction to stimuli of exogenous 
origin, such as infectious agents and chemical toxins, but can also be the 
consequence of an endogenous stimulus, which is the case in autoimmune 
diseases. The purpose of the sequence of events in an inflammatory reaction 
comprises the removal of the origin of the stimulus and subsequently the 
repair of the damaged tissue, which is often accompanied with accumulation 
of scar tissue. In the inflammatory response immune cells are directed to the 
inflammatory stimulus by increased blood supply and vascular permeability, 
which allows chemotactic peptides, neutrophils, and mononuclear cells to 
leave the intravascular compartment. Once arrived at the site of action, the 
immune cells start to produce cytokines, such as interleukins, interferons, 
growth factors, and chemokines, which catalyze the inflammatory response. 
Since many of the inflammatory processes are also observed in 
atherosclerosis, such as increased endothelial permeability, expression of 
adhesion molecules, with subsequent migration of leukocytes, and the 
production of inflammatory cytokines which can modulate the disease, 
atherosclerosis is considered a complex inflammatory disease rather than 
just an accumulation of lipids in the vascular wall.4 The major stimuli that 
initiate the inflammatory process leading to atherogenesis are formed by the 
group of factors that induces the endothelial dysfunction. If the immune 
system does not effectively neutralize or remove the offending agents, the 
inflammatory processes can continue indefinitely, giving rise to an 
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atherosclerotic lesion. Apart from the factors that activate the endothelial 
layer, several other atheroma-associated factors are identified as potential 
stimuli that drive inflammation, including both endogenous and exogenous 
antigens.4 The first line of defense in the inflammatory response is formed by 
the innate immune system, in which endothelial cells, smooth muscle cells, 
and macrophages are stimulated by the antigen to produce a variety of 
cytokines and adhesion molecules that enhance the inflammatory response 
by for example stimulating further leukocyte recruitment.18 Macrophages and 
dendritic cells express toll-like receptors (TLRs) that recognize the antigens 
which enhance inflammation by intracellular signaling through the activator 
protein-1 and NFκB pathways.19 The second line of defense is formed by the 
adaptive immune response and starts with the presentation of antigens by 
the macrophages via major histocompatibility complex class II (MHC-II) to 
antigen-specific CD4+ T lymphocytes. These CD4+ lymphocytes become 
activated and may differentiate into several kinds of T lymphocytes that 
regulate the immune repsonse.20 The balance between the different types of 
T lymphocytes, which differentiate upon activation, is thought to be important 
for the development of atherosclerosis.21     
 
4.1. Endogenous antigens in atherosclerosis 
 
An extensively studied endogenous antigen that activates the immune 
system and drives inflammation during atherogenesis is LDL, which may be 
modified by oxidation, glycation, aggregation, association with proteoglycans, 
or incorporation into immune complexes.22-24 Modified LDL can induce injury 
to the endothelium and underlying smooth muscle cells, resulting in 
increased expression of inflammatory mediators, such as P-selectin, 
monocyte chemoattractant protein 1 (MCP-1), GRO, and M-CSF, which 
contribute to enhanced recruitment of monocytes and differentiation into 
macrophages.25-29 Uptake of oxidized LDL (oxLDL) by macrophages via 
scavenger receptors is an attempt to take away the inflammatory stimuli for 
endothelial and smooth muscle cells. However, oxLDL activates the 
macrophages by inducing the expression of inflammatory cytokines, such as 
interleukin 1 (IL-1).30  Antibodies to oxLDL have been found in human and 
rabbit plasma and in atherosclerotic lesions, indicating an immune response 
against oxLDL.31-33 Furthermore, anti-oxLDL antibodies have been 
associated with atherosclerotic disease,34 but whether these antibodies are 
beneficial or detrimental for atherogenesis remains to be established. In 
addition, T-cell clones responsive to oxLDL have been isolated from human 
lesions.36 Induction of tolerance for oxLDL has been shown to reduce 
atherosclerosis in several animal models,37,38,19 but the mechanism of 
protection against atherosclerosis still has to be unraveled. 
Other endogenous antigens that are related to atherosclerosis are heat shock 
proteins (HSPs), which form a group of proteins that are present in all cells 
and are evolutionarily conserved proteins that show high sequence homology 
between different species, from bacteria to humans.39 Under normal 
conditions these proteins intracellularly regulate the sufficient folding of many 
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proteins.40 However, under stress conditions, such as exposure to oxLDL, 
biomechanical stress, oxidants, infections and cytokines, HSPs are 
presented on the surface of the cell and form highly powerful inducers of the 
immune system.41,42 A role for HSP in atherosclerosis is suggested by 
several observations. HSP60 was immunohistochemically detected in 
atherosclerotic lesions on endothelial, smooth muscle and mononuclear cells, 
whereas arteries that were not affected by atherosclerosis did not show any 
HSP staining.43 A role for HSPs was further indicated by the fact that 
antibodies against HSP65 correlate with human carotid atherosclerosis.44 A 
contributory role of HSP65 in the development of atherosclerosis was 
indicated by the fact that induction of tolerance for HSP65 reduced 
atherosclerosis in LDL receptor deficient mice.45,46 Furthermore, T 
lymphocytes were isolated from rabbit atherosclerotic lesions that were 
specifically responsive to HSP65.47 Activation of T lymphocytes can lead to 
increased production of chemotactic factors, resulting in the enhanced 
migration of leukocytes or smooth muscle cells. In addition, direct contact of 
HSP60 with macrophages induces the expression of cytokines, such as 
tumor necrosis factor alpha (TNF-α) and IL-12, which further enhance the 
inflammatory response and have been shown to promote atherosclerosis.48,49 
 
4.2. Exogenous antigens in atherosclerosis 
 
Since atherosclerosis was considered an inflammatory disease many studies 
focused on the role of infectious agents in atherosclerosis. Apart from a direct 
influence of infectious agents on cells involved in atherosclerosis, these 
exogenous antigens may also have an indirect effect on atherosclerosis by 
stimulating the immune system which contributes to the development of 
atherosclerosis. The most extensively studied pathogens in the context of 
atherosclerosis comprise Helicobacter pylori (H. pylori), Cytomegalovirus 
(CMV), and Chlamydia pneumoniae (C. pneumoniae).   
Initially, the gram negative bacterium H. pylori was linked to atherosclerosis 
with the observation that high serum triglyceride and total cholesterol levels 
were significantly elevated in individuals with IgG and IgA antibodies against 
H. pylori.50 Furthermore, it was shown that chronic H. pylori infection was an 
independent risk factor for ischemic cerebrovascular disease.51 Although 
these data suggested a role for H. pylori in the development of 
atherosclerosis many seroepidemiological, animal and pathology studies 
resulted in conflicting results leading to a lack of convincing evidence for a 
role of this bacterium in atherosclerosis.52  
CMV is a member of the herpes virus family and a potential role for CMV in 
atherosclerosis has been extensively studied. Some seroepidemiological 
studies show an association between serum anti-CMV antibodies and 
atherosclerosis.53,54 However, other studies did not find these associations or 
concluded that multiple reactivation of latent viruses might be the 
consequence rather than the cause of atherosclerosis.55 CMV is present in 
the majority of atherosclerotic plaques and plaques in a later stage contain 
more virus than plaques in an early stage, suggesting a role for CMV in the 
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progression of atherosclerosis.56 However, CMV has also been detected in 
arteries not affected by atherosclerosis.57 ApoE-/- mice infected with CMV 
have been shown to develop more severe atherosclerosis, indicating a role 
for CMV in atherosclerosis.58 In conclusion, more studies have to be 
performed to show definite proof for a causal relation between CMV and 
atherosclerosis. 
The most extensively studied pathogen in relation to atherosclerosis is C. 
pneumoniae. In the present thesis we focus on this pathogen and therefore 
its characteristics, clinical consequences, and potential role in atherosclerosis 
are described in a separate section.   
 
4.3. Chlamydia pneumoniae and atherosclerosis 
 
C. pneumoniae is an obligate intracellular gram-negative bacterium and, 
upon transmission by aerosol droplets, may lead to mild upper respiratory 
tract infections, including pharyngitis, sinusitis, bronchitis, community 
acquired pneumonia, and otitis media.59,60 However, infections with these 
bacteria often remain subclinical.60 C. pneumoniae is a common human 
pathogen, which is illustrated by the fact that by the age of 20, anti-C. 
pneumoniae antibodies are found in 50% of the individuals and by the age of 
65, these antibodies are present in 80% of the male and 70% of the female 
population.61,62 Actually, the majority of people are repeatedly infected with C. 
pneumoniae during a lifetime.62 
In the unique life cycle of C. pneumoniae, the bacterium can be found in two 
versions with their own characteristics; the elementary body and the 
reticulate body. The C. pneumoniae elementary body can be found 
extracellularly and is small (300-400 nm) and infectious, but not able to 
replicate, while the reticulate body can be found intracellularly and is 
relatively large (800-1000 nm), noninfectious, but able to replicate. For its 
replication C. pneumoniae is dependent on host cells and therefore the life 
cycle of C. pneumoniae starts with the adherence of elementary bodies to a 
host cell, after which the elementary bodies are endocytosed and prevent 
phagosome-lysosome fusion in order to circumvent degradation. Thereafter, 
the elementary bodies start to differentiate into reticulate bodies, which are 
able to proliferate inside the inclusions. The reticulate bodies can either 
continue with proliferation or may adopt a non-replicating persistent form, 
which is able to stay inside the host cell for a long time. After replication the 
reticulate bodies are reorganized into elementary bodies which are secreted, 
usually by cytolysis, and can infect new host cells to start the next life cycle. 
The duration of a single life cycle of C. pneumoniae usually comprises 48-72 
hours.63,64  
Although C. pneumoniae causes respiratory tract infections, these bacteria 
were detected at many other places after infection, such as the spleen, liver, 
blood and atherosclerotic lesions.65,66 The most widely accepted explanation 
for this fact is that the C. pneumoniae bacteria may be disseminated from the 
lungs via the circulation while residing inside monocytes, which deliver the 
bacteria to other organs and atherosclerotic lesions.67-69 
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The enormous amount of data concerning the potential role of C. 
pneumoniae in atherosclerosis is obtained by several lines of research.70,71 
Seroepidemiological studies aimed to show associations between anti-
C.pneumoniae antibody titers and atherosclerosis or ischemic diseases. 
Pathology-based studies were designed to indicate the presence of C. 
pneumoniae inside atherosclerotic lesions. Animal studies in which infections 
with C. pneumoniae  were combined with a variety of models for 
atherosclerosis were performed to evaluate a potential causal role for these 
bacteria in atherosclerosis. Furthermore, many in vitro studies have 
evaluated the effect of C. pneumoniae on cells types, which are associated 
with atheroma formation, such as macrophages, smooth muscle cells, and 
endothelial cells. Finally, antibiotic treatment trials aimed to reduce 
cardiovascular disease by elimination of C. pneumoniae. Although all lines of 
research accurately indicated a (causal) relation between C. pneumoniae and 
atherosclerosis, the same lines of research also offered a variety of data that 
contradict the role of C. pneumoniae in atherosclerosis, indicating the need 
for additional studies giving definite proof.  
 
5. Interleukins in atherosclerosis 
 
The inflammatory response during atherosclerosis, induced by either 
endogenous or exogenous stimuli, is regulated to a large extent by 
interleukins, which function as messenger molecules between cells involved 
in the immune system.72 The presence of interleukins has been indicated in 
atherosclerotic lesions and circulating levels of certain interleukins have been 
correlated with atherosclerosis. Furthermore, in vitro studies showed the role 
of interleukins in processes that are associated with lesion formation. In 
addition, a causal contribution of several interleukins has been confirmed by 
changes in the extent of atherosclerosis in mice that are deficient or 
transgenic for specific interleukins. In a healthy artery the contribution of anti- 
and pro-inflammatory interleukins are in balance, whereas in atherosclerosis 
affected arteries the pro-inflammatory interleukins predominate over the anti-
inflammatory interleukins, contributing to enhanced inflammation and 
atherosclerosis. Pro-inflammatory and pro-atherogenic interleukins comprise 
IL-1, IL-2, IL-6, IL-8, IL-12, IL-15, IL-17, and IL-18, whereas the anti-
inflammatory and anti-atherogenic interleukins comprise IL-1 receptor 
antagonist, IL-9 and IL-10.72 
During the adaptive immune response the development of a dysbalance 
between pro- and anti-inflammatory cytokines, including interleukins, is 
largely depending on the differentiation of CD4+ naïve T helper cells (Th0) 
towards either T helper 1 (Th1) or T helper 2 (Th2) cells. The Th1 cells 
primarily produce pro-inflammatory cytokines, whereas Th2 cells primarily 
produce anti-inflammatory cytokines.73-77 One of the key factors that stimulate 
the differentiation of naïve T helper cells towards Th1 cells is IL-12.78-80  
IL-12 is a heterodimeric cytokine (p70), which consists of a 35-kDa light chain 
(p35) and a 40-kDa heavy chain (p40) and is produced by neutrophils, 
macrophages or dendritic cells, by stimulation with various antigens such as 
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infectious agents, CD40 ligand expressing T cells, or extracellular matrix 
components.81 IL-12 has been shown to play a causal role in the 
development of atherosclerosis by the fact that daily administration of IL-12 
promoted atherosclerosis in apoE-/- mice.82 Furthermore, apoE/IL-12 double 
knock out mice show less atherosclerosis than mice only deficient in apoE.83 
Apart from its contribution to Th1 cell development IL-12, particular in 
combination with the proinflammatory IL-18, is able to directly stimulate 
macrophages, resulting in enhanced production of inflammatory cytokines.84 
Taking these actions of IL-12 together, this interleukin may be considered a 
suitable target in the development of novel therapies for atherosclerosis. 
Another interleukin that may contribute to an enhanced inflammatory 
environment during atherosclerosis is IL-17. This interleukin is a variably 
glycosylated ~20kDa homodimeric polypeptide which is mainly produced by 
activated memory T lymphocytes and Th1/Th0 cells.85 IL-17 induces the 
expression of many pro-inflammatory cytokines by a variety of cell types, as 
is illustrated by enhanced production of IL-6 and IL-8 by stromal cells, or by 
elevated expression levels of IL-1, IL-6, and TNF-α upon exposure of 
macrophages to IL-17.86,87 Furthermore, binding of IL-17 to its receptor leads 
to stimulation of NF-κB activity,88 which is a nuclear factor that regulates the 
expression of many interleukins (IL-1, IL-2, IL-3, IL-6, IL-8, and IL-12), 
enzymes (inducible nitric oxide synthase and cyclooxygenase-2), and 
adhesion molecules involved in chronic inflammation.89 The role of IL-17 in 
atherosclerosis has not yet been unraveled, but its pro-inflammatory 
characteristics make this interleukin a potential pro-atherogenic candidate, 
which may offer novel therapeutic opportunities. 
 
6. Interference in the immune system as a treatment for atherosclerosis 
 
Currently, there are several treatments for atherosclerosis. By changes in life 
style, such as switching to a low fat diet, giving up smoking, or increasing 
physical activity and by using drugs that lower circulating cholesterol levels 
(statins) or decrease coagulation, the development of atherosclerosis and its 
clinical consequences can be limited. However, there are many patients that 
comply with these instructions but nevertheless are still confronted with 
ischemic diseases. Furthermore, statins are associated with side effects, 
such as liver toxicity and muscle inflammation,90 whereas anticoagulants may 
lead to uncontrolled bleeding. Therefore, the development of other strategies 
that reduce atherosclerosis and its consequences is needed.  
A novel approach in the development of effective treatments for 
atherosclerosis is based on interference in the immune system leading to 
reduced inflammation and subsequent lesion formation.91 Since several 
endogenous and exogenous antigens that provoke inflammation were 
indicated to be associated with atherosclerosis (modified LDL, HSPs, 
bacteria, and viruses) and since the unraveling of the inflammatory 
mechanisms in response to these antigens has progressed rapidly during the 
recent years, many therapeutic options have been created to interfere in the 
immune system.  There are roughly three approaches to attenuate the 
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inflammatory response: 1) Removal of the stimulus that causes inflammation, 
2) tolerance induction for the antigens involved in triggering inflammation, 
and 3) modulation of the immune response by regulating the expression or 
blocking the function of key players in the inflammatory response. 
 
6.1. Removal of stimulus for inflammation 
 
Apart from the removal of stimuli that initiate inflammation in atherosclerosis 
by inducing endothelial dysfunction, such as smoking or hypertension, 
antigens that drive inflammation can be removed. The removal of 
endogenous antigens, such as HSPs or oxLDL, is hard to achieve, but there 
are two major methods through which exogenous antigens (bacteria and 
viruses) can be removed. By using antibiotics or antiviral medication the 
pathogens can be removed. Several studies have focuses on the effect of 
anti-C. pneumoniae antibiotics, such as azithromycin, on cardiovascular 
disease. Some studies show promising effects on cardiovascular disease and 
other studies contradict these results.92-94 However, the fact that C. 
pneumoniae can be present in cells in a latent state makes it difficult to 
eradicate the bacteria totally. Therefore, results obtained in those studies 
should be interpreted with great care. Protection against atherosclerosis 
associated pathogens may also be established by vaccination strategies, but 
although several studies attempted to develop such vaccines, these vaccines 
were either not fully protecting or were not safe for human use.95-98      
 
6.2. Tolerance induction 
 
Tolerance for immunogens can be induced by oral or nasal administration of 
endogenous antigens, such as oxLDL or HSPs. Although the exact 
mechanisms are still not clear, activation of the mucosa-associated lymphoid 
tissue can induce tolerance for the antigen and has been shown to 
ameliorate certain experimental autoimmune diseases, such as rheumatoid 
arthritis and diabetes mellitus.99 Furthermore, several animal studies show 
that induction of tolerance for HSP65 or oxLDL leads to reduced 
atherosclerosis, indicating that tolerance induction may contribute to novel 
therapies against atherosclerosis.45,46,100  
 
6.3. Regulation of immune response by inducing or blocking key players in 
inflammation 
 
Although at the moment there are several kinds of anti-inflammatory and 
immunosuppressive medication available, such as cyclosporin A, rapamycin 
or corticosteroids, the amount of side effects of these drugs do not make 
them suitable for wide and long-lasting use in the prevention and treatment of 
atherosclerosis. More specific treatment with factors that have been shown to 
reduce inflammation and atherosclerosis development is needed, such as 
treatment with IL-10.101-103 At the other hand, blockade of interleukins that are 
involved in the enhanced inflammatory response during atherosclerosis, such 
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as IL-12, may contribute to novel therapies against atherosclerosis.82,83 
Suitable methods for specific blockade of endogenous factors are passive 
immunization, which provides temporary immunity, or active immunization, 
which provides long-lasting immunity against the target molecule. Passive 
immunization, in which antibodies against a target molecule are 
administered,  has been proven to be a successful approach in the treatment 
of several autoimmune diseases. Blockade of TNF-α by antibody 
administration appears to be successful in the treatment of rheumatoid 
arthritis and preliminary clinical studies indicate that Crohn’s disease can be 
treated by the administration of antibodies against IL-12. Furthermore, 
antibodies against platelet glycoprotein IIb/IIIa receptor are used in the 
treatment of unstable angina and restenosis.104-107 However, with passive 
immunization there is always a risk for an immune response against the 
administered foreign protein, as has for example been seen with anti-TNF-α 
therapy in Crohn’s disease.108 Active immunization, in which the antibodies 
against the target molecule or target cells are induced by a vaccine in the 
individuals that have to be protected against the target molecule, circumvents 
the risks of immune reactions against foreign proteins. The induction of long-
lasting protection and the relatively low costs of active immunization make 
this approach potentially useful in the development of novel treatments 
against atherosclerosis. 
 
7. Active immunization in atherosclerosis 
 
With active immunization it is possible to induce two kinds of immune 
responses, namely humoral or cellular immune responses. A humoral 
response is characterized by the production of antibodies by B lymphocytes 
against the target antigen, while a cellular immune response induces the 
development of CD8+ cytotoxic T lymphocytes which specifically kill cells that 
present the target antigen. Although it is possible with active immunization to 
interfere in the immune response during atherogenesis by impairing the 
function of molecules involved in atheroma associated inflammation, it is also 
possible to block other factors that are involved in the development of 
atherosclerosis, for example proteins that contribute to the lipid metabolism.  
Induction of a humoral response against endogenous factors that play a role 
in atherosclerosis by vaccination forms an interesting new strategy to reduce 
atherosclerosis. However, the development of a vaccine that induces a 
humoral immune response against endogenous antigens requires coupling of 
the endogenous factor (containing a B cell epitope) to a peptide sequence 
that induces the required T cell help, for example PanDRepitope (PADRE) or 
ovalbumine (OVA) or hen egg lysozyme (HEL) sequences.109-111 Upon 
intramuscular injection of the complex of PADRE-endogenous antigen or 
OVA-endogenous antigen complex or HEL-endogenous antigen complex, B 
lymphocytes endocytose the complex after binding to the B cell epitope and 
start to process the complex. The highly immunogenic PADRE, OVA or HEL 
sequences are presented by the MHC-II to CD4+ T helper lymphocytes which 
start to stimulate the B lymphocytes to differentiate into cells that produce 
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high amounts of antibodies against the endogenous factor which was also 
endocytosed by the B lymphocyte. Injection of the vaccine in the presence of 
an adjuvant can lead to a high induction of the immune system increasing the 
production of self-antibodies. In this way immune responses were for 
example induced against ubiquitin, a highly conserved endogenous peptide, 
making use of OVA and HEL,112 while anti-IL-12 antibodies were induced by 
making use of a PADRE-IL-12 complex.113 Another study used tetanus toxin 
as T cell epitope and showed that coupling of this epitope to B cell epitopes 
of cholesteryl ester transfer protein (CETP) elicited high levels of antibodies 
against CETP, which resulted in increased high density lipoprotein (HDL) 
levels and reduced LDL levels, leading to attenuated atherosclerosis.114 
Induction of a cellular immune response against cells that contribute to lesion 
formation may form a suitable method to inhibit atherosclerosis. A recently 
developed method for induction of cellular immunity by vaccination makes 
use of the live attenuated bacterium Salmonella  typhimurium carrying a 
vector plasmid encoding the gene that is presented by the target cells.115 This 
vaccine can be administered orally and passes through M-cells of the 
gastrointestinal tract to the Peyer’s patches and is transferred to antigen 
presenting  cells, which become activated by the live attenuated bacteria 
leading to migration of these cells to inductive sites of the immune system 
and the expression of the target gene. Peptide fragments of this gene are 
presented by the MHC class I to CD8+ T cells, which become activated and 
start to clonally expand, leading to the breaking of tolerance against the cells 
that present the target gene.116 This method has elegantly been used by the 
group of Reisfeld for several target genes. Using this vaccination strategy 
they induced cellular immunity against vascular endothelial growth factor 
receptor 2 (VEGFR2), which is highly expressed by proliferating endothelial 
cells, and blocked in this way tumor angiogenesis and subsequent tumor 
growth.117 Furthermore, vaccination against multidrug resistance 1 (MDR-1), 
which is highly expressed by a multitude of different malignancies, has been 
shown to result in reduced tumor growth and increased life span of mice.118  
Not much is known about the effects of removal of cells that are involved in 
atherosclerosis on the progression of this disease. However, specific 
targeting of cells that are involved in processes that contribute to 
atherosclerosis may lead to decreased atherosclerosis. Cells that are 
involved in the enhanced inflammatory response during atherosclerosis may 
form interesting targets. Furthermore, induction of specific cellular immunity 
against cells that contribute to atheroma-associated angiogenesis, such as 
VEGFR2 or TIE2 overexpressing cells, by vaccination may potentially 
contribute to novel therapies against atherosclerosis.119,120        
 
8. Outline of this thesis 
 
The research described in this thesis focuses both on the pathogenesis of 
atherosclerosis as well as on the development of novel therapeutic strategies 
for atherosclerosis.  
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Chapter 2 describes a study in which the influence of a lung infection with C. 
pneumoniae on atherosclerosis was evaluated in mice. The moment of 
infection in relation to the induction of atherosclerosis appeared to be crucial 
for the exerted effect of C. pneumoniae on atherosclerosis. Therefore, this 
study partly supports the hypothesis that lung infection with C. pneumoniae 
contributes to lesion formation. 
Chapter 3 describes a study in which the direct effects of the presence of C. 
pneumoniae in the vascular wall on lesion formation were evaluated. Upon 
local delivery of C. pneumoniae to the vascular wall atherosclerosis was 
promoted, fully supporting the contributory role of C. pneumoniae in 
atherosclerosis once it has infected the atherosclerotic lesion. 
Chapter 4 describes a study in which mice were vaccinated against IL-17 by 
a novel DNA vaccination strategy. Atherosclerosis was dramatically reduced 
and therefore, this study supports the hypothesis that interference in the 
immune system by vaccination can be of potential use in the development of 
novel treatments against atherosclerosis. 
Chapter 5 describes a novel protein vaccination method that blocks the 
function of the pro-inflammatory cytokine IL-12, and leads to attenuated 
atherosclerosis (68.5%) in mice. Furthermore, upon vaccination against IL-12 
the atherosclerotic lesions are more stable, from which we conclude that 
blockade of IL-12 by vaccination may be a promising new strategy in the 
treatment of atherosclerosis.    
Chapter 6 describes a study in which specific cytotoxicity is induced against 
VEGFR2 overexpressing cells by a novel DNA vaccination technique. 
Specific killing of VEGFR2 overexpressing cells reduced both the initiation 
and the progression of atherosclerosis. However, post-interventional 
neointima formation was promoted by this approach, indicating that 
vaccination against VEGFR2 may only be useful in the treatment of a limited 
selection of patients. However, this is the first study that shows that removal 
of potential pro-atherogenic cells by vaccination reduces atherosclerosis. 
Chapter 7 describes a study in which specific cytotoxicity is induced against 
TIE2 overexpressing cells by the same vaccination technique that was used 
for the killing of VEGFR2 expressing cells. This approach also reduced the 
degree of atherosclerosis in mice, and therefore further supports the 
hypothesis that removal of pro-atherogenic cells by DNA vaccination may be 
used in the treatment of atherosclerosis. 
Chapter 8 discusses the outcome and perspectives of both the studies that 
focused on the pathogenesis of atherosclerosis and the studies that focused 
on potential novel therapeutic strategies for atherosclerosis. 
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Abstract 
 
C. pneumoniae has been implicated to play a role in the pathogenesis of 
atherosclerosis. However, lack of consensus about its contribution to 
atherosclerosis encourages further studies. In the present study we aimed to 
provide insight into the importance of the moment of C. pneumoniae infection 
in relation to the onset of atherosclerosis to exert its effects on 
atherosclerosis. Atherosclerosis was induced in carotid arteries of LDL 
receptor deficient mice by perivascular collar placement. Transtracheal 
inoculation with C. pneumoniae was performed at different moments in 
relation to the initiation of atherosclerosis by collar placement. After 6 to 8 
weeks atherosclerosis was quantified in the carotid artery and aortic root. In 
another experiment the amount of macrophages in the carotid lesions was 
quantified at mRNA level at several time points during atherosclerosis 
development. Inoculation with C. pneumoniae and collar placement at the 
same time resulted in a significant 2.1-fold increase in neointima area, 
translating to significant 2.5- and 2.2-fold increases in intima/media and 
intima/lumen ratios, respectively. Inoculation 2 weeks before or inoculation 2 
or 3 weeks after collar placement did not result in enhanced lesion formation. 
Repeated inoculation with C. pneumoniae resulted in a significant 1.7-fold 
increased neointima area in the aortic root, whereas in the same experiment 
no differences in lesion formation were observed in the carotid arteries. In 
conclusion, the moment of infection with C. pneumoniae in relation to the 
initiation of atherosclerosis is important to exert an aggravating effect on 
atherosclerosis, which may explain some of the different convictions 
concerning the contributory role of C. pneumoniae in atherosclerosis. 
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Introduction 
 
Since atherosclerosis has been appreciated as an inflammatory disease,1 the 
potential involvement of infectious agents in this disease has been 
extensively studied. Several lines of evidence have implicated the gram-
negative bacterium, Chlamydia pneumoniae, in the pathogenesis of 
atherosclerosis. This obligate intracellular micro-organism causes mild 
respiratory tract infections and is highly prevalent, indicated by the fact that in 
the elderly anti-C. pneumoniae antibodies are detected in 70-80% of the 
human population.2 
From the late 80’s, data have accumulated in which C. pneumoniae was 
linked to atherosclerosis. Sero-epidemiological studies, in which the finding of 
anti-C.pneumoniae antibodies appeared to be correlated with cardiovascular 
disease, promoted the hypothesis of C. pneumoniae playing a role in 
atherosclerosis.3 Furthermore, the presence of C. pneumoniae has been 
demonstrated in up to 50% of the human atherosclerotic lesions.4 Several 
preliminary clinical trials, in which antibiotics were used to treat patients with 
coronary artery disease, showed attenuated progression of atherosclerosis 
and reduced incidence of death, myocardial infarction and unstable angina 
upon treatment with antibiotics.5-7 In addition, animal models have shown that 
C. pneumoniae could enhance atherosclerosis,8,9 which was substantiated by 
in vitro studies that described the pro-inflammatory and pro-atherosclerotic 
effects of C. pneumoniae upon infection of vascular smooth muscle cells 
(VSMCs), monocytes/macrophages, and endothelial cells (ECs).10-17  
However, recently many of the initial, often convincing, indications for a link 
between C. pneumoniae and atherosclerosis, have been refuted by recent, 
extensive clinical and animal studies.18,19 The conflicting results in many 
experimental studies may be attributed to the different setup of these studies. 
For example, it was speculated that C. pneumoniae could only exert its effect 
on atherosclerosis in mouse models if the experiments were performed under 
hypercholesterolemic conditions.20 Furthermore, the amount and the strain of 
the applied C. pneumoniae elementary bodies, the type of animal and the 
duration of atherosclerosis development have been indicated to be important 
factors for the exerted effect of C. pneumoniae on atherosclerosis.9 In 
addition, we recently showed that the presence of C. pneumoniae in the 
vessel wall after local delivery of these bacteria to the carotid artery 
accelerates atherosclerosis.21 These data indicate that it may be important 
that dissemination from the lungs to the vessel wall takes place and that 
factors that influence the dissemination of C. pneumoniae from the lungs are 
crucial for the  effect that these bacteria exert on atherosclerosis.  
In the present study we hypothesized that the time point of infection in 
relation to the time point of initiation of atherosclerosis may be important for 
the potential pro-atherogenic effects exerted by C. pneumoniae. We used a 
mouse model in which the induction of atherosclerosis could be accurately 
controlled by placing collars around the carotid arteries of low density 
lipoprotein receptor deficient (LDLr-/-) mice on a Western type diet. In several 
experiments the moment of a lung infection with C. pneumoniae was varied 
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in relation to the initiation of atherosclerosis. This study shows that the 
moment of infection may be crucial for the observed effects of C. 
pneumoniae on atherosclerosis. This observation may explain some of the 
conflicting results obtained in the past. 
 
 
Methods 
 
Chlamydia pneumoniae 
C. pneumoniae strain AR39 (Washington Research Foundation, Washington, 
USA) was cultured in Buffalo Green Monkey (BGM) cells. The titer was 
determined by counting the inclusions formed by BGM cells 3 days after 
infection, as previously described.22 All stock solutions were stored at minus 
80°C prior to use. 
 
Induction of atherosclerosis and inoculation with C. pneumoniae 
All animal work was approved by the regulatory authority of Leiden University 
and carried out in compliance with Dutch government guidelines. Male LDLr-/- 
mice, 10-12 weeks of age, were put on a Western type diet, containing 0.25% 
cholesterol and 15% cocoa butter (Special Diet Services, UK). Diet and water 
were provided ad libitum until the end of the experiment. After two weeks of 
Western type diet feeding atherosclerosis was induced in both common 
carotid arteries by perivascular collar placement, as previously described.23 
The effect of a (or repeated) lung infection with C. pneumoniae on the 
induced atherosclerosis was studied by transtracheal inoculation with 1x104 
infection forming units (IFU) C. pneumoniae in 20 μl of sucrose-phosphate-
glutamic acid (SPG) medium at indicated time points (Fig.1). Inoculation with 
these bacteria was performed before (experiment I), at the same time 
(experiments IIa and IIb), or after (experiments III and IV) the induction of 
atherosclerosis by collar placement. Furthermore, the effect of repeated lung 
infection with C. pneumoniae on atherosclerosis was studied (experiment V). 
Inoculation with 20 μl SPG medium served as control inoculation. Sacrifice 
and subsequent analysis of the amount of atherosclerosis was performed at 
6 or 8 weeks after collar placement (Fig.1). Furthermore, Western type diet 
induced atherosclerosis was determined in the aortic root. 
 
Cholesterol assay 
Blood was collected at several time points during the experiments by tail vein 
transsection. Plasma was obtained by centrifugation at 10000 rpm for 10 
minutes. Levels of total plasma cholesterol were measured using a 
spectrophotometer and enzymatic procedures (Roche Diagnostics, The 
Netherlands), in which the standardized serum, Precipath (Boehringer 
Mannheim, Germany), served as internal standard. 
 
Tissue harvesting and histology 
At indicated time points (Fig.1) mice were sacrificed and exsanguinated by 
femoral artery transsection. Carotid arteries and hearts were obtained upon 
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in situ perfusion for 15 min. using PBS and subsequent perfusion using 
formalin (Formal-fixx; Shandon Scientific Ltd., UK) for 30 min.23 Fixated 
carotid arteries were embedded in OCT compound (Sakura Finetek, The 
Netherlands), snap-frozen in liquid nitrogen and stored at -20°C until further 
use. Transverse 5 μm cryosections, prepared in a proximal direction from the 
carotid bifurcation, were routinely stained with hematoxylin (Sigma 
Diagnostics, MO) and eosin (Merck Diagnostica, Germany). Each vessel was 
assessed ~0.5 mm proximal to the collar, and the site of maximal stenosis 
was used for morphometric assessment. Fixated hearts were bisected at the 
level of the atria and 10 μm cryosections of the aortic root were made and 
stained with Oil red O. Mean lesion area was calculated from 10 Oil red O-
stained sections, starting at the appearance of the aortic semilunar valves.24 
Quantification of atherosclerosis in carotid arteries and aortic roots was 
performed using a DM-RE microscope and LeicaQwin software (Leica 
Imaging Systems, UK). 
 
 
Figure 1. Representation of the set up of 5 different experiments in which the moment 
of infection (In) was varied in relation to the moment of collar placement around 
carotids of LDLr-/- mice (C). S indicates the moment of sacrifice and D indicates the 
moment of providing Western type diet. Experiment II was repeated with the same 
conditions, resulting in experiment IIa and IIb. The amount of mice (n), inoculated with 
C. pneumoniae (Cp) or control inoculation (Con), is indicated for each experiment. 
The distance between 2 ticks represents 1 week.  
 
Quantification of macrophages in atherosclerotic lesions 
In a separate experiment the amount of macrophages in collar induced 
atherosclerotic lesions in LDLr-/- mice (n=45) was determined by 
quantification of the expression of the macrophage marker, CD68, at mRNA 
level. At 0, 2, 4, 6 and 8 weeks after collar placement 9 mice were sacrificed 
and, after perfusion with PBS, the atherosclerosis affected part of the right 
carotid artery (∼1 mm proximally from the collar) was taken out for total RNA 
isolation. Of these 9 atherosclerosis affected carotid segments 3 segments 
were pooled resulting in n=3 per time point. Total RNA isolation, generation 
of cDNA, quantitative RT-PCR, calculations of the ratios of target genes and 
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the house hold gene, Hypoxanthine-guanine phosphoribosyl-transferase 
(HPRT), and the design of primers were performed as previously described.25     
 
 
Data analysis 
Values are expressed as mean±sem. A 2-tailed Student’s t-test was used to 
compare individual groups of mice or cells. Levels of p<0.05 were considered 
significant. 
 
 
Results 
 
Influence of C. pneumoniae on atherosclerosis  
During the various experiments that we have performed we did not observe 
that either a single or a repeated lung infection with C. pneumoniae affected 
serum cholesterol levels, as compared to control treated LDLr-/- mice. Serum 
cholesterol levels, measured in experiment IIa, in which collar placement and 
infection was performed at the same time, are presented in figure 2A. To 
assess the effect of a lung infection with C. pneumoniae on atherosclerosis, 
we conducted several experiments, in which the moment of infection in 
relation to the moment of induction of atherosclerosis was varied. From the 
different experimental settings we studied, there was only a single situation in 
which lung infection with C. pneumoniae enhanced collar-induced 
atherosclerosis. The combination of induction of atherosclerosis by collar 
placement and inoculation with C. pneumoniae at the same time point 
(experiment IIa) led to significant 2.1-fold increased neointima formation in 
the carotid artery (Fig.2D; 12,136±2,114 vs 25,736±5,670 μm2; p<0.05) as 
compared to control-treated mice. Furthermore, inoculation with C. 
pneumoniae resulted in this situation in significant 2.5-fold increased 
intima/media ratios (Fig.2E; 0.32±0.03 vs 0.80±0.17; p<0.05) and 2.2-fold 
increased intima/lumen ratios (Fig.2F; 0.19±0.03 vs 0.41±0.09; p<0.05). In 
order to exclude the possibility of a coincidence in this situation, we repeated 
the experiment in the same setting (experiment IIb). Again, we observed a 
significant increase in the amount of atherosclerosis in the group of mice that 
was inoculated with C. pneumoniae as compared to control mice that were 
inoculated with SPG medium, reflected by a significant increase in intima 
area and significantly increased intima/media ratios. Neither infection 2 
weeks before nor infection 2 or 3 weeks after collar placement did affect the 
amount of atherosclerosis in the carotid artery. Interestingly, the degree of 
atherosclerosis in the aortic root was not affected by infection when infection 
and collar placement were performed at the same time. Furthermore, while 
the amount of collar induced atherosclerosis in the carotid artery did not 
change upon repeated infection with C. pneumoniae (at 6, 5, 4 weeks before 
and 1 week after collar placement), atherosclerosis in the aortic root was 
significantly increased upon repeated infection, as compared to control mice 
(Fig.3; 186,214±43,168 vs 312,976±40,969 μm2; p<0.05). In the other 
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Figure 2. Lung infection with C. pneumoniae promotes carotid atherosclerosis in 
LDLr-/- mice exclusively if inoculation and induction of atherosclerosis by collar 
placement are performed at the same time, which is illustrated by the results of 
experiment IIa. While serum cholesterol levels remain unaffected (A), infection with C. 
pneumoniae leads to 2.1-fold significantly increased neointima formation (C) 
compared to control inoculation (B)(D). Furthermore, intima/media and intima/lumen 
ratio upon infection increased 2.5- and 2.2-fold, respectively (E and F). *P<0.05.   
 
 
 
Figure 3. In experiment V, in which repeated inoculation with C. pneumoniae was 
performed, we found that inoculations with C. pneumoniae (C) promoted 
atherosclerosis in the aortic root as compared to control inoculations (B), while lesion 
formation in the carotid artery was unaffected by repeated inoculation. Quantification 
of the neointima area in Oil red O stained sections of the aortic root revealed a 
significant 1.7-fold increase upon C. pneumoniae inoculation as compared to control 
inoculation (A). *P<0.05. 
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Quantification of macrophages in collar induced lesions 
To determine the stage in which the highest macrophages migration from the 
circulation to the atherosclerotic plaque took place after collar placement, the 
amount of macrophages in the collar induced atherosclerotic plaque was 
quantified at mRNA level using CD68 as a marker for macrophages. Within 2 
weeks after collar placement the relative expression of CD68 increased 4-
fold, indicating the early onset of macrophage influx.  
 
Figure 4. In a separate experiment, in which no 
inoculations with C. pneumoniae were performed, 
the amount of macrophages in collar induced 
atherosclerotic lesions was monitored at week 0, 2, 
4, 6, and 8 weeks after collar placement. 
Quantification of a marker for macrophages, CD68, 
at mRNA level revealed a significant 4-fold 
increase in relative expression of this marker 2 
weeks after collar placement. After 2 weeks the 
relative expression of CD68 gradually increased to 
a maximum expression level at 8 weeks post collar 
placement. Significant increase in CD68 
expression level as compared to the expression at 
t=0 weeks is represented by *(P<0.05) and  
***(P<0.005). 
 
During the subsequent 6 weeks of collar induced atherosclerosis 
development the relative CD68 expression gradually increased every 2 
weeks to a maximal expression at 8 weeks post collar placement, illustrated 
by a 5-fold increased CD68 expression as compared to the expression level 
at 2 weeks post collar placement (Fig.4). 
 
 
Discussion 
 
Chlamydia pneumoniae has been linked to the inflammatory process of 
atherosclerosis by several lines of research. Presence of C. pneumoniae in 
the vasculature or serum antibodies against these bacteria has been 
correlated to atherosclerosis or its consequences in humans.3,4 
Subsequently, animal models and in vitro systems were applied to evaluate 
the potential causal or contributory role of C. pneumoniae in atherosclerosis. 
These studies initially indicated a causal or contributory role for C. 
pneumoniae in atherosclerosis.8,9 However, later on the outcome of these 
studies appeared to be dependent on the kind of model that was used, which 
contributed to the lack of consensus about the role of C. pneumoniae in 
atherosclerosis that we face at the moment. For example, hyperlipidemia 
appeared to be one of the essential circumstances in which C. pneumoniae 
can exert its effect on atherosclerosis.20 Furthermore, the kind of animal or C. 
pneumoniae strain, the amount of applied C. pneumoniae elementary bodies, 
and the duration of atherosclerosis development appeared to be important 
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factors that determine the exerted effect of C. pneumoniae on 
atherosclerosis.9 
In vitro studies have shown that C. pneumoniae has many pro-atherogenic 
effects on atheroma-associated cell types, such as induction of adhesion 
molecules, chemokines, pro-inflammatory cytokines, matrix metallo 
proteases, and stimulation of LDL oxidation and foam cell formation.10-17 
Recently, we showed that the presence of C. pneumoniae in the vessel wall 
(bacteria were introduced by local intraluminal delivery to the vessel wall) is 
sufficient to stimulate collar induced atherosclerosis in carotid arteries of 
hyperlipidemic LDLr-/- mice and that a lung infection with C. pneumoniae in 
itself is not an essential stimulus for the induction of atherosclerosis.21 In the 
present study, we hypothesized that the effect of C. pneumoniae on 
atherosclerosis after a mild lung infection may depend on the stage of 
atherosclerosis at the moment of infection.    
Several studies indicate that the obligate intracellular bacterium, C. 
pneumoniae, is disseminated from the respiratory tract via the circulation to 
peripheral organs, while residing in monocytes.26-28 These monocytes, 
containing C. pneumoniae, can enter the atherosclerotic lesion and deliver 
the bacteria to the atherosclerotic plaque where these bacteria enhance the 
inflammatory process of atherosclerosis. Presence of C. pneumoniae inside 
monocytes causes activation of these cells leading to enhanced infiltration of 
infected monocytes into the vessel wall and increased expression of a variety 
of pro-inflammatory cytokines.13,14 Apart from its contribution to enhanced 
migration of monocytes and subsequent production of pro-inflammatory 
mediators, C. pneumoniae stimulates foam cell formation, which also 
contributes to atherosclerosis.15,16,29  In the present study, we hypothesized 
that these pro-atherogenic actions of C. pneumoniae influence 
atherosclerosis primarily during the early stages of atherosclerosis and that 
therefore the moment of infection with C. pneumoniae is important for the 
exerted effect on atherosclerosis. 
To test this hypothesis, we used an animal model in which the moment of 
induction of atherosclerosis could be strictly controlled. After putting LDLr-/- 
mice on a Western type diet for 2 weeks carotid atherosclerosis was induced 
by perivascular collar placement and 6-8 weeks later the mice were sacrificed 
to analyse the amount of atherosclerosis. In several separate experiments 
the moment of infection with C. pneumoniae was varied in relation to the 
induction of atherosclerosis. Significantly increased carotid atherosclerosis 
upon infection with C. pneumoniae was exclusively observed if collar 
placement and inoculation with C. pneumoniae were performed at the same 
time. This observation was confirmed by a second experiment. Infection 2 
weeks before or 2 or 3 weeks after collar placement did not affect 
atherosclerosis. In one experiment mice were repeatedly inoculated with C. 
pneumoniae (3 times with one week intervals starting 6 weeks prior to collar 
placement, and 1 week after collar placement). This experimental setting did 
not result in increased carotid atherosclerosis. From this experiment it can 
not be concluded that a single inoculation 1 week after collar placement does 
not affect carotid atherosclerosis, because immunity against C. pneumoniae 
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may be induced by the 3 initial inoculations with these bacteria.30,31 These 
results indicate that the moment of infection with C. pneumoniae in relation to 
the moment of induction of atherosclerosis is crucial for the effect of these 
bacteria on atherosclerosis. Lung infection with C. pneumoniae in mice 
results within 3 days in a positive detection of these bacteria in peripheral 
blood mononuclear cells and these cells remain positive for up to at least 7 
days.26 Due to the fact that macrophage influx occurred already in the first 2 
weeks after collar placement, lung infection and simultaneous collar 
placement likely caused the entrance of C. pneumoniae to the vessel wall in 
a very early stage of atherogenesis in which activated monocytes have a 
strong potential of enhancing atherosclerosis, whereas infection at another 
time point may have resulted in positively infected monocytes at a less 
important time point for stimulation of atherosclerosis. The course of 
development of atherosclerosis in the aortic root upon starting Western type 
diet feeding deviates from the course of development of carotid 
atherosclerosis after collar placement. Therefore, atherosclerosis was also 
analysed in the aortic root. Analysis of the degree of atherosclerosis in the 
aortic root upon repeated infection revealed a significant increase in lesion 
size in the C. pneumoniae infected group as compared to the control group. 
In the other experiments no differences in atherosclerosis in the aortic root 
were observed upon infection, which could either implicate the importance of 
the moment of infection or the importance of repeated inoculation presumably 
resulting in a more chronic infection as compared to single inoculation. 
Atherosclerosis in humans develops in decades and therefore data obtained 
in mice models in which the course of atherosclerosis takes only 6 to 8 weeks 
remain difficult to extrapolate to the human situation, if the moment of 
infection is important. However, when there is an optimal moment for 
infection with C. pneumoniae in humans to exert its effects on 
atherosclerosis, it may implicate that many cardiovascular disease affected 
individuals may never experience a harmful effect on atherosclerosis after 
infection with C. pneumoniae. Anti-C.pneumoniae treatments, such as 
administration of antibiotics or vaccines against these bacteria, may therefore 
only in a limited population lead to beneficial effects on cardiovascular 
disease. In conclusion, we showed that the moment of infection with C. 
pneumoniae is important for the effect on collar-induced atherosclerosis in 
LDLr-/- mice. Therefore, this study partly supports the contributory role of C. 
pneumoniae in atherosclerosis. If the moment of infection with C. 
pneumoniae also turns out to be important in humans, anti-C.pneumoniae 
treatment of infected atherosclerosis affected patients should be adapted to 
the stage in which atherosclerosis exists at vital sites in the circulation of 
these individuals.  
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Abstract 
 
The role of Chlamydia pneumoniae in atherosclerosis is still debated. In this 
study a novel mouse model was applied to determine the direct impact of C. 
pneumoniae on the arterial wall and the development of atherosclerosis. 
Direct effects of C. pneumoniae on collar-induced atherosclerosis were 
studied after local delivery of C. pneumoniae to carotid arteries of LDLr-/- 
mice. The presence of C. pneumoniae in the vessel wall was quantified by 
RT-PCR (6.2 x 104 copies/artery) and resulted in a 2.0-fold increase in 
intima/media ratios (p<0.05) and a 1.7-fold increase in stenosis (p<0.05). 
Immunostaining revealed a 2.98-fold (p<0.01) increased macrophage content 
and a tendency towards lower numbers of smooth muscle cells and collagen 
in lesions of infected carotid arteries. Direct delivery of another respiratory 
pathogen, M. pneumoniae, to the carotids did not affect size or composition 
of the atherosclerotic lesions. Presence of C. pneumoniae in the carotid 
arteries resulted within 7 days in a marked upregulation of the expression of 
MCP-1 (p<0.01) and ICAM-1 as determined on mRNA and protein level. 
These in vivo data were in line with data obtained with in vitro infections of 
macrophages and endothelial cells with C. pneumoniae. We conclude that C. 
pneumoniae in carotid arteries leads to more pronounced atherosclerotic 
lesions with a more vulnerable morphology and that this model is suitable to 
monitor the direct effects of C. pneumoniae on atherosclerosis. 
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Introduction 
 
Atherosclerosis is considered to be an inflammatory disease1 and possible 
involvement of infectious agents has been studied. Until now most evidence 
indicates that Chlamydia pneumoniae may promote atherogenesis. This 
gram-negative bacterium, a common human pathogen, causes mild upper 
respiratory tract infections. The majority of people are repeatedly infected 
with C. pneumoniae during lifetime. By the age of 65, anti-C. pneumoniae 
antibodies are found in 80% of the male and 70% of the female population.2  
Epidemiological studies show an association of serum antibodies against C. 
pneumoniae and cardiovascular disease.3 Accumulating data revealed that, 
due to its obligate intracellular character, C. pneumoniae is able to 
disseminate via the circulation throughout the body within monocytes and can 
in this way enter the atherosclerotic lesion.4 Its ability to infiltrate lesions is 
illustrated by the observation that in up to 50% of the human atherosclerotic 
lesions C. pneumoniae is detected.5 Data from sero-epidemiological and 
pathology studies underline the possible relation between C. pneumoniae 
and atherosclerosis, but cannot provide definite proof for a causal relation 
between C. pneumoniae infection and atherosclerosis. Several clinical trials 
with antibiotics against these bacteria attempted to demonstrate a causal role 
in cardiovascular disease, but did not always show decreased pathology.6 In 
vitro, C. pneumoniae has various pro-atherosclerotic effects on atheroma-
associated cell types. Infection of endothelial cells (ECs) leads to increased 
expression of adhesion molecules, such as E-selectin, intercellular adhesion 
molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1),7 
chemokines, such as monocyte chemoattractant protein-1 (MCP-1),8 and 
cytokines, such as interleukin (IL)-1, IL-8, and tumor necrosis factor-α (TNF-
α),9 resulting in pro-atherosclerotic processes, such as enhanced adherence 
and migration of monocytes.8 Infection of monocytes with C. pneumoniae 
increases adherence of infected monocytes to ECs10,11 and promotes low 
density lipoprotein (LDL) oxidation,12 resulting in accelerated uptake of 
cholesterol by macrophages and subsequent foam cell formation. Increased 
LDL oxidation was also observed upon infection of ECs with C. 
pneumoniae.13 Smooth muscle cells (SMCs) respond to C. pneumoniae 
infection by elevated expression of matrix metalloproteinases (MMPs), which 
may contribute to plaque destabilization.14 Although in vitro data point to pro-
atherosclerotic effects of C. pneumoniae, most of these still have to be 
confirmed in vivo. Many groups have used animal models to chart the relation 
between C. pneumoniae infection and cardiovascular disease. However, until 
now these models did not result in a general consensus about the 
contribution of C. pneumoniae to atherosclerosis.15-16 The differences in the 
observed effects of C. pneumoniae on atherosclerosis, may arise from the 
fact that C. pneumoniae could not always be detected at the site of 
atherosclerosis after initial lung infection.  
Therefore, we developed a novel model in which the impact of C. 
pneumoniae on the arterial wall and subsequent atherogenesis can be 
studied. C. pneumoniae was delivered to the carotid artery of LDL receptor 
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deficient (LDLr-/-) mice by means of local intra-vascular incubation. 
Subsequently, the influence of C. pneumoniae, present in the vessel wall, on 
atherosclerosis was studied by collar placement around the incubated carotid 
artery. In addition we determined the effect of Mycoplasma pneumoniae on 
lesion formation in the carotid artery. M. pneumoniae is, like C. pneumoniae, 
a mild respiratory pathogen that has directly been detected in atherosclerotic 
lesions.17 The epidemiological behavior of M. pneumoniae and its ability to 
produce chronic sequelae following respiratory infection may point to a role 
for M. pneumoniae in atherosclerosis similar to C. pneumoniae.18 Since C. 
pneumoniae may also affect cardiovascular disease by interfering with the 
thrombogenicity of the vessel wall or atherosclerotic plaque, we also 
determined the effect of C. pneumoniae presence in the vascular wall on 
acute arterial thrombus formation. 
 
 
Methods 
 
Bacteria  
C. pneumoniae strain AR39 (Washington Research Foundation, Washington, 
USA) was cultured in Buffalo Green Monkey cells. The titer was determined 
as previously described.19 M. pneumoniae was kindly provided by dr 
Brugman and dr Thuis from the National Institute for Public Health and 
Environment (Bilthoven, The Netherlands). 
 
Delivery of C. pneumoniae and induction of atherosclerosis 
Animal work was carried out in compliance with guidelines issued by the 
Dutch government, which are conform with NIH guidelines. Male LDLr-/- mice, 
12-14 weeks old, were put on a “Western-type” diet, containing 0.25% 
cholesterol and 15% cocoa butter (Special Diet Services, UK). After two 
weeks mice were anesthetized as previously described,20 and injected 
intravenously with 200 μl 20 U/ml heparin (Leo Pharma, Netherlands). 
Subsequently, 15 mice were inoculated with 5x105 C. pneumoniae infection 
forming units (IFU) in 10 μl sucrose-phosphate-glutamic acid (SPG) medium 
by instillation into the right common carotid artery via the external carotid 
artery.21 Carotids of 14 control mice were incubated with SPG medium. An 
additional group of mice (n=9) was incubated with 5x105 M. pneumoniae 
bacteria. Suspensions were left inside the common carotid artery for 60 
minutes and subsequently were aspirated from the common carotid artery. 
Thereafter, the external carotid artery was ligated to prevent blood loss.21 
Immediately after incubation atherosclerosis was induced by bilateral 
perivascular collar placement.20 Furthermore, 83 male LDLr-/- mice were 
locally incubated (40 mice with C. pneumoniae and 43 mice with SPG 
medium) without induction of atherosclerosis by collar placement. Twelve 
mice per time point were sacrificed at day 1, 2, 4, and 7 post infection for 
gene expression studies. Another 16 mice were sacrificed 7 days post 
infection for DNA isolation or immunohistochemistry and in the remaining 19 
animals acute thrombus formation was induced prior to their sacrifice at day 7 
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post infection. Acute thrombosis was induced in the right carotid artery by 
peri-arterial application of FeCl3 (40%) resulting in the formation of platelet 
and fibrin-rich thrombi, as previously described.22 A Doppler flow probe was 
used to measure blood flow. Time to occlusion was defined as the time after 
initiation of arterial injury with FeCl3, required for blood flow to decline to <0.2 
ml/min.  
 
Immunohistochemistry 
For immunohistochemistry carotid arteries were perfused and isolated as 
previously described.20 Transverse 5 μm cryosections, prepared in a proximal 
direction from the carotid bifurcation, were routinely stained with hematoxylin 
(Sigma Diagnostics, MO) and eosin (Merck Diagnostica, Germany). Each 
vessel was assessed ~0.5 mm proximal to the collar, and the site of maximal 
stenosis was used for morphometric assessment.20 Corresponding sections 
were stained immunohistochemically with antibodies against a macrophage-
specific antigen (MOMA-2, polyclonal rat IgG2b, diluted 1:50; Research 
Diagnostics Inc., NJ), alpha smooth muscle cell actin (monoclonal mouse 
IgG2a (clone 1A4), dilution 1:500; Sigma Diagnostics), and ICAM-1 
(monoclonal rat IgG2a (clone BSA2), dilution 1:200; R&D Systems, UK). 
Slides were incubated with primary antibodies for 2 hours at room 
temperature. As secondary antibodies goat anti mouse IgG peroxidase 
conjugate (dilution 1:500; Nordic, The Netherlands) and goat anti-rat IgG 
alkaline phosphatase conjugate (dilution 1:50; Sigma Diagnostics) were used 
(one hour of incubation at room temperature), with 3,3’-diamino-benzidine 
(Sigma Diagnostics), nitro blue tetrazolium (Sigma Diagnostics) and 5-bromo-
4-chloro-3-indolyl phosphate (Sigma Diagnostics) as enzyme substrates.20 
Sections were stained for collagen by a Picrosirius Red (Direct red 80) 
staining. Sections were analyzed using a Leica DM-RE microscope and 
LeicaQwin software (Leica Imaging Systems, UK). Contens of macrophages, 
smooth muscle cells, and collagen were obtained by dividing the area of 
specific staining within the intima by the total intima area. 
 
Detection of C. pneumoniae 
DNA was isolated from incubated carotid arteries, after perfusion with PBS, 
using a QIAamp DNA MiniKit (Westburg, Netherlands). For detection of C. 
pneumoniae DNA quantitative PCRs were performed on an ABI PRISM 7700 
machine (Applied Biosystems, CA) using primers for the outer membrane 
protein A (OMP A) gene (table 1), which is highly conserved within C. 
pneumoniae species,23 and probe 5’-AAACTTAACTGCATGGACCCTTCTTT 
ACTAGG-3' (FAM), (reverse primers; 300 nM, forward primers; 900 nM, and 
probes; 200 nM). PCR conditions were the same as used in the gene 
expression assays. Amounts of C. pneumoniae copies were obtained after 
performing regression analysis on a standard curve, which was created by 
performing PCRs under the same conditions on dilutions of plasmids 
containing the OMP A gene in the presence of representative amounts of 
DNA isolated from murine carotids.  
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Table 1. Primer sequences used in quantitative PCR. 
 
Cell Culture 
Murine macrophages (RAWs) and endothelial cells (H5Vs) were cultured in 
DMEM containing 10% Fetal Bovine Serum (FBS), 2 mmol/L L-glutamine, 
100 U/ml penicillin, and 100 μg/ml streptomycin (BioWhittaker Europe) in a 
humidified atmosphere (5% CO2) at 37°C. Prior to infection cells were 
transferred into 24-well plates (2.5x105 RAWs/well or 1.0x105 H5Vs/well) and 
incubated overnight. 
 
In vitro infection  
Cells were washed twice with DMEM containing 10% FBS and 2 mmol/L L-
glutamine and subsequently inoculated with C. pneumoniae with a m.o.i of 1. 
Mock infection was performed with SPG medium. Immediately after 
inoculation, plates were centrifuged for 60 minutes with 800xg at 37°C. After 
another 60 minutes of inoculation with C. pneumoniae, infected cells were 
washed twice and incubated for 0, 2, 4, 6, and 8 hours prior to total RNA 
isolation.    
  
Analysis of gene expression by real time quantitative PCR 
Total RNA was isolated from RAWs, H5Vs and carotid arteries using TRIzol 
reagent (Invitrogen, Netherlands) according to manufacturer's instructions. 
Two arteries were pooled resulting in n=3 per treatment per time point. 
Generation of cDNA, quantitative RT-PCR, calculations of ratios of target 
genes and the house hold gene, Hypoxanthine-guanine phosphoribosyl-
transferase (HPRT), and the design of primers (table 1) were performed as 
previously described.24  
 
Data analysis 
Values are expressed as mean±sem. A 2-tailed Student’s t-test was used to 
compare individual groups of mice or cells. Levels of p<0.05 were considered 
significant. 
 
 
Gene Forward primer (5’- ‘3) Reverse primer (5’- ‘3) 
E-selectin CCCTGCCCACGGTATCAG CCCTTCCACACAGTCAAACGT 
HPRT TTGCTCGAGATGTCATGAAGGA AGCAGGTCAGCAAAGAACTTATAG 
ICAM-1 GGACCACGGAGCCAATTTC CTCGGAGACATTAGAGAACAATGC 
IL-1β TGGTGTGTGACGTTCCCATTA AGGTGGAGAGCTTTCAGCTCATAT 
IL-6 GAAGAATTTCTAAAAGTCACTTT 
GAGATCTAC 
CACAGTGAGGAATGTCCACAAAC 
IL-12 AGTGAAAATGAAGCTCTGCATCC GATAGCCCATCACCCTGTTGA 
MCP-1 GCATCTGCCCTAAGGTCTTCA GCATCTGCCCTAAGGTCTTCA 
OMP A TCCGCATTGCTCAGCC AAACAATTTGCATGAAGTCTGAGAA 
TF TCCTGGCCACCATCTTTATCAT GCAGGCAGTGAGCGTTAG 
TNFα GCCAGCCGATGGGTTGTA AGGTTGACTTTCTCCTGGTATGAGA 
VCAM-1 ACAAAACGATCGCTCAAATCG CGCGTTTAGTGGGCTGTCTATC 
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Results 
 
Local incubation of the right common carotid artery with C. pneumoniae did 
not affect total serum cholesterol levels (Fig.1C). Successful infection of the 
arterial wall with C. pneumoniae was confirmed by quantitative RT-PCR on 
the OMP A gene of C. pneumoniae. Every artery incubated with C. 
pneumoniae was highly positive for the OMP A gene and on average, 
6.2x104 C. pneumoniae copies were detected in bacteria incubated carotid 
arteries 7 days post local incubation. C. pneumoniae DNA was absent in 
lungs, livers and spleens of C. pneumoniae incubated mice and in right 
carotid arteries of control incubated mice. 
 
Effect of C. pneumoniae presence in the vessel wall on atherosclerosis 
After positive identification of the presence of C. pneumoniae we determined 
the effect of C. pneumoniae on de novo atherosclerosis in carotid arteries of 
LDLr-/- mice. Five weeks after local incubation of carotid arteries and 
simultaneous collar placement we determined the degree of atherosclerosis. 
Incubation of the carotid artery with C. pneumoniae resulted in 1.87-fold 
increased neointima area (Fig.1A,B,D; 57,711±10,943 vs 30,891±9,997 μm2), 
which translated into markedly 2.03-fold increased intima/media ratios 
(Fig.1E; 1.27±0.23 vs 0.62±0.15, p<0.05) and a 1.74-fold increased degree of 
lumen stenosis (Fig.1F; 0.53±0.08 vs 0.30±0.07, p<0.05), as compared to 
SPG medium incubated arteries.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Five weeks after collar placement and simultaneous C. pneumoniae 
infection mice were sacrificed and carotid arteries were isolated for quantification of 
lesion formation. Representative cross-sections of collar induced plaques in carotid 
arteries of LDLr-/- mice are shown after incubation with C. pneumoniae (B) or SPG 
medium (A). During the experiment total serum cholesterol levels were monitored (C). 
Using computer assisted morphometric analysis we determined intima area (D), 
intima/media ratio (E), and intima/lumen ratio (F) after incubation with C. pneumoniae 
or SPG medium (*=p<0.05). 
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In comparison we performed similar experiments and incubated the carotid 
artery with M. pneumoniae. Incubation with M. pneumoniae did not affect the 
extent of atherosclerosis as compared to SPG medium incubated arteries, 
which was reflected by similar intima area, intima/media and intima/lumen 
ratios. 
Figure 2. Immunohistochemical analysis of plaques developed upon C. pneumoniae 
incubation (B,E,H) or control incubation (A,D,G). Increased MOMA-2 staining per 
intima area was observed in bacteria incubated arteries (A,B,C). Both ASMA (D,E) 
and Picrosirius Red staining (G,H) per intima area were diminished in bacteria 
incubated arteries as compared to controls (F,I, respectively) (**= p<0.01) 
 
Figure 3. Analysis of 
inflammatory effects 
of C. pneumoniae on 
the arterial wall. 
Seven days post 
incubation antibody 
staining showed that 
C. pneumoniae in 
the arterial wall 
increased ICAM-1 
expression (B, arrows) as compared to controls (A). Expression of MCP-1 in the 
arterial wall on mRNA level was increased markedly at day 2 and 4 after local 
incubation with C. pneumoniae (▲) as compared with control incubation (□). (C, **= 
p<0.01). 
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Plaque morphology 
The composition of collar induced lesions was determined by histological and 
immunohistochemical staining techniques. The increased lesion size in C. 
pneumoniae infected arteries was found to be largely attributable to a 
significant 2.98-fold increased macrophage content of the lesion, as 
determined by MOMA-2 staining (Fig.2C; 0.145±0.025 vs 0.048±0.020, 
p<0.01). The higher macrophage content was accompanied by a decrease in 
smooth muscle cells and collagen. In C. pneumoniae infected carotid arteries 
a tendency towards less staining for alpha-smooth muscle cell actin per 
intima area was observed as compared with control incubated carotid arteries 
(Fig.2F; 0.027±0.007 vs 0.064±0.031), which was in parallel with the lower 
collagen content after C. pneumoniae incubation (Fig.2I; 0.136±0.055 vs 
0.069±0.018). Again incubation with M. pneumoniae did not change the 
composition of the atherosclerotic plaques as compared to SPG medium 
incubated carotid arteries.  
 
Inflammatory effect on the vessel wall 
Since M. pneumoniae in no way affected the size or composition of the 
plaque we subsequently focused on the effect of the presence of C. 
pneumoniae  on the expression of inflammatory markers in the vessel wall 
both at mRNA and protein level in LDLr-/- mice without induction of 
atherosclerosis. The presence of C. pneumoniae in the vessel wall after local 
incubation resulted seven days later in a marked increase in ICAM-1 
expression at protein level. Increased ICAM-1 staining was mainly located at 
the endothelial cell layer (Fig.3A,B). Furthermore, at day 2 and 4 after local 
incubation with C. pneumoniae mRNA levels of MCP-1 in C. pneumoniae 
incubated carotids appeared to be significantly elevated 4.64- (p<0.01) and 
6.79-fold (p<0.01), respectively (Fig.3C), whereas no changes in mRNA 
levels for ICAM-1, VCAM-1, E-selectin, IL-6, IL-12, and Tissue Factor (TF) 
were observed. 
 
Effect of C. pneumoniae on acute arterial thrombosis 
The effect of C. pneumoniae in the vessel wall on the thrombogenicity of the 
carotid artery was assessed using a FeCl3-induced acute arterial thrombosis 
model. Seven days after infection of the carotid artery with C. pneumoniae no 
significant differences in time to occlusion after thrombus induction were 
observed between SPG medium and bacteria incubated arteries (1001±138 
vs 1147±164 sec, respectively). 
 
In vitro effect of C. pneumoniae on macrophages and endothelial cells 
To further elucidate by which mechanisms C. pneumoniae is capable of 
stimulating atherogenesis, effects of C. pneumoniae on different cell types, 
present in the vessel wall, such as ECs and macrophages were evaluated at 
mRNA level. The initial level of expression was measured at t=0 hrs post 
infection, which represents the time point immediately after 1 hour of 
centrifugation plus 1 hour of incubation with C. pneumoniae. Infection of 
H5Vs with C. pneumoniae showed an inflammatory response, reflected in  
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Figure 4. Effects of C. pneumoniae on H5Vs (A-F) or RAWs (G,H). Cells were 
incubated with C. pneumoniae (▲) or SPG medium (□) for 2 hours, including 1 hour of 
centrifugation at 800xg. Subsequently, cells were washed and incubated with medium 
prior to RNA isolation at indicated timepoints. Quantitative RT-PCR revealed that 
expression levels of several adhesion molecules, such as ICAM-1, VCAM-1, and E-
selectin were markedly elevated upon infection of H5Vs (A-C). Infection of H5Vs also 
caused an upregulation of MCP-1, TNF-α and IL-6 (D-F). Expression levels of MCP-1 
and TNF-α were also elevated in RAWs upon infection with C. pneumoniae (*= 
p<0.05, **= p<0.01). 
 
 
increased mRNA levels for MCP-1, for a number of adhesion molecules (E-
selectin, ICAM-1, and VCAM-1) and for the cytokines TNF-α and IL-6. Peak 
values were observed at 2-6 hrs post infection (Fig.4A-F). At 8 hrs post 
infection differences in expression levels between control and infected cells 
were smaller, while cell viability did not change. In RAWs, TNF-α and MCP-1 
expression levels were elevated upon infection (Fig.4G,H) and reached a 
maximum within the first hour, which was earlier than in H5Vs. 
 
 
Discussion 
 
In the present study, we investigated how direct infection of the vessel wall 
with C. pneumoniae affects atherosclerosis and thrombogenicity of the 
carotid artery. Although many groups have studied effects of lung infection 
with C. pneumoniae on atherosclerosis, little is known about the direct effect 
of C. pneumoniae in the vessel wall on this inflammatory process. Local 
administration of C. pneumoniae in coronary arteries of pigs or rabbits has 
been reported,25,26 but was never performed in atherosclerosis prone mice. 
Therefore, we established a novel model in which C. pneumoniae is delivered 
from the luminal side of the carotid artery to the vessel wall. This model 
mimics the delivery of C. pneumoniae to the arterial wall by infected 
monocytes and subsequent infection of arterial wall cells by C. pneumoniae 
after proliferation within macrophages. Using this model we can be sure that  
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the arterial wall is infected. Therefore, this model may be preferred to study 
the in vivo effect of C. pneumoniae on the arterial wall, since in previous 
publications effects of C. pneumoniae on atherosclerosis via airway infection 
were not always accompanied by the positive identification of C. pneumoniae 
in the arterial wall. The fact that infection via the respiratory tract does not per 
se lead to positive infection of the arterial wall with C. pneumoniae may 
explain some of the conflicting results on the effects of C. pneumoniae in 
atherosclerosis prone mice. Furthermore, this local incubation model offers 
the opportunity to study the role of C. pneumoniae in the arterial wall without 
interference of indirect effects, such as effects on lipid metabolism or on 
systemic inflammation. 
By means of local intra-vascular incubation with C. pneumoniae in the 
common carotid artery it is possible to introduce these bacteria in the vessel 
wall, which was confirmed by detecting the C. pneumoniae specific Omp A 
gene in the vessel wall 7 days after incubation in all C. pneumoniae 
incubated arteries. This detection method circumvents the problems that are 
met when using immunohistochemistry, in which antigens may be missed 
while cutting sections or when cross-reactivity with non-chlamydial plaque 
constituents may occur.27 In addition, by detecting C. pneumoniae specific 
DNA it is possible to quantify the number of bacteria that infected the arterial 
wall. While C. pneumoniae was detected in high amounts in the arterial wall 
of incubated arteries, these bacteria were not detected in the lungs, liver and 
spleen of the mice that were locally incubated with C. pneumoniae, indicating 
the lack of systemic infection upon local incubation. Since ECs form the first 
barrier that has to be past and C. pneumoniae is able to infect these cells, 
both in vivo and in vitro, and replicate inside ECs,28,29 entrance of the 
elementary bodies seems to occur via infection of ECs. Although this model 
not entirely mimics the physiological situation, in which bacteria are 
presumed to enter the vessel wall primarily while residing in monocytes and 
in which relatively less C. pneumoniae is found in the atherosclerotic plaque, 
it offers the opportunity to study effects of the actual presence of C. 
pneumoniae in the vessel wall.  
With this local incubation model we demonstrate that C. pneumoniae in the 
vessel wall enhances collar-induced atherosclerosis in carotid arteries of 
LDLr-/- mice. Larger lesions were observed in bacteria incubated arteries, 
which translated into significant larger intima/media and intima/lumen ratios. 
These results indicate that presence of C. pneumoniae in the arterial wall 
creates inflammatory stimuli that enhance atherosclerosis and that systemic 
inflammation as induced by airway infection with C. pneumoniae is not a 
necessary stimulation for atherosclerosis development. In contrast, infection 
of the carotid artery with M. pneumoniae, a mild respiratory pathogen that 
has also been implicated in atherosclerosis, did not affect the size and 
composition of the atherosclerotic lesions in LDLr-/- mice. 
In order to further evaluate the role of C. pneumoniae in different processes 
involved in atherosclerosis, lesion composition was elucidated by 
immunohistochemistry. Although larger lesions usually contain relatively less 
macrophages than smaller lesions, in this experiment the larger lesions in the 
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bacteria incubated group contained relatively more macrophages. Presence 
of mononuclear infiltrates in vascular tissue upon infection with C. 
pneumoniae was studied previously. However, the outcome of these studies 
was not univocal.30-33 The higher macrophage content observed after C. 
pneumoniae infection is in line with our in vitro and in vivo data, which 
showed elevated expression levels of ICAM-1 and MCP-1 upon infection, 
which can result in increased adherence of circulating monocytes to the 
endothelium and attraction of these cells into the intima. Furthermore, the 
finding that C. pneumoniae infection of monocytes can rescue these cells 
from apoptosis can also contribute to the increased macrophage content.34 
Lesions developed after C. pneumoniae incubation showed a tendency 
towards decreased α-actin and Picrosirius Red staining, which is indicative 
for reduced numbers of VSMCs and reduced collagen content, respectively. 
In vitro studies have shown that proliferation of SMCs can be stimulated by 
C. pneumoniae both directly and indirectly.35,36 However, conditioned medium 
from C. pneumoniae infected SMCs inhibits proliferation of SMCs through 
induction of prostaglandin E2.37 The sum of the in vitro C. pneumoniae 
induced effects is not well documented in vivo. Distinct observations have 
been reported in which both stimulatory and inhibiting actions of C. 
pneumoniae on SMCs proliferation were suggested.38,39,25 Our study makes a 
net stimulatory effect of C. pneumoniae on SMCs in vivo less likely. Since 
collagen is mainly produced by the VSMCs in atherosclerotic lesions, the 
observed trend in the amount of collagen in the C. pneumoniae incubated 
carotids fits with the decreased amount of SMCs observed in the 
atherosclerotic lesions. Several groups have reported that upon infection with 
C. pneumoniae both macrophages and SMCs produce MMPs,40,14 which are 
able to degrade collagen. Previously, enhanced MMP-2 and MMP-9 
production was observed in atherosclerotic lesions upon infection with C. 
pneumoniae in LDLr/ApoE double knock out mice.39 This lesion morphology 
with more macrophages and the lack of compensatory elevated amounts of 
VSMCs and collagen points to a net destabilizing effect of C. pneumoniae.  
Presence of C. pneumoniae in the vessel wall resulted in enhanced 
expression of MCP-1 at mRNA level. It remained unclear from these 
experiments to which cell types this increased expression can be contributed. 
However, since both ECs, macrophages and VSMCs41 in vitro show elevated 
expression of MCP-1 upon infection with C. pneumoniae they can be all 
involved in this response. Immunohistochemistry revealed increased ICAM-1 
protein expression mainly on ECs, which, combined with the found elevated 
MCP-1 expression level, could contribute to the increased macrophage 
content, as observed in infected lesions. The lack of increased expression of 
ICAM-1 at mRNA level could be explained by the fact that expression levels 
at mRNA level were not specifically measured in the endothelium, but in the 
total vessel wall, which may dilute the ICAM-1 signal. 
In vitro studies have shown that C. pneumoniae increases the expression of 
the pro-coagulant proteins TF and plasminogen activator inhibitor-1 in ECs, 
SMCs and macrophages,42,43 and accelerates clotting and phosphatidylserine 
exposure in several cell types.44 However, in our in vivo model, in which 
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acute thrombus formation was induced by peri-arterial application of FeCl3, 
no pro-thrombotic effect was observed 7 days after delivery of C. 
pneumoniae to the arterial wall. In addition, no upregulation of mRNA levels 
for TF were detected in the vessel wall during the first week after delivery of 
C. pneumoniae. These data suggest that previously shown in vitro indications 
for increased thrombogenicity upon infection with C. pneumoniae may be 
compensated by antithrombotic actions of C. pneumoniae in vivo, such as 
induction of the anti-thrombotic cytokine IL-10,34,45 resulting in the absence of 
a significant effect of C. pneumoniae in the vessel wall on thrombogenicity. 
In vitro infections of mouse ECs and macrophages with C. pneumoniae were 
performed to support the results observed in vivo. As demonstrated 
previously, infection of ECs induced an inflammatory response marked by 
elevated mRNA levels of IL-6, TNF-α, E-selectin, ICAM-1, and VCAM-1. 
Combined with the elevated MCP-1 expression in both macrophages and 
ECs, these data suggest that C. pneumoniae promotes monocyte adhesion 
and migration to the inner layers of the vessel wall, which is in accordance 
with the in vivo results.  
In conclusion, this study demonstrates that direct infection of the carotid 
artery with C. pneumoniae enhances atherosclerosis in a novel model. C. 
pneumoniae affects the composition of the developing lesions towards a 
more vulnerable morphology via an increase in macrophage content, which 
was not observed after infection of the carotid artery with M. pneumoniae. 
Therefore, this study supports the specific contribution of C. pneumoniae to 
the progression of atherosclerosis. Enhanced macrophage content caused 
the major increase in lesion formation, and chemokines contributed to this 
increase. This local delivery model offers the opportunity to further elucidate 
the site-specific influences of C. pneumoniae on atherosclerosis. 
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Abstract 
 
Interleukin 17 (IL-17) is a T cell-derived pro-inflammatory cytokine that has 
been linked to several autoimmune diseases. IL-17 exhibits pleiotropic effects 
on atheroma-associated cell types and induces the secretion of pro-
inflammatory cytokines, chemokines and matrix metalloproteinases, which 
enhances the inflammatory response in atherosclerotic lesions. In the present 
study we aimed to study the effect of IL-17 blockade by vaccination on the 
initiation of atherosclerosis. A plasmid (pcDNA3.1) encoding IL-17 and the 
dominant T helper cell epitope HEL was used to vaccinate LDL receptor 
deficient mice prior to induction of atherosclerosis by feeding a Western type 
diet and collar placement. Successful functional blockade of IL-17 upon 
vaccination was shown by reduced induction of serum IL-6 levels after 
administration of IL-17. DNA vaccination by intramuscular injection of the 
HEL-IL-17 plasmid or by oral administration of S. typhimurium transformed 
with this plasmid resulted in a decrease in atherosclerosis of 90% and 75%, 
respectively. Oral vaccination of LDLr-/- mice with S. typhimurium transformed 
with an IL-17 plasmid without the HEL sequence did not affect 
atherosclerosis. We conclude that effective interruption of the IL-17 pathway 
by DNA vaccination depended on the presence of the HEL epitope in the IL-
17 DNA vaccine. Effective blockade of IL-17 by DNA vaccination resulted in a 
vast decrease in atherosclerosis and it may be speculated that IL-17 
production by the newly identified IL-17 memory cells form a major target for 
IL-17 vaccination. 
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Introduction 
 
Atherosclerosis is the leading cause of mortality in the Western world and 
atherosclerotic lesion initiation and progression has been shown to depend 
on persistent and chronic inflammation of the arterial wall.1,2 Already in the 
early stages of atherogenesis macrophages and T cells are present in the 
intima and play a crucial role in the development and progression of the 
atherosclerotic plaque.1,3,4 Atherosclerosis is considered to be a T helper (Th) 
cell driven immunopathological condition in which a disturbed balance of 
differentiation of naive CD4+ T cells into either Th1 or Th2 cells plays a 
prominent role. Th1 cells predominate in atherosclerosis and create a pro-
inflammatory environment within the plaque by secreting cytokines and 
chemokines, resulting in enhanced recruitment and activation of other 
inflammatory cells.5,6 
An important pro-inflammatory cytokine is interleukin (IL)-17, which already 
has been shown to be involved in (auto)immune diseases.7-9 IL-17 is a mainly 
T cell-derived pro-inflammatory cytokine and it exhibits pleiotropic biological 
actions on the various atheroma-associated cell types, such as endothelial 
cells, vascular smooth muscle cells, and macrophages.10-12 IL-17 activates 
these cells and induces the secretion of pro-inflammatory cytokines and 
chemokines including IL-6, IL-8, and monocyte chemoattractant protein 1 
(MCP-1).10 IL-17 also acts synergistically with other cytokines including tumor 
necrosis factor (TNF)-α and IL-1, creating an even more pro-inflammatory 
microenvironment.10-12 Furthermore, the IL-17 pathway is also involved in the 
production of matrix metalloproteinases (MMPs)  3, 9 and 13, thereby 
possibly interfering with plaque stability.13  
Although IL-17 is produced by activated T cells, previous reports have not 
provided clear classification of IL-17 within the paradigm of Th1 and Th2 
polarized cytokine profiles.14  
However, recently a new subset of T helper cells with a T memory cell 
phenotype has been identified and these cells may form a major source of IL-
17 in several (auto)immune diseases.15 
The development of these IL-17 expressing memory T cells from naïve CD4+ 
T cells is mainly driven by IL-23 in the presence of a specific antigen and is 
distinct from Th1/Th2 development.16 Th1 and Th2 cytokines, such as IFN-γ 
and IL-4 respectively, inhibit the IL-17 expressing memory T cell 
development, but fully differentiated IL-17 expressing memory T cells show a 
stable phenotype and are not responsive anymore to IFN-γ and IL-4.17 These 
IL-23 dependent IL-17 producing T memory cells have already been 
identified in several autoimmune diseases, such as Experimental 
Autoimmune Encephalomyelitis (EAE) and rheumatoid arthritis and a 
possible role may be anticipated in atherosclerosis.7,18 In this study we 
vaccinated against IL-17 using a novel DNA vaccination technique to block 
endogenous IL-17 and determine the effect of IL-17 in the process of 
atherogenesis. To break T cell tolerance for IL-17 a specific immunodominant 
T helper cell epitope was used.19 This epitope, which is derived from the hen 
egg-white lysozyme (HEL), enables a polyclonal antibody response against 
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the self-antigen. This approach has been proven successful with protein 
vaccination against TNF-α.20 We show in this study that two different 
vaccination protocols, the first using an i.m. injection of the naked HEL-IL-17 
plasmid and the second using an oral administration of attenuated 
Salmonella typhimurium (S. typhimurium), transformed with the HEL-IL-17 
plasmid both establish a strong protection against atherosclerosis, indicating 
that vaccination against IL-17 may contribute to the development of novel 
therapies against atherosclerosis. 
 
 
Methods 
 
Vaccine preparation  
Plasmids for vaccination were cloned into pcDNA3.1(-) (Invitrogen, The 
Netherlands) with a CMV promoter for expression in eukaryotic cells. cDNA 
coding for murine IL-17  was obtained by PCR on stimulated murine spleen 
cells. The following primers were used: forward primer 5’- GAT CAG GAC 
GCG CAA ACA- 3’, reverse primer 5’- GGGTTTCTTAGGGGTCAG- 3’. The 
IL-17 PCR product was cloned into pcDNA3.1(-). The HEL sequence was 
derived from the amino acid sequence 81-95 of hen egg lysozyme and was 
cloned upstream of IL-17.21 The following sequences were used: upper 
strand, 5'- CTA GAA TGT CAG CCC TGC TGA GCT CAG ACA TAA CAG 
CGA GCG TGA ACT GCG CGC CT- 3' lower strand 5'- CTA GAG GCG CGC 
AGT TCA CGC TCG CTG TTA TGT CTG AGC TCA GCA GGG CTG ACA 
TT- 3'. Expression of constructs was tested by transient transfection of COS7 
cells with the plasmid.  
 
Transient transfection 
COS7 cells were transfected with pcDNA3.1-HEL-IL-17 and pcDNA3.1 using 
Exgen500 according to manufacturer’s protocol (Fermentas, Germany). 
Supernatant was collected 24 and 48 hours after transfection. Expression of 
IL-17 was determined with a specific murine IL-17 ELISA according to 
manufacturer’s protocol (BD Bioscience, The Netherlands). 
  
Vaccination 
All animal work was carried out in compliance with the guidelines issued by 
the Dutch government. For intramuscular vaccination male low-density 
lipoprotein receptor deficient mice (LDLr-/-), 10-12 weeks old, were used. 
Three days prior to first vaccination mice received a bilateral Cardiotoxin I 
(Sigma, USA) i.m. injection, 10 μM, 50 μl per muscle. Mice were vaccinated 
by three bilateral i.m. injections of 100 μg plasmid in 100 μl PBS, 50 μl per 
muscle, with two-week intervals.  
For the S. typhimurium vaccination, LDLr-/- mice were pretreated 10 minutes 
before each vaccination with 100 μl of 7.5% sodium bicarbonate (CHNaO3) 
by oral gavage. Hereafter mice were immunized three times at two-week 
intervals with 100 µl PBS containing 1.108 attenuated S. typhimurium 
harboring empty plasmid or HEL-IL-17 plasmid, by oral gavage. In a second 
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experiment mice were treated in the same manner but in this experiment 
mice received attenuated S. typhimurium, transformed with the IL-17 plasmid 
or with empty plasmid without the HEL sequence. In these two groups of 
mice atherosclerotic lesions were analyzed at the site of the semilunar valves 
in the aortic root.  
Immediately after the last vaccination mice were put on a Western type diet, 
containing 0.25% cholesterol and 15% cocoa butter (Special Diet Services, 
UK). After two weeks of Western type diet feeding, atherosclerosis was 
induced in carotid arteries by bilateral perivascular collar placement, as 
described previously.22 During the experiment plasma samples were obtained 
by tail vein bleeding.  
To confirm the functional blockade of IL-17 after vaccination, we performed 
an experiment in which we made use of the fact that IL-17 is able to induce 
IL-6 production. In a separate experiment, LDLr-/- mice were vaccinated 
against IL-17 or control vaccinated. Three days after the last injection of the 
vaccine 200 ng mouse IL-17 (Biosource, The Netherlands) in 200 μl PBS was 
injected intravenously. Four hours after the injection of IL-17 blood was 
collected for quantification of serum IL-6 levels by a mouse IL-6 ELISA 
(eBioscience, The Netherlands).    
 
Tissue harvesting 
Six weeks after collar placement, carotid arteries were obtained after in situ 
perfusion for 15 minutes using PBS. Carotids were embedded in OCT 
compound (Sakura Finetek, The Netherlands), snap-frozen in liquid nitrogen 
and stored at -20°C until further use. Transverse 5 μm cryosections were 
prepared in a proximal direction from the carotid bifurcation and were 
mounted on a parallel series of slides. For analysis of atherosclerosis at the 
site of the aortic semilunar valves 10 µm transverse cryosections were made 
of the aortic root as previously described.22,23 
 
Histological analysis and morphometry 
Cryosections were routinely stained with hematoxylin (Sigma Diagnostics, 
MO) and eosin (Merck Diagnostica, Germany). Corresponding sections were 
stained for lipids by Oil red O staining. Hematoxylin-eosin stained sections of 
right carotid arteries were used for morphometric analysis of atherosclerotic 
lesions. Each vessel was assessed ~0.5 mm proximal to the collar, and the 
site of maximal stenosis was used for morphometric assessment. 
Atherosclerosis in the aortic root was quantified with Oil red O stained 
sections of plaques developed in the region of the aortic semilunar valves, as 
previously described.23  
 
Data analysis 
Values are expressed as mean±SEM. A Mann-Whitney test was performed to 
compare individual groups of mice. A level of p<0.05 was considered 
significant. 
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Results 
 
In vitro expression of HEL-IL-17 
In vitro experiments were performed to determine the expression and 
functionality of the used construct. COS7 cells were transfected with the 
HEL-IL-17 plasmid and the supernatant was collected after 24 and 48 hours 
of incubation. Twenty-four hours after transfection the HEL-IL-17 protein was 
detectable in the supernatant of the COS7 cells using an IL-17 ELISA. At 48 
hours the concentration of HEL-IL-17 protein in the supernatant was almost 
doubled (Fig.1). Cells transfected with the empty pcDNA3.1 plasmid or 
control treated cells showed no expression of IL-17 (Fig.1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Relative expression of HEL-IL-17 of transfected COS7 cells. 
Culture supernatant was colleted 24 or 48 hours after transfection with either 
HEL-IL-17 construct, an empty plasmid or PBS. IL-17 was determined using 
an mouse IL-17 specific ELISA. The optical density was measured with a 
wavelength of 450 nm. *p< 0.05; **p<0.01. 
 
Effect of vaccination against IL-17 on IL-17 induced IL-6 levels 
To determine whether functional blockade of IL-17 was established by 
vaccination, male LDLr-/- mice were vaccinated against IL-17 or control 
vaccinated. Three days after the last i.m. injection of the vaccine mouse IL-17 
was administered intravenously and 4 hours thereafter blood was collected 
for quantification of serum IL-6 levels. Upon administration of IL-17 the serum 
concentration of IL-6 was significantly reduced by 31% in the anti-IL-17 
vaccinated mice as compared to the control vaccinated mice, indicating the 
impaired functional activity of IL-17 by vaccination (Fig.2). 
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Figure 2. Serum IL-6 concentration 4 hours after 
administration of IL-17 to mice that were either 
vaccinated against IL-17 or control vaccinated. 
Induction of IL-6 by IL-17 was significantly 
impaired by 31% after vaccination against IL-17 
as compared to IL-6 levels in control vaccinated 
mice. *p<0.05. 
 
 
 
 
 
Effect of IL-17 vaccination on atherogenesis 
To study the effect of IL-17 vaccination on de novo plaque formation we used 
LDLr-/- mice fed a Western type diet. The first group of mice was vaccinated 
three times intramuscularly at a two-week time interval with the naked HEL-
IL-17 plasmid after pre-treatment of the mice with cardiotoxin. The second 
group of mice was vaccinated three times orally at a two-week time interval 
with attenuated S. typhimurium, transformed with the HEL-IL-17 plasmid. For 
both vaccination protocols control groups of mice were vaccinated with the 
same plasmid without the HEL-IL-17 encoding region. After the last DNA 
vaccination the LDLr-/- mice were fed a Western type diet (0.25% cholesterol) 
followed two weeks later by perivascular carotid collar placement to induce 
atherosclerosis. Both types of anti-IL-17 vaccinations did not affect serum 
cholesterol levels and similar cholesterol levels were observed in anti-IL-17 
vaccinated and control vaccinated mice (Fig.3).  
 
Figure 3. Mice were vaccinated 
by i.m. injection of HEL-IL-17 
plasmid or empty plasmid (left 
panel) or by administration of 
attenuated S. typhimurium (S.t.) 
transformed with HEL-IL-17 
plasmid or empty plasmid (right 
panel). Subsequently mice were 
put on a Western type diet and 
two weeks later equipped with a perivascular collar. At the indicated time points 
cholesterol levels were determined in the various groups of mice. 
 
Six weeks after collar placement mice were sacrificed and the plaque size 
proximal of the collar was quantified in HE stained sections. Intramuscular 
vaccination with naked HEL-IL-17 plasmid significantly reduced the formation 
of atherosclerotic lesions by 90.2%, indicating that atherosclerosis in the IL-
17 vaccinated group was almost completely blocked (Fig.4).  
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Figure 4. Mice were vaccinated by intramuscular injection (I.M.) of HEL-IL-17 plasmid 
(n=9) or empty plasmid (n=8) (upper panel) or by administration of attenuated S. 
typhimurium (S.t.) transformed with HEL-IL-17 plasmid (n=8) or empty plasmid (n=7) 
(lower panel). Subsequently mice were put on a Western type diet and two weeks 
later equipped with a perivascular collar. Six weeks after collar placement mice were 
sacrificed and the degree of atherosclerosis was determined. *p<0.05, **p<0.01. 
 
Oral vaccination of LDLr-/- mice with the HEL-IL-17 plasmid carried by the 
attenuated S. typhimurium strain also resulted in a significant 75.3% 
decrease in atherosclerosis in the carotid artery, but the inhibition of 
atherosclerosis was less than that obtained with the intramuscular 
vaccination (Fig.4). 
 
Figure 5. Mice were vaccinated by administration 
of attenuated S. typhimurium transformed with IL-
17 plasmid (without HEL sequence) or empty 
plasmid (n=9). Subsequently mice were put on a 
Western type diet and eight weeks later mice were 
sacrificed and the degree of atherosclerosis was 
determined at the site of the semilunar aortic 
valves. 
 
 
 
In contrast, vaccination with attenuated S. typhimurium transformed with the 
IL-17 plasmid without the HEL sequence did not result in a significant 
difference in the degree of atherosclerosis as determined in the aortic valve 
region (Fig.5). 
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Discussion 
 
Atherogenesis is an autoimmune-like inflammatory process in the context of 
high plasma cholesterol levels and a high expression of pro-inflammatory 
cytokines plays an important role in the initiation and progression of 
atherosclerosis. This disturbed cytokine profile contributes largely to the 
pathological condition that is observed in a number of autoimmune diseases. 
CD4 positive T helper cells play an essential role in the development of 
immune responses and the two types of helper cells, Th1 and Th2 cells, 
secrete pro-inflammatory and anti-inflammatory, respectively. Atherogenesis 
results from an exaggerated pro-inflammatory response due to an enhanced 
development of Th1 cells and blockade of pro-inflammatory cytokines by 
vaccination may form a new therapy for atherosclerosis. We showed recently 
that vaccination against the prominent Th1 cytokine IL-12 reduces 
atherosclerosis in LDLr-/- mice.24 Along this line we argued that the blockade 
of IL-17 may improve atherosclerosis and developed a DNA vaccine against 
IL-17 and studied the effect of anti-IL-17 vaccination on atherogenesis. One 
of the sources of IL-17 is a recently described T cell subset, the IL-17 
producing T memory cell that has been identified in various autoimmune 
diseases.15 These IL-17 producing cells are regulated independently of 
Th1/Th2 cytokines but are dependent on the pro-inflammatory cytokines IL-
23 and IL-15 and the presence of a specific antigen for their maturation.15 IL-
17 produced by these cells may have pleiotropic effects on several cell types 
within the atherosclerotic lesion and may stimulate a pro-inflammatory 
environment.  
For the vaccination against IL-17 we cloned murine IL-17 into a pcDNA3.1 
preceded by a specific immunodominant T-helper epitope to break T cell 
tolerance. To determine the expression of IL-17 upon transfection with the 
HEL-IL-17 plasmid we transiently transfected COS cells. We detected 
relatively high concentrations of IL-17 in the supernatant of the transfected 
cells using an ELISA specific for murine IL-17, indicating that the HEL peptide 
did not interfere with the excretion of the protein into the medium, which is 
important for the vaccination procedure. 
Subsequently we vaccinated LDLr-/- mice three times at a two-week interval 
by an intramuscular injection of the HEL-IL-17 plasmid or by an oral 
administration of attenuated S.typhimurium transfected with the same 
plasmid. The intramuscular vaccination of naked DNA was preceded by 
treatment of the hind leg muscles with cardiotoxin I, which induces a mild 
skeletal muscle necrosis and subsequently an inflammatory environment that 
improves the outcome of DNA vaccinations.25 In the present study we show 
that the function of IL-17 is blocked by vaccination against IL-17. 
Administration of IL-17 led to significant reduced induction of serum IL-6 
levels in the anti-IL-17 vaccinated group as compared to the control group. 
The S. typhimurium approach has so far been successfully applied in our 
laboratory to generate a cytotoxic response mediated by CD8 positive T cells 
that recognize cells overexpressing the gene encoded by the plasmid with 
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which the S.typhimurium was transformed.26 So far this route of vaccination 
has not been used to vaccinate against soluble factors, although unpublished 
results from our laboratory show that using the same vaccination protocol 
and anti-IL-15 vaccination resulted in a mild increase in the level of anti-IL-15 
antibodies.27  
After three vaccinations and six weeks after induction of atherosclerosis by 
collar placement the mice were sacrificed and the carotid artery was removed 
and analyzed. During the experiment no effect of either vaccination protocol 
on plasma cholesterol levels was observed. Within the intramuscular 
vaccinated group a highly significant reduction in atherosclerosis of 90% was 
observed as compared to the control group (p=0.0055), while a reduction of 
75 % in plaque size observed within the S.typhimurium group (p=0.014). 
Interestingly we observed that vaccination using the attenuated S. 
typhimurium transformed with an IL-17 plasmid lacking the HEL sequence did 
not result in an attenuation of atherosclerosis, which indicates that the 
introduction of the HEL sequence is essential for breaking the self tolerance 
against IL-17 and therefore essential for the success of the anti-IL-17 
vaccination. Previous studies on the vaccination against TNF-alpha, IL-9 and 
IL-12 indicated that the presence of a HEL sequence or a comparable T cell 
epitope is necessary for the induction of antibodies against self cytokines.   
Interruption of the IL-17 pathway resulted in an even larger reduction in 
atherosclerosis than after blockade of IL-12/IL-23 or IL-15 by vaccination.24,27 
It is interesting that these two cytokines are involved in the induction of the 
so-called IL-17 memory cells and we may speculate that the production of Il-
17 by these memory cells may be of great importance in the development of 
atherosclerosis.  
Next to the initiation of atherosclerosis, IL-17 may induce a more vulnerable 
plaque phenotype since IL-17 induces the expression of matrix 
metalloproteinases in macrophages and smooth muscle cells and it may be 
expected that anti-IL-17 vaccination may improve the stability of the plaque. 
The plaques we observed after vaccination were however too small to 
reliably determine the effect of anti-IL-17 vaccination on plaque stability. 
Future experiment on anti-IL-17 vaccination in mice with pre-existing lesions 
will therefore be needed to determine the effect of interruption of the IL-17 
pathway on plaque stability. The fact that a bone marrow transplantation from 
IL-17 receptor deficient mice into LDLr-/- mice inhibited atherosclerosis by 
50% indicates that the response of macrophages to IL-17 contributes 
significantly to the initiation of atherosclerosis.28 Besides the induction of 
MMP’s in macrophages the induction of IL-8 and TNF-α in macrophages by 
IL-17 may contribute to the development of the plaque. 
Since IL-17 independent of IL-12 and INF-gamma plays a role in the early 
host defense against different gram-negative bacteria and fungi, we have to 
determine whether the anti-IL-17 vaccination results in an increased risk of 
infection.29,30  
We conclude that anti-IL-17 vaccination using the HEL-IL-17 plasmid results 
in a significant inhibition of the initiation of atherosclerosis and future 
experiments will have to be performed whether the anti-IL-17 resulted in 
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lower numbers of IL-17 producing T helper memory cells or the effect of IL-17 
was directly blocked within the atherosclerotic lesions. 
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Abstract 
 
Interleukin 12 (IL-12) has been identified as a key inducer of a type 1 T 
helper cell cytokine pattern, which is thought to contribute to the development 
of atherosclerosis. We aimed to study the role of IL-12 in atherosclerosis by 
inhibition of IL-12 using a newly developed vaccination technique that fully 
blocks the action of IL-12. LDLr-/- mice were vaccinated against IL-12 by five 
intra-muscular injections of IL-12-PADRE complex in combination with 
adjuvant o/w emulsion (low dose)/MPL/QS21 every two weeks. Two weeks 
thereafter atherogenesis was initiated in the carotid artery by perivascular 
placement of silastic collars. IL-12 vaccination resulted in the induction of 
anti-IL-12 antibodies that functionally blocked the action of IL-12 as 
determined in an IL-12 bioassay. Blockade of IL-12 by vaccination of LDLr-/- 
mice resulted in significantly reduced (68.5%, p<0.01) atherogenesis as 
compared to control mice, without changing serum cholesterol levels. IL-12 
vaccination also resulted in a significant decrease in intima/media ratios 
(66.7%, p<0.01) and in the degree of stenosis (57.8%, p<0.01). Upon IL-12 
vaccination, smooth muscle cell and collagen content in the neointima 
increased 4.2- (p<0.01) and 2.8-fold (p<0.01), respectively. In conclusion, 
functional blockade of endogenous IL-12 by vaccination resulted in a 
significant 68.5% reduction in atherogenesis in LDLr-/- mice. Vaccination 
against IL-12 also improved plaque stability, from which we conclude that the 
blockade of IL-12 by vaccination may be considered to be a promising, new 
strategy in the treatment of atherosclerosis. 
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Chapter 5 
Introduction 
 
Atherosclerosis is an inflammatory disease, which is driven by a disturbed 
balance in the differentiation of naïve CD4+ T-lymphocytes towards either T-
helper 1 (Th1) or Th2 lymphocytes and the cytokines produced by these 
cells.1-3 In a number of autoimmune diseases, such as Crohn’s disease, 
arthritis, and also atherosclerosis, Th1 cells predominate over Th2 cells4-6, 
which leads to an excess of pro-inflammatory cytokines, such as interferon 
(IFN)-γ and interleukin (IL)-2, produced by Th1 lymphocytes. These cytokines 
regulate cell-mediated immunity and can activate macrophages, which is an 
important hallmark of atherosclerosis.1 During atherosclerosis, Th2 cells are 
less abundant and production of anti-inflammatory, atheroprotective 
cytokines such as IL-10 by these cells is too low to prevent plaque 
formation.7-9 Diminished differentiation of T-helper lymphocytes towards the 
Th1 phenotype and promotion of Th2 lymphocyte differentiation by 
administration of pentoxifylline has been shown to attenuate 
atherosclerosis.10 
The immunoregulatory cytokine IL-12 favours the development of a 
proatherosclerotic Th1 cell phenotype.11-13 IL-12 is a heterodimeric (p70) 
cytokine, which consists of a 35 kD light chain  (p35) and a 40 kD heavy 
chain (p40). IL-12 is produced by various cell types such as monocytes, 
neutrophils, dendritic cells, and macrophages upon activation of these cells 
by pathogens, by CD40 ligand expressing T-cells or by extracellular matrix 
components, such as the glycosaminoglycan hyaluronan.14 Due to its early 
production in response to these stimuli and its ability to enhance Th1 cell 
differentiation, IL-12 forms a bridge between the innate and adaptive 
immunity. Furthermore, IL-12, particularly in combination with IL-18, is a 
potent inducer of the production of the proinflammatory cytokine IFN-γ15, 
which has aggravating effects on atherosclerosis.16 
Data on the involvement of IL-12 in atherosclerosis are accumulating. 
Immunohistochemical studies show the increased presence of IL-12 p70 in 
human atherosclerotic plaques as compared to normal arteries.17 In aortas of 
apolipoprotein E deficient (ApoE-/-) mice IL-12 p40 and IL-12 p70 appear to 
be elevated in an early stage of atherosclerosis on mRNA and protein level, 
respectively.18 Combined with this IL-12 upregulation IFN-γ, but not IL-4, is 
elevated. Other studies show that the IL-12 expression patterns are not only 
associated with the initiation of atherosclerosis but also indicate that IL-12 
may accelerate atherosclerosis. ApoE/IL-12 p40 double knock out mice show 
less atherosclerosis in the aortic root at 30 weeks of age as compared to 
ApoE-/- mice.19 In addition, daily administration of IL-12 promotes 
atherosclerosis in young ApoE-/- mice as compared to control treated mice.18 
These studies, in which the proatherosclerotic role of IL-12 is described, 
indicate that IL-12 may be a suitable target in the treatment of 
atherosclerosis. 
We therefore aimed to attenuate atherosclerosis by blocking endogenous IL-
12 function. Using a novel vaccination technique20 we were able to induce 
antibodies against IL-12 p40, which specifically blocked the function of IL-12 
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in low density lipoprotein receptor deficient (LDLr-/-) mice. Blockade of 
functional IL-12 led to a significant decrease in atherosclerosis and an 
increase in plaque stability. Therefore, inhibition of IL-12 function by means of 
protein vaccination against IL-12 may be a promising novel strategy for the 
treatment of atherosclerosis. 
 
 
Methods 
 
Vaccine preparation  
Mouse IL-12, histidine-tagged on p35, was prepared as previously 
described.21 This product was coupled to Pan DR epitope (PADRE) 
(aKXVAAWTLKAAC, where X = cycloexylamine), by overnight reaction at 4 
°C with 20 mM glutaraldehyde in 0.1 M phosphate buffer at pH 6. The 
reaction was stopped by addition of Tris-HCL pH 9 and the resulting complex 
was dialysed against phosphate buffered saline (PBS). For coupling to 
PADRE peptide a 5/1 molar ratio per IL-12 subunit was used. The resulting 
complex was used for vaccination. 
 
Vaccination and surgery 
All animal work was carried out in compliance with the guidelines issued by 
the Dutch government. The vaccine complex was administered in 
combination with a novel adjuvant o/w emulsion (low dose)/MPL/QS21, which 
we kindly obtained from GSK (Rixensart, Belgium). This adjuvant comprises 
monophosphoryl lipid A and an immunostimulatory saponin derived from the 
bark of Quillaja Saponaria Molina.  
Female LDLr-/- mice (n=12), 10-12 weeks old, were vaccinated by five times 
bilateral intramuscular injections of 2 μg of IL-12-PADRE complexes in the 
presence of adjuvant in 100 μl PBS, 50 μl per muscle, with two week 
intervals. Control mice (n=10) received sham-PADRE complexes in the 
presence of adjuvant. Immediately after the last injection, mice were put on a 
“Western-type” diet, containing 0.25% cholesterol and 15% cocoa butter 
(Special Diet Services, UK). After two weeks of Western-type diet, 
atherosclerosis was induced in carotid arteries by bilateral perivascular collar 
placement, as described previously.22 During the experiment plasma samples 
were obtained by tail vein bleeding.   
   
Tissue harvesting 
Six weeks after collar placement, carotid arteries were obtained after in situ 
perfusion for 15 minutes using PBS and subsequent perfusion using formalin 
for 30 minutes. Fixated carotids were embedded in OCT compound (Sakura 
Finetek, The Netherlands), snap-frozen in liquid nitrogen and stored at -20°C 
until further use. Transverse 5 μm cryosections were prepared in a proximal 
direction from the carotid bifurcation and were mounted on a parallel series of 
slides.  
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Histological analysis 
Cryosections were routinely stained with hematoxylin (Sigma Diagnostics, 
MO) and eosin (Merck Diagnostica, Germany). Corresponding sections were 
stained immunohistochemically with antibodies against a macrophage-
specific antigen (MOMA-2, polyclonal rat IgG2b; Research Diagnostics Inc., 
NJ) alpha smooth muscle cell actin (monoclonal mouse IgG2a (clone 1A4); 
Sigma Diagnostics) or IFN-γ (rat IgG1, clone XMG1.2, BD PharMingen, The 
Netherlands). Sections were incubated with primary antibodies for 2 hours. 
As secondary antibodies goat anti-mouse IgG peroxidase conjugate (Nordic, 
The Netherlands), goat anti-rat IgG alkaline phosphatase conjugate (Sigma 
Diagnostics), or biotinylated goat anti rat polyclonal Ig (BD PharMingen) in 
combination with the streptABComplex (DAKO, The Netherlands) were used 
(1 hour incubation), with 3,3’-diamino-benzidine (Sigma Diagnostics), nitro 
blue tetrazolium (Sigma Diagnostics) and 5-bromo-4-chloro-3-indolyl 
phosphate (Sigma Diagnostics) as enzyme substrates. Sections were stained 
for collagen by Picrosirius Red (Direct red 80) and for lipids by Oil red O 
staining. 
 
Morphometry 
Hematoxylin-eosin stained sections of carotid arteries were used for 
morphometric analysis of atherosclerotic lesions. Each vessel was assessed 
~0.5 mm proximal to the collar, and the site of maximal stenosis was used for 
morphometric assessment.22  
 
IL-12 bioassay  
Functional IL-12 activity was measured in vitro by testing the inhibition of IL-
12 induced proliferation of the murine hemopoietic BaF/3 cell line, in which 
the IL-12 receptor was expressed as follows. The murine IL-12Rbeta 1 
coding sequence was amplified by RT-PCR from Con A stimulated C57Bl/6 
T-cells using the following primers: 5’-ACTCGGCTCCTCATGGACAT-3’ 
(sense primer) and 5’-TGCAACAGTCAGGCTCTT-3’ (antisence primer). The 
murine IL-12Rbeta 2 coding sequence was amplified by using the following 
primers: 5’-TGCATTCTGGAGTTGAAGACT-3’ (sense primer) and 5’-
GTATCAAGCCTCATTACTCAT-3’ (antisense primer). Both cDNAs were 
cloned into the pCR2.1 vector (Invitrogen), sequenced, and subcloned into 
the EcoRV site of the pEF-Bos.puro expression vector. 5 million BaF/3 cells 
were co-electroporated with 30 μg of each pEF-Bos.puro-IL-12Rb1 and pEF-
Bos.puro-IL-12Rb2 in 400 μl H16 medium supplemented with 10 % fetal calf 
serum (FCS). Transfected BaF/3 cells were cultured in H16 medium 
supplemented with 10 % FCS and IL-3 (100 U/ml) for 48 hours. After 48 
hours, transfected cells were cloned by limiting dilution and selected by 
adding puromycin to the medium (3 μg/ml). Survival and proliferation of 
puromycin-resistant clones were tested in the presence of IL-12 to identify a 
clone that expressed both chains of the IL-12 receptor.  
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IFN-γ and anti-IL12 ELISA 
Serum IFN-γ levels were determined using the Femto-High Sensitivity IFN-γ 
ELISA Kit according to manufacturer's instructions (eBioscience, CA). For 
detection of anti-IL-12 antibodies by ELISA, Maxisorb Nunc-Immunoplates 
(Nalge Nunc International, U.K.) were coated with IL-12 or BSA as a control 
(both at 5 μg/ml) in 20 mM glycine buffer pH 9.3. After blocking with 1% BSA 
in PBS, sera diluted in blocking buffer were added to plates and incubated at 
37 °C for 2 hours, followed by incubation with peroxidase-coupled goat anti-
mouse IgG, IgG1, IgG2a, or IgG2b (Transduction Laboratories, KY), and 
subsequent incubation with Ultra-TMB substrate (Pierce, IL). The specificity 
of these antisera was further analysed by pre-incubating appropriately diluted 
samples with IL-12 heterodimers or p40 homodimers (R&D, Mn) both at 1 
μg/ml for 2 hours before transfer to IL-12 or p40 coated plates.  
 
Data analysis 
Values are expressed as mean±sem. A two-tailed Student’s t-test was used 
to compare individual groups of mice or cells. A Mann-Whitney test was 
performed to compare serum levels of IFN-γ and Fisher’s exact test to 
compare IFN-γ expression within atherosclerotic plaques. A level of p<0.05 
was considered significant. 
 
 
Results 
 
Effect of vaccination on anti-IL12 autoantibody induction 
Mice were vaccinated five times with two-week intervals. Three days after the 
fifth injection with IL-12 PADRE complex in the presence of adjuvant o/w 
emulsion (low dose)/MPL/QS21, serum was collected in order to determine 
the effect of vaccination on the induction of anti-IL-12 autoantibodies. 
Immunization of LDLr-/- mice with this vaccine resulted in the production of 
high anti-IL-12 IgG antibody titers as determined by ELISA (Fig.1A). Further 
evaluation of the subclasses of IgG in the vaccinated mice revealed elevated, 
comparable levels of anti-IL-12 IgG1 and IgG2a, while the level of anti-IL-12 
IgG2b was elevated to a lower extent (data not shown). Uyttenhove et al. 
recently showed that these high levels of anti-IL-12 antibodies appeared to 
remain high for up to 24 weeks in mice on a C57Bl/6 background.20  
 
Effect of vaccination on IL-12 bioavailability 
We used an IL-12 bioassay, in which serum was tested for its capacity to 
inhibit IL-12-induced proliferation of IL-12 receptor expressing BaF/3 cells, to 
determine whether the raised anti-IL-12 antibodies were able to functionally 
block the action of IL-12. It is clear from figure 1B that the anti-IL-12 
autoantibodies were able to block IL-12 function.  
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Figure 1. Induction of autoantibodies against IL-12. Serum obtained from LDLr-/- mice 
three days after the fifth vaccination with IL-12 PADRE complex in the presence of 
adjuvant o/w emulsion/MPL/QS21 or with adjuvant alone was tested for the presence 
of anti-IL-12 antibodies and the ability of these antibodies to block IL-12 function. 
ELISA plates coated with IL-12 or BSA (control) were incubated with serial serum 
dilutions and antibodies bound were detected by reaction with HRP-conjugated goat 
anti-mouse IgG antibodies followed by a peroxidase substrate. Indicated titers 
correspond to serum dilutions giving 5 times the blank, which was created by 
incubating IL-12 coated plates with 1% BSA (A). IL-12 induced proliferation of the 
murine hemopoietic BaF/3 cell line was determined in the presence of serum from IL-
12 PADRE vaccinated mice or control mice (B). The apparent “single” data point in 
the control group in figure A and B represents the observed values for antibody titers 
(A) or IL-12 inhibition (B), and the titers were <102 in all control animals. 
 
Uyttenhove et al. showed that the IL-12 function is also blocked in vivo, 
where IFN-γ induction was dramatically reduced upon IL-12 administration in 
vaccinated mice as compared to a strong induction of IFN-γ in control mice.20 
Furthermore, 8 weeks after the last booster injection and 6 weeks after 
induction of atherosclerosis we observed a significant decrease in serum 
IFN-γ levels in IL-12 vaccinated animals (Fig.2).   
 
Figure 2. IFN-γ levels upon vaccination against 
IL-12. Eight weeks after the last injection booster 
serum was collected and levels of IFN-γ were 
determined with ELISA. Significantly reduced 
levels of IFN-γ were observed upon vaccination 
against IL-12 as compared to controls. (*=p<0.05)  
 
 
 
Specificity of anti-IL-12 antibodies 
The complexes used for immunization were produced using recombinant IL-
12 p70 (p40-p35 heterodimers). Since the antisera showed antibody binding 
to IL-12 p70 coated plates and were able to block the action of IL-12, 
competition experiments were carried out to analyse the relative interaction of 
the anti-IL-12 antibodies with the p40 subunit alone and the complete IL-12 
p70. Appropriately diluted sera were incubated with IL-12 p70 or p40 
homodimers prior to transfer to IL-12 coated plates. p40 dimers and IL-12 
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had equivalent inhibitory activities on the binding of anti-IL-12 antibodies to 
IL-12 p70, indicating that most of the anti-IL-12 antibodies reacted with the 
p40 subunit (Fig.3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Specificity of the raised anti-IL-12 antibodies. Plates were coated with BSA, 
p40 dimers or IL-12 (p70). Sera from LDLr-/- mice vaccinated with IL-12 PADRE 
complex in the presence of adjuvant o/w emulsion/MPL/QS21 or with adjuvant alone 
were brought on the coated plates after pre-incubation with IL-12 heterodimers or p40. 
Bound antibodies were detected by subsequent incubation with goat anti-mouse Ig-
peroxidase conjugate and peroxidase staining. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Vaccination against IL-12 inhibits the development of atherosclerosis. 
Plasma samples were withdrawn from the mice at various time points after induction 
of atherosclerosis and the cholesterol levels were monitored using an enzymatic 
assay (A). Mice were killed 6 weeks after collar placement and carotid arteries of 
sham vaccinated (B) and IL-12 vaccinated mice (C) were sectioned and stained with 
hematoxylin-eosin. Lesions from all mice were quantified by computer assisted 
morphometric analysis and the intima area (D), intima/media ratio (E), and 
intima/lumen ratio (F) were determined. (**=p<0.01). 
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Effect of IL-12 vaccination on atherosclerosis 
The effect of vaccination against IL-12 on de novo atherosclerosis was 
studied in LDLr-/- mice. Following the last booster injection, LDLr-/- mice were 
put on a Western-type diet and two weeks later collars were placed. During 
the experiment we did not observe any effect of IL-12 vaccination on serum 
cholesterol levels (Fig.4A). Six weeks after collar placement, mice were 
sacrificed and atherosclerotic plaque formation was analysed in the carotid 
arteries after staining sections of carotids with haematoxylin and eosin 
(Fig.4B,C). IL-12 vaccination resulted in a significant 68.5% reduction in 
intima area (Fig.4D; 52,183±12,528 vs 16,442±2,847 μm2, p<0.01) as 
compared to control treated mice. IL-12 vaccination also resulted in 66.7% 
decreased intima/media ratios (Fig.4E; 1.45±0.26 vs 0.48±0.07, p<0.01) and 
a 57.8% decrease in the amount of stenosis (Fig.4F; 0.59±0.19 vs 0.25±0.05, 
p<0.01).  
 
Plaque morphology 
The effect of IL-12 vaccination on the composition of the plaques was 
determined by immunohistochemical staining techniques. Alpha actin staining 
showed that vaccination resulted in a marked 4.2-fold increase in the smooth 
muscle cell (SMC) content of the lesions in IL-12 vaccinated mice (Fig.5D-F; 
0.018±0.009 vs 0.079±0.018, p<0.01). In addition, Sirius Red staining 
showed that upon IL-12 vaccination, the collagen content of the lesion was 
increased 2.8-fold as compared to control vaccinated mice (Fig.5A-C; 
0.119±0.075 vs 0.335±0.021, p<0.01). The macrophage content in the intima 
did not change upon IL-12 vaccination, as determined by MOMA-2 staining 
(Fig. 5G-I). Furthermore, the number of IFN-γ positive cells was determined 
by an IFN-γ specific immunohistochemical staining. We observed that lesions 
of IL-12 vaccinated mice (n=10) never contained IFN-γ positive cells, whereas 
50% of the lesions of control vaccinated mice (n=12) contained IFN-γ positive 
cells, which led to a significant decrease in plaque specific IFN-γ staining in 
IL-12 vaccinated mice (Fisher’s exact test (p<0.05)). On average 18.2 ± 8.8 
IFN-γ positive cells were detected in lesions of control mice (Fig. 6A,B).  
The relative lipid staining (lipid/intima ratio) was not different between the IL-
12 vaccinated and control vaccinated group, as determined with Oil red O 
staining (data not shown). However, since the plaque area was significantly 
smaller in the IL-12 vaccinated group, this results in a significantly smaller 
absolute Oil red O stained area (µm2 Oil red O area) in the IL-12 vaccinated 
mice versus the control vaccinated mice. 
 
 
Discussion 
 
Inflammation is a hallmark of atherosclerosis and takes place as a 
consequence of the response to either endogenous antigens, such as heat 
shock proteins or oxidized LDL, or exogenous antigens, such as infectious 
agents.23 The progression of this inflammatory response is primarily 
Chapter 5 
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regulated by specific patterns of cytokine expression. The two major 
regulatory groups of cytokines are formed by pro-inflammatory Th1 type 
cytokines and anti-inflammatory Th2 type cytokines. The importance of these 
patterns of cytokines for atherosclerosis has been demonstrated by the fact 
that in vivo downregulation of Th1 immune responses by pentoxifylline 
reduces atherogenesis.10 IL-12 is the most important stimulator of the 
production of Th1 type cytokines, and could therefore enhance 
atherosclerosis. This pro-atherosclerotic role of IL-12 is supported by our 
present findings. However, the stimulatory effect of IL-12 on atherosclerosis 
is already indicated by the fact that ApoE/IL-12 double knock out mice 
develop smaller atherosclerotic lesions than mice only deficient in ApoE.19 In 
addition, daily administration of IL-12 promoted atherosclerosis in young 
ApoE-/- mice.18 The fact that IL-10, a Th2 cytokine, inhibits IL-12 production24 
and reduces atherosclerosis in LDLr-/- and ApoE-/-mice7-9, suggests an 
important role for IL-12 in atherosclerosis.  
This role is further supported by the fact that oxidized LDL, which promotes 
atherosclerosis, is able to modulate immune reactions by an IL-12 dependent 
mechanism.25 Therefore, we hypothesized that blockade of IL-12 function by 
vaccination may affect atherosclerosis. The present study shows that this 
approach may be a new and effective strategy to treat atherosclerosis.   
In this study we vaccinated LDLr-/- mice against endogenous IL-12 by a novel 
protein vaccination technique, in which murine IL-12, coupled to the MHC 
class II-binding peptide (PADRE), was injected repeatedly with two week 
intervals in combination with a novel adjuvant o/w emulsion (low 
dose)/MPL/QS21. Coupling of IL-12 to the foreign peptide PADRE is 
necessary for the appropriate T-cell help in the induction of anti-IL-12 
antibody formation by B-cells. We have chosen to treat the control vaccinated 
group of LDLr-/- mice with a mixture of PADRE peptide and adjuvant in order 
to exclude that the effect of IL-12 vaccination on atherosclerosis resulted 
from the adjuvant as was described for other adjuvants.26 We can thus 
conclude that the effect of IL-12 vaccination was specifically induced by the 
anti-IL-12 antibodies raised. We did not immunize control mice against a non-
related, non-mouse antigen, such as BSA, since such an immunization will 
not have an additional effect as compared to adjuvant alone. In our 
experiments mice were immunized prior to the induction of atherosclerosis 
and the immune response to such an exogenous antigen will already have 
been extinguished at the time point of induction of atherosclerosis due to the 
absence of the exogenous antigen in mice and will therefore not affect 
atherosclerosis. 
Three days after the fifth vaccination we observed a high antibody titer 
against IL-12. From the recent publication of Uyttenhove et al., who 
described the vaccination protocol, it is clear that once established, anti-IL-12 
antibody titers remain remarkably stable (at least up to 24 weeks) without 
further booster injections20. This implicates that during the 8-week time 
interval of the atherosclerosis experiment endogenous IL-12 is blocked in the 
IL-12 vaccinated LDLr-/- mice. 
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Figure 5. Vaccination against IL-12 promotes a more stable phenotype of the 
atherosclerotic plaque. Mice were killed 6 weeks after collar placement and carotid 
arteries of sham vaccinated and IL-12 vaccinated mice were sectioned and stained for 
collagen with Sirius Red, for smooth muscle cells with an alpha actin antibody 
staining, and for macrophages with an MOMA-2 antibody staining. Sirius Red staining 
revealed a 2.8-fold increase in collagen content in the plaques after vaccination 
against IL-12 (A-C). Alpha actin staining showed that IL-12 vaccination leads to 
plaques with a 4.2-fold higher smooth muscle cell content (D-F), while with MOMA-2 
staining no changes were detected in the macrophage content after vaccination 
against IL-12 (G-I). (**=p<0.01). 
 
 
 
 
 
 
 
** 
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Figure 6. Vaccination against IL-12 leads to a decreased amount of IFN-γ positive 
lesions. Figure A shows a lesion from a control vaccinated mouse in which the arrows 
indicate the location of IFN-γ positive cells. The area within the rectangle is enlarged 
in figure B. Quantification of the amount of lesions with IFN-γ positive cells revealed a 
significant decrease in IFN-γ positive lesions upon vaccination against IL-12 (table, 
Fisher’s exact test. (p<0.05)).  
 
The anti-IL-12 antibodies blocked the function of IL-12, since the serum 
obtained from vaccinated mice impaired the IL-12 induced proliferation of IL-
12 responsive BaF/3 cells as compared to the serum obtained from control 
mice. Studies by the group of van Snick indicated that vaccinated mice no 
longer produced IFN-γ in response to repeated administration of IL-12, which 
illustrates the successful functional blockade of IL-12 in vivo.20 In the present 
study, we found decreased levels of IFN-γ 8 weeks after IL-12 vaccination, 
which indicated that IL-12 function was still blocked in vivo at the end of the 
experiment. 
Since the cytokine IL-12 is a heterodimer that consists of two subunits, p35 
and p40, competition studies were carried out to analyse the relative 
interactions of the anti-IL-12 antibodies with p40 and p70 in the vaccinated 
mice. These experiments showed that the antibodies were specific for the 
p40 subunit. Although the function of IL-12 is certainly blocked by this 
vaccination we must assume that the antibodies also interact with the p40 
subunit of IL-23. IL-23 is, similar to IL-12, a heterodimer consisting of the 
subunit p40 and p19.  The interaction of the antibodies raised against IL-12 
may also block the function of IL-23. IL-23 is just like IL-12 involved in the 
polarization towards Th1 responses, because IL-23 is responsible for the 
maintenance and proliferation of the Th1 committed memory T-
lymphocytes.27 Furthermore, IL-23 modulates T-cell dependent immunity 
through regulation of the antigen presenting functions of dendritic cells.27 
These immunoregulatory functions of IL-23 suggest that potential blockade of 
IL-23 may also contribute to reduced atherogenesis. 
The IL-12 vaccination technique has recently been shown to lead to a TH1-
Th2 switch in C57Bl/6 mice by the group of van Snick.20 70 days post 
 IFN-γ positive lesions IFN-γ negative lesions 
Control 6 6 
Vaccinated 0 10 
A B 
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subcutaneous infection with Leishmania major (L.major) in the footpath of 
these mice popliteal lymph node cells were isolated and restimulated with 
L.major antigen. IL-12 vaccination led to an impaired induction of IFN-γ, 
combined with an increased production of IL-5 and IL-4. In addition, 
peritoneal macrophages isolated from IL-12 vaccinated mice showed an 
impaired nitric oxide (NO) production upon stimulation with IFN-γ or LPS as 
compared to control macrophages, which illustrates the decrease in 
microbicidal activity, a typical sign of Th2 responses. Furthermore, proteo 
lipid protein (PLP) induced experimental autoimmune encephalomyelitis in 
SJL mice was strongly diminished by vaccination against IL-12. In vaccinated 
mice a clear increase in IgG1 anti-PLP titers and a reduction in IgG2a was 
observed.20  
These results indicated that this vaccination against IL-12 leads to a shift 
from Th1 to Th2 responses and that this shift leads to a depression in 
protective effector functions. Our observation that vaccination against IL-12 
reduced serum IFN-γ levels confirms the stimulation of a Th2 response upon 
blockade of IL-12 function. 
In this study the effect of vaccination against endogenous IL-12 on de novo 
atherosclerosis was investigated in LDLr-/- mice, in which atherosclerosis was 
induced in the carotid artery by perivascular collar placement 2 weeks after 
the last boost with the IL-12-PADRE complex. 
While serum cholesterol profiles did not differ between vaccinated and control 
mice during the experiment, 6 weeks post collar placement a dramatic 
reduction of atherosclerosis was observed in IL-12 vaccinated mice as 
compared to control mice. This reduction in atherosclerosis was highly 
significant and was reflected in a diminished lesion area (68.5%), a reduced 
intima/media ratio (66.7%), and a reduced degree of stenosis (57.8%). The 
protective effect of vaccination against IL-12 is in line with the previously 
demonstrated stimulatory effect of IL-12 administration on atherosclerosis in 
ApoE-/- mice18 and the inhibitory effect of loss of IL-12 function on 
atherosclerosis in ApoE/IL-12 double knock out mice.19 The fact that in vivo 
downregulation of Th1 immune responses leads to reduced atherogenesis 
and that IL-12 stimulates Th1 immune responses supports the idea that loss 
of IL-12 function attenuates atherosclerosis via modulation of the Th1-Th2 
balance. Development of Th1 or Th2 responses to either endogenous or 
exogenous antigens takes place both inside the plaque as well as on other 
sites, such as the spleen. Therefore, modulation of these responses by 
vaccination against IL-12 leads to both changes in the circulating cytokine 
pattern, which was confirmed by changing the IL-12 induced IFN-γ production 
by vaccination20 and our found reduced serum levels of IFN-γ upon 
vaccination, but also leads to a shift in cytokine patterns within the 
atherosclerotic plaque.3 Our finding that IFN-γ positive cells were totally 
absent in the lesions of mice vaccinated against IL-12, whereas half of the 
lesions of control animals were positive for  IFN-γ underlines that the function 
of IL-12 is also blocked within the atherosclerotic plaques upon vaccination 
against IL-12. Although the relative contribution of those changes to 
atherogenesis is not fully dissected yet, the Th1 cytokine pattern, with 
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elevated levels of IFN-γ, IL-2, and TNF-α, influences atherogenesis by 
interfering in processes, such as adhesion of monocytes to the endothelium, 
proliferation of vascular SMCs, further differentiation of T-cells, foam cell 
formation, and macrophage activation or apoptosis. IL-12 is a strong inducer 
of IFN-γ production by several cell types, not only by T-cells, and IFN-γ is able 
to enhance atherosclerosis16 not only by regulating the immune response but 
also by directly affecting plaque metabolism by upregulating the expression 
of vascular cell adhesion molecule (VCAM), major histocompatibility complex 
II, and scavenger receptors.28-30 Therefore, impaired IFN-γ production as a 
consequence of vaccination against IL-12 may also contribute to reduced 
atherogenesis. Furthermore, IL-12 is involved in the migration31, 
differentiation and activation of natural killer (NK) cells32 and depletion of 
these cells has been shown to inhibit atherosclerosis in LDLr-/- mice.33 In 
addition, systemic IL-12 has been indicated to stimulate the expression of CC 
chemokine receptor 5 on T-cells34, which upon binding to macrophage 
inflammatory protein promotes the infiltration of T-cells to the site of 
inflammation. 
Recently, the stability of the atherosclerotic plaque has been considered to 
be clinically at least as important as the actual degree of stenosis. Unstable 
angina pectoris or myocardial infarction is often the consequence of rupture 
of an unstable atherosclerotic plaque. It has already been demonstrated that 
elevated levels of serum IL-12 is associated with unstable angina pectoris.35 
However, a causal role for IL-12 in destabilizing the atherosclerotic plaque 
has never been described. Therefore, we evaluated the effect of vaccination 
to IL-12 on the composition of the atheroslerotic lesions. Immuno-
histochemical staining revealed a significant 4-fold increase in SMC and 3-
fold increase in collagen content in the lesions of mice in which endogenous 
IL-12 function was blocked. Although smaller lesions (as observed after IL-12 
vaccination) normally contain relatively more macrophages as compared to 
large lesions, in this study no significant differences were observed in the 
macrophage content of the lesions between the two groups, which suggests 
that loss of IL-12 function leads to a decrease in macrophage content. 
Elevated levels of SMCs and collagen and a decrease in the macrophage 
content are considered to be markers for stable atherosclerotic lesions that 
are not prone to rupture.  One of the likely explanations for the increased 
collagen levels could be that the SMCs, which are the major producers of 
collagen in the vascular wall, are also more abundant in the IL-12 vaccinated 
mice. Furthermore, some recent findings suggested that IL-12, particularly in 
synergy with IL-18, may modulate the production of certain matrix 
metalloproteinases (MMPs)36,37, which take care of the collagen metabolism. 
However, whereas the Th1 cytokine TNF-α promotes MMP activity38, IFN-γ 
inhibits this activity39, which illustrates the need to perform additional 
experiments to determine the overall effect of a Th1 cytokine pattern on MMP 
production and activation. With regard to SMC proliferation the same divers 
effects are observed in which TNF-α promotes proliferation40 and IFN-γ 
inhibits proliferation of SMCs.41 Our findings suggest that blockade of IL-12 
  88
Chapter 5 
function leads to an overall stimulation of survival or proliferation of SMCs in 
the neointima.   
Because of the long duration of the therapeutic efficacy, the relatively low 
costs, and the lack of immune responses against the administration of foreign 
proteins, as can be seen with anti-TNF-α therapy in Crohn’s disease42, this 
vaccination technique has clear advantages over anti-IL-12 antibody 
administration. The increased risk of infection with intracellular pathogens 
upon anti-IL-12 vaccination should be seriously taken into account since 
initial studies on three IL-12Rβ1 deficient patients showed an increased risk at 
idiopathic Mycobacteria and Salmonella infections.43 However, a larger, more 
recent study on 41 IL-12Rβ1 deficient adult individuals showed a relative 
resistance to infection, suggesting that human IL-12 is redundant in the 
protective immunity against most micro-organisms other than Mycobacteria 
and Salmonella. IL-12 is also redundant for primary immunity to Mycobacteria 
and Salmonella in many individuals and for secondary immunity to 
Mycobacteria but not to Salmonella in most individuals.44 In addition, a recent 
study, in which IL-12 function was blocked by administration of anti-IL-12 
antibodies to treat active Crohn’s disease in humans, did not lead to an 
increased incidence of infections.45  However, the effects of long-term 
blockade of IL-12 function  by vaccination on the incidence of specific 
infections deserves further investigation, as blocking IL-12 function forms an 
attractive strategy for the treatment of atherosclerosis. 
In summary, our study demonstrates that vaccination against endogenous IL-
12 results in a functional blockade of IL-12 and an attenuation of 
atherosclerosis and leads to lesions with a more stable phenotype. Although 
the potential changes in susceptibility to intracellular infections have to be 
taken into account, the combination of these anti-atherosclerotic effects and 
the long-standing nature of this protection by this novel vaccination technique 
makes this strategy a promising way to treat atherosclerosis. 
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Abstract 
 
Vascular endothelial growth factor receptor 2 (VEGFR2) overexpressing cells 
form potential targets in the treatment of atherosclerosis, because of their 
involvement in processes that potentially contribute to this disease, such as 
angiogenesis. VEGFR2 overexpressing cells were targeted by a novel, orally 
administered DNA vaccine, encoding murine VEGFR2 carried by the live 
attenuated S. typhimurium, which induces cellular immunity against cells that 
overexpress VEGFR2. Vaccination of hypercholesterolemic mice resulted in 
the induction of VEGFR2 specific CD8+ cytotoxic T cells. Specific lysis of 
VEGFR2 expressing target cells by T cells was 4.6-fold increased (p<0.005) 
upon vaccination against VEGFR2. VEGFR2 vaccination resulted in 50% 
(p<0.01) decreased angiogenesis as confirmed by a hind limb ischemia 
model in apoE-/- mice. Interestingly, VEGFR2 vaccination strongly reduced 
the progression of pre-existing advanced atherosclerotic lesions in the 
brachiocephalic artery of apoE-/- mice by 66% (p<0.05). In a second 
experiment we determined the effect of VEGFR2 vaccination on the initiation 
of atherosclerosis in the carotid arteries of LDLr-/- mice, which was attenuated 
by 77% (p<0.05) upon vaccination, translating to 2.7- (p<0.01) and 3.0-fold 
(p<0.01) reduced intima/media and intima/lumen ratios, respectively. 
Furthermore, the effect of VEGFR2 vaccination on neointima formation after 
endothelial denudation was studied in LDLr-/- mice. One week after 
denudation the endothelial replacement was delayed (p<0.05), which resulted 
in a 2.7-fold (p<0.01) increase in neointima formation 5 weeks after 
vaccination against VEGFR2. In conclusion, vaccination against VEGFR2 
blocks both the initiation and progression of atherosclerosis, but enhances 
neointima formation after vascular injury by endothelial denudation, indicating 
the prominent role of VEGFR2 positive cells in the development of vascular 
disorders. Induction of cellular immunity against atherosclerosis-associated 
cells by DNA vaccination may contribute to the development of novel 
therapies against atherosclerosis.  
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Introduction 
 
Atherosclerosis is a multifactorial disease, which is regulated by a variety of 
inflammatory mechanisms.1 Many cell types contribute to the initiation and 
progression of the atherosclerotic plaque. The process of atherosclerosis is 
initiated by the activation of endothelial cells upon exposure to various 
stimuli, such as high levels of atherogenic lipoproteins or shear stress, 
leading to enhanced migration of leukocytes from the circulation into the 
intima. The accumulation and activation of macrophages with subsequent 
foam cell formation after uptake of atherogenic lipoproteins within the intima 
are key processes that induce the formation of an atherosclerotic plaque. 
Changes in proliferation, migration, and activation of smooth muscle cells 
also regulate the process of atherosclerosis. More recently identified 
inflammatory regulators in atherosclerosis are T cells, B cells, dendritic cells, 
and NKT cells.2,3  
In the present study, we focused on the role of a specific cell population in 
atherosclerosis that highly expresses vascular endothelial growth factor 
receptor 2 (VEGFR2), and we aimed to diminish the amount of these cells 
and study the effect thereof on atherosclerosis. Highly VEGFR2 expressing 
cells comprise proliferating endothelial cells and (endothelial) progenitor 
cells,4 which are involved in angiogenesis,5-7 a process that potentially 
contributes to the initiation and progression of  atherosclerotic plaques.8,9 
Furthermore, VEGFR2 is highly expressed on the activated endothelial cell 
layer that covers the atherosclerotic plaque, whereas the healthy vascular 
wall shows much lower expression levels of VEGFR2 on the luminal 
endothelial cells.10 In addition, some studies indicate that VEGFR2 positive 
progenitor cells or VEGFR2 positive endothelial cells can differentiate into 
non-endothelial cells, such as smooth muscle cells that may contribute to 
atherosclerosis.11-13 Moreover, VEGF has been demonstrated to promote the 
progression of atherosclerosis and lead to increased macrophage content in 
the atherosclerotic plaque, indicating that interference in the interaction of 
VEGF with its main receptor, VEGFR2, may result in reduced 
atherogenesis.14 These pro-atherogenic effects are substantiated by the fact 
that binding of VEGF to VEGFR2 induces inflammatory responses in both 
macrophages and endothelial cells by NFκB activation. VEGFR2 is 
expressed on activated macrophages, including atheroma-associated 
macrophages,15 and is involved in the migration and proliferation of these 
cells.16 Furthermore, binding of VEGF to VEGFR2 induces elevated 
expression levels of vascular endothelial cell adhesion molecule 1 (VCAM-1), 
intercellular adhesion molecule 1 (ICAM-1), and endothelial selectin (E-
selectin) in endothelial cells leading to increased adherence of monocytes.17    
In the present study, we targeted cells that overexpress VEGFR2 with a 
novel DNA vaccination technique. By oral administration of the live 
attenuated bacterium Salmonella typhimurium containing a VEGFR2 
encoding plasmid, we induced a cytotoxic CD8+ T cell response against 
VEGFR2 overexpressing cells in atherosclerosis prone mice. Recently, the 
induction of specific cytotoxicity against cells that overexpress VEGFR2 by 
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this vaccination strategy has been shown to block tumor angiogenesis 
leading to dramatically reduced tumor growth and prolonged survival of mice 
that were challenged by several tumor cell lines.18 In the present study, we 
confirmed that vaccination against VEGFR2 resulted in specific cytotoxicity 
against cells that overexpress VEGFR2 in hypercholesterolemic mice leading 
to reduced angiogenesis. Interestingly, vaccination against VEGFR2 resulted 
in attenuation of both the intitiation and progression of atherosclerosis in 
mice, but led to enhanced post-interventional neointima formation. This study 
clearly indicates that VEGFR2 overexpressing cells play an important role in 
stenotic vascular processes. Furthermore, we show for the first time that 
targeting of specific subpopulations of cells by vaccination may be a valuable 
strategy in the development of novel therapies against atherosclerosis.  
 
 
Methods 
 
Vaccination strategy 
Plasmid pcDNA3.1 (Invitrogen, CA) encoding murine VEGFR2 was 
constructed and electroporated in attenuated S. typhimurium Aro/A (strain 
SL7207) bacteria, as previously described.18 Mice were immunized by 3 
times oral administration with 2-week intervals with 1x108 S. typhimurium 
bacteria transformed with pcDNA3.1-VEGFR2 or pcDNA3.1 (control) in 100μl 
PBS, as described previously.18  
 
Induction of VEGFR2 specific cytotoxic CD8+ T-cells 
The potential of spleen cells, isolated from vaccinated or control apoE-/- mice 
3 weeks after the last administration of the vaccine, to lyse VEGFR2 
expressing cells was determined as follows. The murine fibroblast (3T3) cell 
line was cultured on cover slips in a 24 wells plate (2.5x104 cells/well) and 
incubated with DMEM containing 10% Fetal Bovine Serum (FBS), 2 mmol/L 
L-glutamine, 100 U/ml penicillin, and 100 μg/ml streptomycin (BioWhittaker 
Europe) in a humidified atmosphere (5% CO2) at 37°C. Cells were co-
transfected with pcDNA3.1-VEGFR2 and pcDNA3.1-GFP using transfection 
reagent ExGen 500 (Fermentas, Germany) according to manufacturer’s 
instructions. After 5 hours of transfection, cells were washed with medium 
and incubated with DMEM o/n. Twentyfour hours after the start of 
transfection 3T3 cells were incubated with splenocytes (2.5x106 cells/well) 
from either vaccinated or control mice for 24 hours. After washing with PBS 
and fixation of cells with formalin, specific lysis of VEGFR2 expressing cells 
was analyzed by counting the GFP-positive cells with a Leica DM-RE 
microscope (Leica Imaging Systems, UK). The degree of specific lysis was 
expressed as a percentage of GFP-positive cells that survived, where the 
situation in which no splenocytes were added represented 100% survival. 
  
Angiogenesis in a hind limb ischemia model 
All animal work was carried out in compliance with guidelines issued by the 
Dutch government. For evaluation of anti-angiogenic effects induced by 
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vaccination against VEGFR2, apolipoprotein E deficient (apoE-/-) mice were 
vaccinated as described (VEGFR2 vaccinated n=6, control vaccinated n=6).18 
One week after the last oral administration of the vaccine mice were 
anesthetized by subcutaneous injection of ketamine (160 mg/kg, Eurovet, 
The Netherlands), xylazine (20 mg/kg, Bayer, The Netherlands), and 
atropinesulfate (0.20 mg/kg, Centrafarm, The Netherlands). Unilateral 
hindlimb ischemia was introduced by coagulation of the left femoral artery 
proximal to the bifurcation of deep and superficial femoral artery. Two weeks 
later, mice were sacrificed and left gastrocnemic muscles were dissected for 
immunohistochemical analysis of ischemia induced angiogenesis.  
 
Induction of atherosclerosis 
The effect of vaccination against VEGFR2 on early and late stages of 
atherosclerosis was studied in two mouse models for atherosclerosis. The 
effect of vaccination against VEGFR2 on advanced lesion was studied in 
apoE-/- mice, which spontaneously develop atherosclerosis on a chow diet. 
Female apoE-/- mice, 22 weeks of age, were vaccinated as previously 
described (VEGFR2 vaccinated n=9, control vaccinated n=18). One day after 
the last immunization, 11 control vaccinated mice were sacrificed. Twelve 
weeks after the last immunization the remaining mice were sacrificed to 
analyze atherosclerosis in brachiocephalic arteries. The effect of vaccination 
against VEGFR2 on the initiation of atherosclerosis was determined in 3 
months old female low density lipoprotein receptor deficient (LDLr-/-) mice. 
Directly after the last immunization booster mice were put on a western type 
diet containing 0.25% cholesterol and 15% cocoa butter (Special Diet 
Services, UK) (VEGFR2 vaccinated n=17, control vaccinated n=15). After two 
weeks mice were anesthesized and atherosclerosis was induced by bilateral 
collar placement around the carotid arteries, as previously described.19 One 
week after collar placement 12 mice (VEGFR2 vaccinated n=6, control 
vaccinated n=6) were sacrificed for analysis of very early effects of 
vaccination on vascular morphology. Six weeks after induction of 
atherosclerosis, the remaining mice were sacrificed and lesion formation was 
analyzed in the carotid artery, as previously described. 
 
Induction of post-interventional neointima formation 
Female 3-months-old LDLr-/- mice were vaccinated (VEGFR2 vaccinated: 
n=15, control vaccinated: n=18) as described. Two weeks after the last 
immunization booster mice were put on a western type diet with continuation 
till the end of the experiment. One week later, mice were anesthetized and 
endothelial denudation of the right common carotid artery was performed by 
triple passing of a 0.36-mm flexible guidewire, which was inserted via an 
incision in the external carotid artery.20 One or 5 weeks after arterial injury 
mice were sacrificed and media area or neointimal lesions were analyzed in 
the common carotid artery. Maximal media area, developed within 1 week, 
was analyzed at sites more than 600 μm proximal from the carotid 
bifurcation. The site of maximal stenosis more than 600 μm proximal from the 
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carotid bifurcation was used for morphometric analysis of neointimal lesions 5 
weeks after denudation.       
 
Tissue harvesting 
Arteries and muscles were isolated after in situ perfusion for 15 minutes 
using PBS and subsequent perfusion using formalin for 30 minutes. Fixated 
tissues were embedded in OCT compound (Sakura Finetek, The 
Netherlands), snap-frozen in liquid nitrogen and stored at -20°C until further 
use. Transverse 5 μm cryosections were prepared and were mounted on a 
parallel series of slides.19 
 
Histology and immunohistochemistry 
Cryosections of arteries were routinely stained with hematoxylin (Sigma 
Diagnostics, MO) and eosin (Merck Diagnostica, Germany). Staining of 
sections for smooth muscle cells (SMCs) was performed with an anti-alpha 
smooth muscle cell actin antibody (clone 1A4, dilution 1:50; Sigma, MO) 
combined with goat anti-mouse IgG peroxidase conjugate as secondary 
antibody (dilution 1:100, Nordic, The Netherlands). Sections of muscles or 
arteries were stained for CD31 with a rat anti-mouse antibody (clone 
MEC13.3, dilution 1:50, Pharmingen, CA) and for VEGFR2 with a rat anti-
mouse antibody (clone Avas 12α1, dilution 1:50, Pharmingen) combined with 
a biotinilated polyclonal anti-rat secondary antibody (dilution 1:100, 
Pharmingen). For visualization the signal was amplified by the CSA system 
(Dako, The Netherlands) using 3,3’-diamino-benzidine as enzyme substrate 
for horse radish peroxidase. Analysis of stained sections was performed with 
a Leica DM-RE microscope and LeicaQwin software (Leica Imaging 
Systems). 
  
Cholesterol and triglyceride assay 
Plasma cholesterol and triglyceride levels were quantified colorimetrically by 
enzymatic procedures using Precipath (Boehringer, Germany) as internal 
standard. 
 
Data analyses 
Values are expressed as mean±sem. A 2-tailed Student’s t-test was used to 
compare individual groups of mice or cells. A level of p<0.05 was considered 
significant. 
 
 
Results 
 
Effect of vaccination on induction of VEGFR2 specific CD8+  cytotoxic 
T-lymphocytes 
Three weeks after the third vaccination of apoE-/- mice by oral administration 
of S. typhimurium transformed with pcDNA3.1-VEGFR2 or pcDNA3.1, 
splenocytes were isolated to determine their capacity to specifically kill 
VEGFR2 expressing cells. 
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Figure 1. Induction cell mediated immunity against VEGFR2 positive cells by DNA 
vaccination.  Murine fibroblasts expressing VEGFR2 and GFP were exposed to 
splenocytes, isolated from either VEGFR2-vaccinated or control-vaccinated mice 3 
weeks after the last immunization with the vaccine. After 24 hours of exposure, 
splenocytes isolated from VEGFR2-vaccinated (C) mice had induced a 2.4-fold (A) 
reduction in survival of VEGFR2/GFP positive cells (arrows) as compared to 
splenocytes isolated from control-vaccinated mice (B), which translates to a 4.6-fold 
increase in specific lysis of VEGFR2/GFP positive cells upon exposure to splenocytes 
isolated from VEGFR2 vaccinated mice. 100% survival defines the situation in which 
no spleen cells were added to the fibroblasts. Evaluation of anti-angiogenic effects of 
vaccination against VEGFR2 was performed by coagulation of the left femoral artery 1 
week after the last immunization. Two weeks after ischemia induction, angiogenesis 
was quantified in the gastrocnemic muscle and revealed a 50% reduction (D) in CD31 
staining upon vaccination against VEGFR2 (F) as compared to CD31 staining in 
control mice (E). ** P<0.01. 
 
 
 
 
 
 
 
 
 
 
Figure 2. Effect of vaccination against VEGFR2 on existing atherosclerotic lesions. 
ApoE-/- mice, which develop atherosclerosis spontaneously, were vaccinated against 
VEGFR2 or control-vaccinated at the age of 22 weeks. One day after the last 
immunization with the vaccine, 1 group of control vaccinated mice was sacrificed for 
lesions analysis in the brachiocephalic artery. Lesion size at this moment, quantified 
from haematoxylin/eosin stained sections, is indicated by the gray line (A). Twelve 
weeks after the last vaccine administration vaccination against VEGFR2 resulted in a 
25% reduction in absolute lesion size (A), which translated to a 66% reduction in 
progression of atherosclerosis since the last immunization as compared to control 
vaccination (B,C). *P<0.05. 
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Figure 3. Vaccination against VEGFR2 inhibits the initiation of atherosclerosis, which 
was induced by collar placement around carotid arteries of LDLr-/- mice two weeks 
after the last immunization. While plasma cholesterol levels remained unaffected 
during the experiment (A), 6 weeks after collar placement the intima area was 
reduced by 77% upon vaccination against VEGFR2 (C,D) as compared to control-
vaccinated mice (B), which translated to 2.7- and 3.0-fold decreases in intima/media 
(E) and intima/lumen ratios (F), respectively. *P<0.05, **P<0.01. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Vaccination against VEGFR2 leads to significantly decreased media area 
(A,C) 1 week after collar placement as compared to control vaccination (B), which 
indicates that vaccination against VEGFR2 interferes with atherosclerosis in a very 
early stage. *P<0.05. 
 
Twenty-four hours after exposure of VEGFR2expressing 3T3 cells to 
splenocytes from VEGFR2 vaccinated mice we observed a dramatic 
decrease in the number of VEGFR2 expressing cells whereas incubation with 
splenocytes from control vaccinated mice did not affect the survival of 
VEGFR2 expressing cells (Fig1.A-C; 86.3±12.5 vs 36.6±7.9%, p<0.005). 
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Anti-angiogenic effect of vaccination against VEGFR2 
To examine whether specific lysis of VEGFR2 overexpressing cells by 
vaccination against VEGFR2  affected angiogenesis, the left femoral artery of 
apoE-/- mice was coagulated unilaterally 1 week after the third vaccination to 
induce ischemia in the gastrocnemic muscle. Two weeks after coagulation, 
muscles were isolated and ischemia induced angiogenesis was quantified by 
measuring the CD31 positive area. Upon vaccination against VEGFR2 a 
significant 2.0-fold decrease in CD31 positive area was observed as 
compared to control mice (Fig1.D-F; 3,422±581 vs 1,743±168 μm2, p<0.01).  
 
Effect of vaccination against VEGFR2 on atherosclerosis 
The effects of vaccination against VEGFR2 on advanced lesions were 
determined using apoE-/- mice (22 weeks of age), which had developed 
atherosclerotic lesions on chow diet. One day after the last vaccine 
administration, a group of control-vaccinated mice was sacrificed and lesion 
formation was quantified in the brachiocephalic artery and compared with 
lesion formation 12 weeks after vaccination against VEGFR2 or control 
vaccination. Vaccination against VEGFR2 significantly reduced the absolute 
plaque size 12 weeks after vaccination by 25% as compared with control 
vaccinated mice (Fig.2A-C; 283,100±15,120 vs 211,767±21,433 μm2 , 
p<0.05), while cholesterol and triglyceride levels remained unchanged in all  
groups. However, when the initial level of atherosclerosis at the time point of 
the last vaccination is taken into account (figure 2, gray line (176,098 μm2)), it 
is clear that the progression of atherosclerosis was dramatically reduced by 
66% upon VEGFR2 vaccination as compared to control vaccination. 
Collar induced atherosclerosis in LDLr-/- mice fed a Western type diet was 
used to determine the effect of vaccination on the initiation of atherosclerosis. 
Vaccination against VEGFR2 reduced the initiation of atherosclerosis by 77% 
(Fig.3D, p<0.05), which translated into a marked 2.7-fold reduction in 
intima/media ratio (Fig.3E, p<0.01) and a 3.0-fold decreased intima/lumen 
ratio (Fig.3F, p<0.01). Furthermore, a trend in decreased media size, which is 
defined as the area between the internal and external elastic lamina, was 
observed six weeks after collar placement in mice vaccinated against 
VEGFR2 as compared to control vaccinated mice (45,292±6,480 vs 
31,715±1,573 μm2, p=0.056). At 7 days after collar placement quantification 
of media size revealed a significantly reduced media area upon vaccination 
against VEGFR2 as compared to controls (Fig.4A-C; 43,750±4,040 vs 
32,960±2,430 μm2, p<0.05), while  lesions were absent at this time.  
 
VEGFR2 positive cells and neovessels in atherosclerosis 
To evaluate the presence of neovessels in atherosclerosis sections were 
stained for CD31. Apart from endothelial cells covering the atherosclerotic 
plaque (Fig.5A) no CD31 positive cells were found within the neointima. 
However, many CD31 positive vessels were found in the media and 
adventitia underlying the atherosclerotic lesion (Fig.5B) and were more 
abundant as compared to arteries in which no atherosclerosis was induced. 
Anti-VEGFR2 staining confirmed that many of these microvessels in media 
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and adventitia were positive for VEGFR2 (Fig.5C,D). In addition, frequently 
VEGFR2 positive cells were identified in the adventitia, which were not 
associated with microvessels (Fig.5E). Apart from occasional VEGFR2 
positive endothelial cells covering the atherosclerotic lesion, no VEGFR2 
positive cells were found within the atherosclerotic plaques of carotid or 
brachiocephalic arteries (Fig.5F). 
 
Effect of VEGFR2 vaccination on post-interventional neointimal 
formation  
To evaluate the effect of vaccination against VEGFR2 on post-interventional 
neointima formation the endothelial layer of right carotid arteries was 
denudated in LDLr-/- mice and vascular wall or neointima formation was 
analyzed 1 or 5 weeks post arterial injury. One week after denudation the 
degree of endothelial replacement was quantified by counting the luminal flat 
shaped haematoxylin stained nuclei of CD31 positive stained cells at the site 
of maximal media area (Fig.6A), which revealed a 31% reduction in 
endothelial cells upon vaccination against VEGFR2 as compared to control 
vaccination (Fig.6B; 43.8±4.3 vs 30.2±3.3, p<0.05). Furthermore, vaccination 
against VEGFR2 resulted in a 1.4-fold increase in media area 1 week after 
denudation (Fig.6C; 34,026±1,020 vs 47,657±4,690 μm2, p<0.05). Five 
weeks after denudation neointimal lesions were stained for SMCs by alpha 
smooth muscle cell actin antibody staining and revealed a typical restenotic 
phenotype in which the main cellular component of intimal lesions is formed 
by smooth muscle cells (Fig.7A). Five weeks after denudation quantification 
of the neointima area revealed a significant 2.7-fold increase in lesion size 
upon vaccination against VEGFR2 as compared to control vaccination 
(Fig.7B-D; 16,028±3,968 vs 43,591±8,943 μm2, p<0.01). 
 
 
Discussion 
 
Despite the use of lipid lowering, anti-inflammatory, or plaque stabilizing 
treatments, atherosclerosis remains the major cause of cardiovascular 
disease, encouraging the development of alternative strategies to reduce 
atherosclerosis. Recently, several studies indicated that cell-based 
treatments could be of potential use in the development of novel therapies for 
atherosclerosis.21-23 Blockade of the recruitment or removal of cells that 
contribute to atherosclerosis may thus result in a reduction in lesion 
formation.24,25  
In the present study, we aimed to reduce atherosclerosis by targeting those 
cells that overexpress VEGFR2 by a novel DNA vaccination technique. Cell-
mediated immunity against VEGFR2 overexpressing cells was induced in 
atherosclerosis prone mice by 3 oral administrations of a vaccine, which 
comprised S. typhimurium carrying a vector encoding mouse VEGFR2. This 
vaccine passes through M cells of the gastroinstestinal tract to the Peyer’s 
patches and is transferred to antigen presenting cells, which become 
activated by the live attenuated bacteria leading to migration of these cells to 
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inductive sites of the immune system and the expression of the VEGFR2 
protein. Peptide fragments of VEGFR2 presented by the MHC class I activate 
CD8+ T cells, which start to clonally expand, leading to the breaking of 
tolerance against endogenous VEGFR2.26 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Quantification of endothelial replacement and media area after denudation 
of the common carotid artery. Two weeks after denudation of carotid arteries of 
VEGFR2 vaccinated or control-vaccinated mice, animals were sacrificed and carotid 
arteries were isolated. After staining for CD31 with haematoxylin counter stain, the 
amount of endothelial cells was quantified by counting all flat shaped nuclei in CD31 
positive cells lining the vessel wall (A). Quantification of these cells revealed a 
significant decrease in endothelial replacement upon vaccination against VEGFR2 
(B). Already 1 week after denudation media area was significantly enlarged upon 
vaccination against VEGFR2 (C). *P<0.05. 
Figure 5. Evaluation of the presence of 
atherosclerosis associated microvessels 
and VEGFR2 positive cells. Upon 
induction of atherosclerosis carotid 
arteries and brachiocephalic arteries 
were isolated and cryosections were 
made. Antibody staining for CD31 with 
haemotoxylin counter stain revealed the 
presence of endothelial cells covering 
the athrosclerotic plaque, but not within 
the neointima (A), and revealed the 
presence of microvessels in the 
adventitia (asterisk in A, B) and in the 
media (not shown) of  atherosclerosis 
affected arteries. VEGFR2 antibody 
staining confirmed neovascularization in 
adventitia both near the media (M) and 
more peripherally in the adventitia (C,D 
respectively) and in the media (not 
shown). Furthermore, anti-VEGFR2 
staining revealed the presence of 
adventitial VEGFR2 positive cells that 
were not associated with neovessels (E) 
and occasionally showed the presence of VEGFR2 positive cells that covered the
atherosclerotic plaque (F). Arrows indicate positive staining.  
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We confirmed that the spleen cells from VEGFR2 vaccinated LDLr-/- mice 
specifically lysed cells that overexpressed VEGFR2, while spleen cells from 
control vaccinated mice were unable to kill the VEGFR2 overexpressing cells, 
which demonstrates the effectiveness of the vaccination. To examine 
whether the functional role of VEGFR2 expressing cells was impaired in vivo 
by vaccination, angiogenesis was induced in a hind limb ischemia model in 
hypercholesterolemic mice (LDLr-/- on a Western type diet). Angiogenesis 
was decreased by 50% upon vaccination against VEGFR2, which is caused 
by the killing of VEGFR2 expressing cells, which normally contribute to 
angiogenesis.5-7 These results are in line with the study of Niethammer et al. 
in which the VEGFR2 vaccine was used to block tumor growth by inhibiting 
tumor angiogenesis. In this study CD8+ T cells colocalised with their target 
site, the tumor vasculature. The fact that CD8+ T cell depletion but not CD4+ 
T cell depletion upon vaccination against VEGFR2 severely impaired the 
effect of vaccination further underline the key role of cytotoxic CD8+ T cells as 
effector cells in the VEGFR2 vaccination.18  
In the present study, we show that vaccination against VEGFR2 inhibits the 
progression of pre-existing atherosclerotic lesions in apoE-/- mice. As 
expected, VEGFR2 vaccination did not affect serum cholesterol levels, but 
resulted in a significantly reduced level of atherosclerosis in the 
brachiocephalic artery at 12 weeks after the last vaccination. When 
compared to the amount of lesion 1 day after the last vaccination, the 
progression of atherosclerosis in this late stage of atherosclerosis was 
impaired by 66% upon vaccination against VEGFR2. We conclude from 
these results that cells, which highly express VEGFR2 promote the 
progression of atherosclerosis since these cells are removed by the CD8+ T 
cells upon vaccination. In a second experiment we determined the effect of 
vaccination against VEGFR2 on the initial phases of atherosclerosis and we 
vaccinated mice directly before induction of atherosclerosis by collar 
placement around the common carotid arteries of LDLr-/- mice on a Western 
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3 )Figure 7. Effect of vaccination
against VEGFR2 on neointima
formation after vascular injury by
denudation. Five weeks after
denudation mice were sacrificed
and neointima formation was
analyzed in the carotid artery,
which revealed a smooth muscle
cell rich lesion, as determined with
an antibody staining against alpha
smooth muscle cell actin (A).
Quantification of lesions five weeks
after denudation revealed a 2.7-fold
increase in neointima formation (B)
upon vaccination against VEGFR2
(D) as compared to control
vaccination (C). **P<0.01. 
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type diet. Collar placement induces a typical atherosclerotic lesion 
characterized by a lipid core which is covered by a fibrous cap containing 
smooth muscle cells and collagen.19 Six weeks after collar placement 
vaccination against VEGFR2 resulted in 77% reduced atherosclerosis, which 
translated to 2.7- and 3.0-fold reduced intima/media and intima/lumen ratios, 
respectively. Lesions, developed upon vaccination against VEGFR2 resulted 
in very small lesions and were reduced to such an extent that it is most likely 
that vaccination against VEGFR2 already interferes in a very initial stage of 
atherosclerosis. Again we conclude that cells that highly express VEGFR2 
are involved in the development of atherosclerosis and that these cells 
regulate atherosclerosis already in a very early stage. Interestingly, a trend 
towards smaller media thickness was observed upon vaccination against 
VEGFR2 6 weeks after collar placement. Since several kinds of cells 
overexpress VEGFR2, the attenuating effect of vaccination on both the 
progression and initiation of atherosclerosis may be exerted by a variety of 
mechanisms. Proliferating endothelial cells have been shown to highly 
express VEGFR2 and contribute to angiogenesis,5-7 which explains our 
observed inhibiting effects on angiogenesis in the hind limb ischemia model 
upon vaccination against VEGFR2. In several studies angiogenesis was 
indicated to contribute to the progression of atherosclerosis,8,9 suggesting 
that blockade of angiogenesis by vaccination against VEGFR2 may result in 
decreased atherosclerosis. Microvessels, indicated by CD31 and VEGFR2 
staining, were identified in the adventitia and media in both models for 
atherosclerosis. However, apart from staining of the endothelial cells, which 
covered the atherosclerotic plaque, we did not identify VEGFR2 or CD31 
positive cells in the neointima, suggesting the lack of intra-plaque 
angiogenesis in these models for atherosclerosis. This lack of intra-plaque 
vessels may be explained by the fact that adaptive hypoxia driven intra-
plaque neovessel formation only occurs when plaque tissue is located >100 
μm from the blood stream or capillaries, which is not the case in our 
models.27 However, we did observe VEGFR2 positive microvessels within the 
media at the side of the lesion, which may indicate the initiation of 
neovascularization of the lesions. These VEGFR2 positive vessels may have 
served as a target for the CD8 positive VEGFR2 specific T cells and that the 
killing of the VEGFR2 positive endothelial cells may have diminished the 
optimal growth of the plaque in the VEGFR2 vaccinated mice. Furthermore, 
after the observation of a correlation between the degree of adventitial 
angiogenesis and the amount of neointima formation, it was suggested that 
adventitial angiogenesis may contribute to atherosclerosis.28,29 In addition, 
stimulation of adventitial angiogenesis, by administration of endothelial 
progenitor cells or adventitial application of VEGF, resulted in increased 
neointima formation.30,31 However, it remains hard to prove an important 
contribution of angiogenesis impairment to the exerted effect of vaccination 
on atherosclerosis since reduced angiogenesis can be the result of reduced 
atherosclerosis rather than the cause of reduced atherosclerosis.  
Recently, data accumulated on the role of progenitor cells in atherosclerosis. 
Circulating hematopoietic stem cells were shown to differentiate into vascular 
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cells that participate in atherosclerosis.21 Furthermore, progenitor cells, 
including VEGFR2 positive cells, were identified in the adventitia.32 These 
progenitor cells were shown to migrate to the intima, where these cells can 
differentiate into vascular smooth muscle cells and promote atherosclerosis. 
In the present study, we confirmed the presence of VEGFR2 positive cells, 
which were not associated with neovessels, in the adventitia of 
atherosclerosis affected arteries. Although their presence in the adventitia 
does not proof a role in atherosclerosis as progenitor cells in our models for 
atherosclerosis, this study shows that VEGFR2 positive cells are at least 
associated with atherosclerosis. In addition, VEGFR2 positive cells, isolated 
from embryonic stem cells, have been indicated as vascular progenitor cells 
that can differentiate into both endothelial and smooth muscle cells.11 A 
recent study confirmed that, although not under atherosclerotic conditions,  
VEGFR2 positive cells are able to differentiate into smooth muscle cells in 
vivo during vascular recovery after denudation.13 Taking these findings and 
our results together, vaccination against VEGFR2 may have resulted in 
reduced amounts of progenitor cells that contribute to atherosclerosis.  
The fact that VEGFR2 is highly expressed on activated endothelial cells, 
which cover the atherosclerotic plaque, may indicate that vaccination against 
VEGFR2 removes these activated cells,10 which become replaced by new 
“healthy” endothelial cells. Furthermore, VEGF has been shown to accelerate 
atherosclerosis in hypercholesterolemic mice and rabbits.14 Although it is still 
not clear what the relative contribution is of the two major receptors for 
VEGF, namely VEGFR1 or VEGFR2, to atherosclerosis development, 
several arguments support an important role for VEGFR2. Binding of VEGF 
to VEGFR2 induces inflammatory responses in both macrophages and 
endothelial cells by NFκB activation. VEGFR2 is expressed on activated 
macrophages, including atheroma-associated macrophages,15 and is 
involved in the migration and proliferation of these cells. Furthermore, binding 
of VEGF to VEGFR2 induces elevated expression levels of VCAM-1, ICAM-
1, and E-selectin in endothelial cells leading to increased adherence of 
monocytes.17 These studies support the hypothesis that interference in the 
binding of VEGF to VEGFR2 by removing VEGFR2 positive cells may lead to 
reduced atherosclerosis.  
To investigate the effect of vaccination against VEGFR2 on post-
interventional neointima formation in which vascular injury takes places, a 
mouse model was used in which the common carotid artery was denudated 
with a guide wire. The kind of injury and the resulting smooth muscle cell rich 
neointima formation are characteristics of a more restenotic process. One 
week after denudation endothelial replacement was significantly reduced in 
mice that were vaccinated against VEGFR2 as compared to control mice. 
This delayed replacement is likely to be caused by the specific attack of 
proliferating endothelial cells which overexpress VEGFR2 by the CD8+ T 
cells. Furthermore, reduced amounts of circulating endothelial progenitor 
cells may have contributed to delayed endothelial replacement, which is in 
line with a recent study in which VEGFR2 positive cells in the peripheral 
blood have been shown to contribute to reendothelialization of balloon injured 
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femoral arteries of mice.13 Already 1 week after denudation vaccination 
against VEGFR2 led to increased media area and 5 weeks after denudation 
neointima formation in VEGFR2 vaccinated mice was 2.7-fold increased. The 
most likely explanation for this increase in post-interventional neointima 
formation upon vaccination against VEGFR2 is the prolonged activation of 
the media, exposed to the blood stream and adhesive platelets, due to the 
delayed reendothelialization. 
Recently, several vaccination strategies revealed promising effects on 
atherosclerosis. Vaccination against modified LDL, apoB100, cholesterol 
ester transfer protein (CETP), and interleukin 12 resulted in reduced 
atherosclerosis by inducing antibodies against these factors.33-36 In contrast 
to the induction of humoral responses by vaccination against soluble proteins 
such as IL-12,  which significantly down-regulates atherosclerosis,36 this 
study shows for the first time that vaccination induced of cell-mediated 
immunity against cells that potentially contribute to atherosclerosis results in 
reduced lesion formation. These results suggest that specific targeting of 
cells that contribute to atherosclerosis may form a new lead for the 
development of immunotherapies against atherosclerosis. The relatively low 
costs and the long duration of the therapeutic efficacy, which was also shown 
for this vaccination strategy (>10 months after the last administration of the 
vaccine),18 make vaccination an attractive tool in establishing protection 
against atherosclerosis. However, since vaccination against VEGFR2 not 
only results in attenuated atherosclerosis, but at the same time increases 
post-interventional neointima formation, VEGFR2 overexpressing cells may 
only be suitable for a limited patient population that does not qualify for 
transluminal angioplasty.  
In summary, our study demonstrates that vaccination against VEGFR2 
induces cell-mediated immunity against VEGFR2 leading to attenuated 
atherosclerosis in both early and advanced stages, but enhanced post-
interventional neointima formation in hypercholesterolemic mice, which 
suggests an important role of VEGFR2 cells in atherosclerosis and 
restenosis.  These results indicate that cell-based therapies can be of 
potential use in the treatment of vascular disorders and that induction of cell-
mediated immunity by vaccination can be a useful tool in targeting specific 
atheroma-associated cell types in order to reduce atherosclerosis.     
 
 
References 
 
1. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340:115-
126. 
2. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl 
J Med. 2005;352:1685-95. 
3. Tupin E, Nicoletti A, Elhage R, Rudling M, Ljunggren HG, Hansson GK, Berne 
GP. CD1d-dependent activation of NKT cells aggravates atherosclerosis. J Exp 
Med. 2004;199:417-22. 
Chapter 6 
  107
4. Shi Q, Rafii S, Wu MH, Wijelath ES, Yu C, Ishida A, Fujita Y, Kothari S, Mohle R, 
Sauvage LR, Moore MA, Storb RF, Hammond WP. Evidence for circulating bone 
marrow-derived endothelial cells. Blood. 1998;92:362-7. 
5. Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML, 
Schuh AC. Failure of blood-island formation and vasculogenesis in Flk-1-deficient 
mice. Nature. 1995;376:62-6.  
6. Li Y, Wang MN, Li H, King KD, Bassi R, Sun H, Santiago A, Hooper AT, Bohlen 
P, Hicklin DJ. Active immunization against the vascular endothelial growth factor 
receptor flk1 inhibits tumor angiogenesis and metastasis. J Exp Med. 
2002;195:1575-84. 
7. Tepper OM, Capla JM, Galiano RD, Ceradini DJ, Callaghan MJ, Kleinman ME, 
Gurtner GC. Adult vasculogenesis occurs through in situ recruitment, 
proliferation, and tubulization of circulating bone marrow-derived cells. Blood. 
2005;105:1068-77. 
8. Moulton KS, Heller E, Konerding MA, Flynn E, Palinski W, Folkman J. 
Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization 
and plaque growth in apolipoprotein E-deficient mice. Circulation. 1999;99:1726-
32. 
9. Moulton KS, Vakili K, Zurakowski D, Soliman M, Butterfield C, Sylvin E, Lo KM, 
Gillies S, Javaherian K, Folkman J. Inhibition of plaque neovascularization 
reduces macrophage accumulation and progression of advanced atherosclerosis. 
Proc Natl Acad Sci U S A. 2003;100:4736-41. 
10. Belgore F, Blann A, Neil D, Ahmed AS, Lip GY. Localisation of members of the 
vascular endothelial growth factor (VEGF) family and their receptors in human 
atherosclerotic arteries. J Clin Pathol. 2004;57:266-72. 
11. Yamashita J, Itoh H, Hirashima M, Ogawa M, Nishikawa S, Yurugi T, Naito M, 
Nakao K, Nishikawa S. Flk1-positive cells derived from embryonic stem cells 
serve as vascular progenitors. Nature. 2000;408:92-6. 
12. Gittenberger-de Groot AC, DeRuiter MC, Bergwerff M, Poelmann RE. Smooth 
muscle cell origin and its relation to heterogeneity in development and disease. 
Arterioscler Thromb Vasc Biol. 1999;19:1589-94. 
13. Nowak G, Karrar A, Holmen C, Nava S, Uzunel M, Hultenby K, Sumitran-
Holgersson S. Expression of vascular endothelial growth factor receptor-2 or Tie-
2 on peripheral blood cells defines functionally competent cell populations 
capable of reendothelialization. Circulation. 2004;110:3699-707. 
14. Celletti FL, Waugh JM, Amabile PG, Brendolan A, Hilfiker PR, Dake MD. 
Vascular endothelial growth factor enhances atherosclerotic plaque progression. 
Nat Med. 2001;7:425-9. 
15. Inoue M, Itoh H, Ueda M, Naruko T, Kojima A, Komatsu R, Doi K, Ogawa Y, 
Tamura N, Takaya K, Igaki T, Yamashita J, Chun TH, Masatsugu K, Becker AE, 
Nakao K. Vascular endothelial growth factor (VEGF) expression in human 
coronary atherosclerotic lesions: possible pathophysiological significance of 
VEGF in progression of atherosclerosis. Circulation. 1998;98:2108-16. 
16. Yang ZF, Poon RT, Luo Y, Cheung CK, Ho DW, Lo CM, Fan ST. Up-regulation of 
vascular endothelial growth factor (VEGF) in small-for-size liver grafts enhances 
macrophage activities through VEGF receptor 2-dependent pathway. J Immunol. 
2004 Aug 15;173:2507-15. 
17. Kim I, Moon SO, Kim SH, Kim HJ, Koh YS, Koh GY. Vascular endothelial growth 
factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell 
adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-kappa B 
activation in endothelial cells. J Biol Chem. 2001;276:7614-20.  
Vaccination against VEGFR2 blocks atherosclerosis 
  108
18. Niethammer AG, Xiang R, Becker JC, Wodrich H, Pertl U, Karsten G, Eliceiri BP, 
Reisfeld RA. A DNA vaccine against VEGF receptor 2 prevents effective 
angiogenesis and inhibits tumor growth. Nat Med. 2002;8:1369-75. 
19. von der Thusen JH, van Berkel TJ, Biessen EA. Induction of rapid atherogenesis 
by perivascular carotid collar placement in apolipoprotein E-deficient and low-
density lipoprotein receptor-deficient mice. Circulation. 2001;103:1164-70.  
20. Schober A, Manka D, von Hundelshausen P, Huo Y, Hanrath P, Sarembock IJ, 
Ley K, Weber C. Deposition of platelet RANTES triggering monocyte recruitment 
requires P-selectin and is involved in neointima formation after arterial injury. 
Circulation. 2002;106:1523-9. 
21. Sata M, Saiura A, Kunisato A, Tojo A, Okada S, Tokuhisa T, Hirai H, Makuuchi 
M, Hirata Y, Nagai R. Hematopoietic stem cells differentiate into vascular cells 
that participate in the pathogenesis of atherosclerosis. Nat Med. 2002;8:403-9. 
22. Silvestre JS, Gojova A, Brun V, Potteaux S, Esposito B, Duriez M, Clergue M, Le 
Ricousse-Roussanne S, Barateau V, Merval R, Groux H, Tobelem G, Levy B, 
Tedgui A, Mallat Z. Transplantation of bone marrow-derived mononuclear cells in 
ischemic apolipoprotein E-knockout mice accelerates atherosclerosis without 
altering plaque composition. Circulation. 2003;108:2839-42.  
23. Abedin M, Tintut Y, Demer LL. Mesenchymal stem cells and the artery wall. Circ 
Res. 2004;95:671-6.  
24. Charo IF, Taubman MB. Chemokines in the pathogenesis of vascular disease. 
Circ Res. 2004;95:858-66.  
25. van Wanrooij EJ, Happe H, Hauer AD, de Vos P, Imanishi T, Fujiwara H, van 
Berkel TJ Kuiper J. HIV Entry Inhibitor TAK-779 Attenuates Atherogenesis in 
Low-Density Lipoprotein Receptor-Deficient Mice. Arterioscler Thromb Vasc Biol. 
2005;25:2642-7. 
26. Reisfeld RA, Niethammer AG, Luo Y, Xiang R. DNA vaccines suppress tumor 
growth and metastases by the induction of anti-angiogenesis. Immunol Rev. 
2004;199:181-90. 
27. Torres Filho IP, Leunig M, Yuan F, Intaglietta M, Jain RK. Noninvasive 
measurement of microvascular and interstitial oxygen profiles in a human tumor 
in SCID mice. Proc Natl Acad Sci U S A. 1994;91:2081-5. 
28. Bhardwaj S, Roy H, Heikura T, Yla-Herttuala S. VEGF-A, VEGF-D and VEGF-D 
induced intimal hyperplasia in carotid arteries. Eur J Clin Invest. 2005;35:669-76. 
29. Langheinrich AC, Michniewicz A, Sedding DG, Walker G, Beighley PE, Rau WS, 
Bohle RM, Ritman EL. Correlation of Vasa Vasorum Neovascularization and 
Plaque Progression in Aortas of Apolipoprotein E-/-/Low-Density Lipoprotein-/- 
Double Knockout Mice. Arterioscler Thromb Vasc Biol. 2005 Nov 17. 
30. Khurana R, Zhuang Z, Bhardwaj S, Murakami M, De Muinck E, Yla-Herttuala S, 
Ferrara N, Martin JF, Zachary I, Simons M. Angiogenesis-dependent and 
independent phases of intimal hyperplasia. Circulation. 2004;110:2436-43. 
31. George J, Afek A, Abashidze A, Shmilovich H, Deutsch V, Kopolovich J, Miller H, 
Keren G. Transfer of Endothelial Progenitor and Bone Marrow Cells Influences 
Atherosclerotic Plaque Size and Composition in Apolipoprotein E Knockout Mice. 
Arterioscler Thromb Vasc Biol. 2005;25:2636-2641. 
32. Hu Y, Zhang Z, Torsney E, Afzal AR, Davison F, Metzler B, Xu Q. Abundant 
progenitor cells in the adventitia contribute to atherosclerosis of vein grafts in 
ApoE-deficient mice. J Clin Invest. 2004;113:1258-65. 
33. Palinski W, Miller E, Witztum JL. Immunization of low density lipoprotein (LDL) 
receptor-deficient rabbits with homologous malondialdehyde-modified LDL 
reduces atherogenesis. Proc Natl Acad Sci U S A. 1995;92:821-5.  
Chapter 6 
  109
34. Fredrikson GN, Soderberg I, Lindholm M, Dimayuga P, Chyu KY, Shah PK, 
Nilsson J. Inhibition of atherosclerosis in apoE-null mice by immunization with 
apoB-100 peptide sequences. Arterioscler Thromb Vasc Biol. 2003;23:879-84. 
35. Rittershaus CW, Miller DP, Thomas LJ, Picard MD, Honan CM, Emmett CD, 
Pettey CL, Adari H, Hammond RA, Beattie DT, Callow AD, Marsh HC, Ryan US. 
Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions 
in a rabbit model of atherosclerosis. Arterioscler Thromb Vasc Biol. 
2000;20:2106-12. 
36. Hauer AD, Uyttenhove C, de Vos P, Stroobant V, Renauld JC, van Berkel TJ, van 
Snick J, Kuiper J. Blockade of interleukin-12 function by protein vaccination 
attenuates atherosclerosis. Circulation. 2005;112:1054-62. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Vaccination against VEGFR2 blocks atherosclerosis 
  110
 
 
 
 
 
 
Chapter 6 
  111
 
 
 
Induction of cellular immunity against TIE2 by DNA 
vaccination attenuates atherosclerosis  
 
A.D. Hauer1, K.L.L. Habets1, E.J.A. van Wanrooij1, P. de Vos1, Th.J.C. van 
Berkel1, R.A. Reisfeld2, J. Kuiper1 
 
1Division of Biopharmaceutics, Leiden/Amsterdam Center for Drug Research, Leiden University, 
2The Scripps Research Institute, La Jolla, USA 
 
 
 
 
 
 
 
 
Abstract 
 
TIE2 positive cells play a crucial role in processes that are potentially 
involved in atherosclerosis, such as angiogenesis. Therefore, the specific 
deletion of TIE2 positive cells by means of DNA vaccination may affect 
atherosclerosis. Cellular immunity against cells that overexpress TIE2 was 
established in LDLr-/- mice by a novel oral DNA vaccination technique, in 
which an attenuated Salmonella typhimurium strain was used as a carrier for 
plasmid pcDNA3.1 encoding TIE2. After three oral vaccinations with 2-week 
time intervals LDLr-/- mice were put on a Western type diet and 
atherosclerosis was induced. Eight weeks after vaccination FACS analysis of 
circulating PBMCs revealed a significant decrease (33%, p<0.05) in TIE2 
positive cells upon vaccination against TIE2, indicating the successful 
induction of cellular immunity following vaccination against TIE2. Six weeks 
after collar placement vaccination against TIE2 resulted in significantly 
decreased carotid atherosclerosis, as indicated by 30% (p<0.05) reduced 
intima area and 27% (p<0.05) reduced intima/lumen ratios. Furthermore, 
atherosclerosis was attenuated in the aortic root by 42% (p<0.05), confirming 
the anti-atherosclerotic effect of vaccination against TIE2. Histochemical 
analysis of the atherosclerotic lesion composition revealed a 1.6-fold (p<0.05) 
increase in collagen content upon vaccination against TIE2, indicating a more 
stable plaque phenotype. We demonstrate that vaccination against TIE2 
induced cellular immunity against cells that overexpress TIE2 and resulted in 
smaller atherosclerotic lesions with a more stable phenotype. Therefore, 
vaccination strategies that target cells that contribute to atherosclerosis, may 
be of potential use in the development of novel treatments against 
atherosclerosis. 
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Introduction 
 
Despite the use of lipid lowering therapies, atherosclerosis remains the major 
cause of cardiovascular disease, which indicates the need to develop novel 
strategies to treat atherosclerosis. Accumulating data suggest that 
vaccination may be an attractive method to induce long-lasting protection 
against endogenous factors that contribute to the development of 
atherosclerosis. Along this line, vaccination against modified low density 
lipoprotein (LDL),1 apolipoprotein B100 (apoB100),2 cholesteryl ester transfer 
protein (CETP),3 and interleukin 12 (IL-12),4 has been proven to successfully 
reduce atherosclerosis in mouse studies. Furthermore, it was suggested that 
a cell-based approach, in which the amount of anti-atherosclerotic cells is 
increased or in which the amount or the recruitment of pro-atherosclerotic 
cells is reduced, may contribute to the development of a novel therapy 
against atherosclerosis.5,6 Recently, we combined these two strategies to 
treat atherosclerosis by vaccination against vascular endothelial growth factor 
receptor 2 (VEGFR2), which resulted in CD8+ T cell driven specific lysis of 
cells overexpressing VEGFR2.7,8 These VEGFR2 positive cells contribute to 
processes that are involved in atherosclerosis, such as angiogenesis 9-11 and 
vaccination against VEGFR2 resulted in a significant reduction in initiation 
and progression of atherosclerosis.7  
In the present study, we aimed to substantiate our hypothesis that targeting 
of pro-atherosclerotic cells by vaccination may be of potential use in the 
treatment of atherosclerosis. To that end we focused in this study on TIE2 
overexpressing cells. TIE2 was recently identified as a receptor tyrosine 
kinase (RTK) that is expressed predominantly on endothelial (precursor) cells 
in both the embryonic and the adult vasculature in a wide range of tissues.12-
14 Natural ligands for TIE2 are angiopoietins, of which Ang1 induces 
phosphorylation of TIE2,15,16 whereas Ang2, although context dependent, 
inhibits TIE2 activation.17 The interaction of angiopoietins with TIE2 has been 
shown to regulate endothelial cell survival and migration, which may at least 
partly explain the essential role of TIE2 in vessel maturation during 
angiogenesis.15 Furthermore, TIE2 has been shown to identify a 
hematopoietic lineage which is able to contribute to neointimal 
angiogenesis.18 In addition, both Ang1 and Ang2 have been shown to 
increase the recruitment of leukocytes leading to enhanced proinflammatory 
responses.19  TIE2 expression is not restricted to endothelial cells but some 
of the subendothelial intimal cells have been shown to be double positive for 
TIE2 and smooth muscle cell markers, but negative for endothelial 
markers.20,21 Moreover,  Ang1 has been shown to promote adhesion of 
monocytes to vascular smooth muscle cells and increase plaque size in 
apoE-/- mice.22  Therefore TIE2 positive cells form an interesting target for 
interference in atherosclerosis and a reduction in their number may be 
beneficial for the outcome of atheroscerosis. 
Therefore, we induced T cell-mediated immunity against endogenous TIE2 
by a novel oral DNA vaccination technique, in which an attenuated strain of 
Salmonella typhimurium, carrying a plasmid encoding TIE2, is used as the 
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vaccine. By inducing cellular immunity against TIE2 we were able to 
significantly attenuate collar induced atherosclerosis in the carotid artery as 
well as spontaneous atherosclerosis development in the aortic root of LDL 
receptor deficient (LDLr-/-) mice. Furthermore, vaccination against TIE2 
increased the collagen content of the atherosclerotic plaque, which indicates 
a more stable phenotype. Therefore, DNA vaccination to target cells that 
contribute to atherosclerosis may form an attractive strategy for the treatment 
of atherosclerosis.  
 
 
Methods 
 
Vaccination strategy 
Plasmid pcDNA3.1 (Invitrogen, CA) encoding murine TIE2 was constructed 
and electroporated in attenuated S. typhimurium Aro/A (strain SL7207) 
bacteria, as previously described. Mice were vaccinated by 3 times oral 
administration with 2-week intervals with 1x108 S. typhimurium bacteria 
transformed with pcDNA3.1-TIE2 or pcDNA3.1 (control) in 100 μl PBS, as 
described previously.8 
 
Induction of atherosclerosis 
All animal work was performed in compliance with the guidelines issued by 
the Dutch government. Female LDLr-/- mice, aged 10 to 12 weeks, were 
vaccinated against TIE2 (n=11) or control vaccinated (n=12) by 3 times oral 
administration of the vaccine with 2-week intervals. Immediately after the last 
administration of the vaccine, mice were put on a Western type diet, 
containing 0.25% cholesterol and 15% cocoa butter (Special Diet Services, 
UK). After 2 weeks of western-type diet feeding, mice were anaesthetized 
and atherosclerosis was induced in carotid arteries by bilateral perivascular 
collar placement, as described previously.23 
 
Tissue harvesting 
Six weeks after collar placement, carotid arteries and hearts were isolated 
after in situ perfusion for 15 minutes with the use of PBS and subsequent 
perfusion with the use of formalin for 30 minutes. Fixated carotids were 
embedded in OCT compound (Sakura Finetek, The Netherlands), snap-
frozen in liquid nitrogen, and stored at -20ºC until further use. Transverse 5-
μm cryosections were prepared in a proximal direction from the carotid 
bifurcation and mounted on a parallel series of slides. For analysis of 
atherosclerosis at the site of the tricuspid valves in the aorta 10 μm 
transverse cryosections were made of the aortic root.  
 
Histochemistry 
Cryosections were routinely stained with hematoxylin (Sigma Diagnostics, 
MO) and eosin (Merck Diagnostica, Germany). Corresponding sections were 
stained immunohistochemically with antibodies against a macrophage 
specific antigen (MOMA-2, polyclonal rat IgG2b; Research Diagnostics Inc, 
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NJ) and α-smooth muscle cell actin (monoclonal mouse IgG2a, clone 1A4; 
Sigma Diagnostics). Sections were incubated with primary antibodies for 2 
hours. As secondary antibodies, goat anti-mouse IgG peroxidase conjugate 
(Nordic, The Netherlands), or goat anti-rat IgG alkaline phosphatase 
conjugate (Sigma Diagnostics), with 3,3’-diamino-benzidine (sigma 
Diagnostics), and 5 bromo-4-chloro-3-indolyl phosphate (sigma Diagnostics) 
were used as enzyme substrates. Sections were stained for CD31 with a rat 
anti-mouse antibody (clone MEC13.3, dilution 1:50, Pharmingen, CA) 
combined with a biotynilated polyclonal anti-rat secondary antibody (dilution 
1:100, Pharmingen). For visualization the signal was amplified by the CSA 
system (Dako, The Netherlands). Corresponding sections were stained for 
collagen by picrosirius red (Direct red 80) staining. Cryosections of lesions in 
the aortic root were stained for lipids with an Oil red O staining (Ltd., 
England). 
 
Morphometry 
Hematoxylin-eosin-stained sections of carotid arteries were used for 
morphometric analysis of atherosclerotic lesions. Sections were analyzed 
using a Leica DM-RE microscope and LeicaQwin software (Leica Imaging 
Systems, UK). Each carotid artery was assessed ~0.5 mm proximal to the 
collar, and the site of maximal stenosis was used for morphometric analysis. 
Contens of macrophages, smooth muscle cells and collagen were obtained 
by dividing the area of specific staining within the intima by the total intima 
area. Analysis of atherosclerotic lesion area in the aortic root was performed 
on the Oil red O stained sections, as previously described.24 
 
Quantification of circulating TIE2 positive cells by flow cytometry 
At the moment of sacrifice blood was collected from the orbital sinus after 
induction of general anesthesia. Peripheral blood mononuclear cells 
(PBMCs) were isolated from the blood on a density gradient (Lympholyte, 
Cedarlane Laboratories, Canada) according to manufacturer’s instructions. In 
a 96 wells plate PBMCs (2x105/well) were stained with a phycoerythrin (PE) 
conjugated antibody against TIE2 (clone TEK4, Immunosource, The 
Netherlands), or with a FITC conjugated antibody against CD34 (Clone 
RAM34, Immunosource) for 45 minutes with a concentration of 2 μg/ml. After 
3 washing steps with PBS 5x104 cells were analyzed with a Becton Dickinson 
FACS Calibur flow cytometer.  
 
Data analyses 
Values are expressed as mean±sem. A 2-tailed Student’s t-test was used to 
compare individual groups of mice or cells. A level of p<0.05 was considered 
significant. 
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Results 
 
Effect of vaccination against TIE2 on atherosclerosis 
To evaluate the effect of vaccination against TIE2 on de novo 
atherosclerosis, LDLr-/- mice were vaccinated orally three times against TIE2 
with two-week time intervals after which mice were put on a Western type 
diet. Two weeks after the last immunization atherosclerosis was induced by 
collar placement around the carotid arteries and six weeks thereafter mice 
were killed and atherosclerotic plaque formation was analyzed in the right 
carotid artery and aortic root. In carotid arteries vaccination against TIE2 
resulted in a significant 30% reduction in intima area (Fig 1C; 90,100±7,780 
vs 63,048±9,670 μm2; p<0.05) as compared to control-treated animals. 
Vaccination against TIE2 also resulted in 27%  decreased intima/lumen ratios 
(Fig 1D; 0.79±0.05 vs 0.58±0.07; p<0.05). To substantiate the effect on 
atherosclerosis we determined the amount of plaque formation at another 
site, namely the aortic root.  Analysis of Oil red O stained sections of the 
semilunar valves in the aortic root revealed a significant 42% reduction in 
lesion area after vaccination against TIE2 (Fig 2; 3.44x105±0.51x105 vs 
1.99±0.41x105 μm2; p<0.05). 
 
Effect of vaccination against TIE2 on lesion composition 
To investigate whether vaccination against TIE2 affects lesion composition 
sections of carotid atherosclerotic lesions were stained for smooth muscle 
cells, macrophages, and collagen. Quantification of the smooth muscle cell 
and macrophage content did not reveal a significant difference between 
control and TIE2-vaccinated mice. However, staining for collagen with a 
picrosirius red staining showed a significant 1.6-fold increase in collagen 
content, reflected by increased picrosirius red/intima ratios, in the neointima 
upon vaccination against TIE2 as compared to control-treated animals (Fig 3; 
0.28±0.02 vs 0.44±0.06; p<0.05). CD31 staining revealed in both vaccinated 
and control treated animals the presence of vessels in media and adventitia 
in atherosclerosis affected carotid arteries, but not within the atherosclerotic 
plaque, which is in line with our previously obtained data.7 
 
Quantification of circulating TIE2 positive cells 
Eight weeks after the last vaccination blood was collected to quantify the 
number of circulating TIE2 positive cells. Upon isolation of PBMCs from the 
blood flow cytometry was used to determine the percentage of TIE2 positive 
and CD34/TIE2 double positive cells. CD34 is expressed on hematopoietic 
and endothelial progenitor cells. TIE2 positive cells represent a small 
population (0.91 %) of the total population of PBMCs and in this population 
the percentage TIE2 positive cells was significantly reduced by 33% (Fig 4A; 
0.91±0.09 vs 0.61±0.10%; p<0.05) upon vaccination against TIE2. When 
gated on CD34 positive cells, the percentage of TIE2 positive cells was 
reduced by 65% (Fig 4B; 14.84±1.72 vs 5.27±0.48%; p<0.005). 
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Figure 1. Effect of vaccination against TIE2 on collar induced atherosclerosis. Mice 
were orally vaccinated with attenuated S. typhimurium containing plasmid pcDNA3.1 
encoding TIE2 prior to Western type diet feeding. Atherosclerosis was induced by 
collar placement around carotid arteries of LDLr-/- mice two weeks after the last 
immunization. Six weeks after collar placement mice were sacrificed and carotid 
arteries were isolated for analysis of the degree of atherosclerosis. Quantification of 
atherosclerosis with haematoxylin-eosin stained sections (A,B) revealed a significant 
33% (p<0.05) reduced intima area (C) and a 27% (p<0.05) reduced intima/lumen ratio 
(D) upon vaccination against TIE2 as compared to control vaccination.*P<0.05.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Effect of vaccination against TIE2 on diet induced atherosclerosis. 
Vaccination against TIE2 attenuated atherosclerosis in the tricuspid valves in the 
aortic root, which was induced by Western type diet feeding during 8 weeks. 
Quantification of atherosclerosis with Oil red O stained sections (B,C) revealed a 42% 
(p<0.05) reduction in intima area (A) upon vaccination against TIE2 as compared to 
control treatment. *P<0.05.  
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Figure 3. Increased collagen content after vaccination against TIE2. Sections of 
atherosclerotic plaques from carotid arteries were stained for collagen by a picrosirius 
red staining (B,C). Collagen content was obtained by dividing the sirius red stained 
area by the total intima area. Six weeks after collar placement, vaccination against 
TIE2 resulted in a 1.6-fold (p<0.05) increased collagen content of the atherosclerotic 
plaque (A).*P<0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion 
 
Atherosclerosis is an inflammatory disease, in which a wide range cells drive 
the initiation and progression of intimal thickening.25 Recently, a variety of 
vaccination strategies has been shown to form an effective way to raise 
antibodies against endogenous pro-atherosclerotic factors, which results in 
long-lasting blockade of the function of these factors, consequently leading to 
attenuated atherosclerosis.1-4 In contrast to the induction of humoral immunity 
against pro-atherosclerotic factors in these studies, we aimed to induce 
cellular immunity against specific surface marker expressing cells that 
potentially contribute to atherosclerosis. In a previous study we showed that  
this approach is feasible and reduces the initiation and progression of 
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Figure 4.  Effect of anti TIE2
vaccination on circulating
PBMCs. Six weeks after
collar placement blood was
collected and PBMCs were 
isolated. With flow cytometry
the percentage TIE2 positive
cells was determined in the
total population of PBMCs
and in a subpopulation of
PBMCs consisting of CD34  
positive cells. Quantification of TIE2 positive cells revealed a 33% (p<0.05) reduction
in percentage of TIE2 positive cells in the total population of PBMCs upon
vaccination against TIE2 (A). In the population of CD34 positive cells a 65% 
(p<0.005) reduction in TIE2 positive cells (B) was observed upon vaccination against
TIE2.*P<0.05, **P<0.005.  
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atherosclerosis by inducing cellular immunity against cells that overexpress 
VEGFR2 by making use of a DNA vaccination strategy.7  
In the present study, we elaborated on the value of this vaccination strategy 
by establishing cellular immunity against a cell population, which 
overexpresses TIE2 and contributes to processes that are potentially 
involved in atherosclerosis. Specific lysis of TIE2 positive cells by CD8+ T 
cells was induced in atherosclerosis prone mice by 3 oral administrations of 
the vaccine, which comprised attenuated S. typhimurium carrying a vector 
encoding TIE2. This vaccine passes through M cells of the gastroinstestinal 
tract into the Peyer’s patches and is subsequently transferred to antigen 
presenting cells, which become activated by the live attenuated bacteria 
leading to migration of these cells to inductive sites of the immune system 
and the expression of the TIE2 protein. Peptide fragments of TIE2 are 
presented by the MHC class I to CD8+ T-cells, which become activated and 
start to clonally expand, leading to the breaking of tolerance against TIE2.26 
Previous studies using the same vaccination protocol have already shown 
that the exerted effects of this vaccination strategy are based on the induction 
of cellular immunity.8,26 For example, CD8+ T cells were isolated upon 
vaccination, which were able to specifically lyse cells that expressed the 
target gene, VEGFR2. Other experiments showed that the effect of 
vaccination against VEGFR2 on tumor growth was totally abrogated when 
CD8+ T cell depletion was performed, whereas CD4+ T cell depletion did not 
affect tumor growth, indicating the critical role of CD8+ T cells in the exerted 
effect of vaccination.8 In the present study, the reduced percentage of 
circulating TIE2 positive cells further illustrates the induction of cellular 
immunity against TIE2 positive cells by this vaccination strategy. 
In order to evaluate the effect of cellular immunity against TIE2 on 
atherosclerosis, LDLr-/- mice were vaccinated against TIE2 after which 
atherosclerosis was induced by a combination of Western type diet feeding 
and perivascular collar placement around the carotid arteries. Six weeks after 
collar placement vaccination against TIE2 resulted in a significant 30% 
reduction in atherosclerosis in the carotid artery and a significant 42% 
reduction in atherosclerosis in the aortic root as compared to control treated 
animals. These results indicate a pro-atherosclerotic role for TIE2 positive 
cells, which may be based on the indicated contribution of these cells to 
processes potentially involved in atherosclerosis, such as angiogenesis.27,28 
However, in murine models it appeared to be difficult to proof a causal role 
for angiogenesis, because relatively low numbers of plaques contain 
microvessels and the observation of less angiogenesis in the plaques can be 
the consequence rather than the cause of reduced atherosclerosis. Many 
studies have shown the involvement of TIE2 in angiogenesis. TIE2-/- mice die 
during embryogenesis due to the lack of proper hierarchical organization of 
the vasculature.15 TIE2 expression in capillaries is stimulated by hypoxia and 
pro-inflammatory stimuli.29 Furthermore, ligands for TIE2 have been shown to 
promote angiogenesis.30 In addition, TIE2 identifies a hematopoietic lineage 
of monocytes that contribute to angiogenesis 31 and TIE2 positive progenitor 
cells contribute to neointimal angiogenesis.18 We showed that vaccination 
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against TIE2 resulted in reduced numbers of circulating TIE2 positive cells, 
which may contribute to reduced angiogenesis. Furthermore, the specific 
lysis of proliferating TIE2 positive endothelial cells that contribute to 
angiogenesis in the outgrowing capillaries may have resulted in reduced 
angiogenesis. Upon staining for CD31 we detected microvessels in the media 
and adventitia of atherosclerosis affected carotid arteries, but did not observe 
any positive staining in the neointima. This lack of intraplaque vessels may 
be explained by the fact that adaptive hypoxia-driven intra-plaque neovessel 
formation only occurs when plaque tissues is located >100μm from a 
capillary,32 which is not the case in these models for atherosclerosis. 
However, recently it was indicated that adventitial angiogenesis was 
correlated with neointima formation and that stimulation of adventitial 
angiogenesis, by administration of endothelial progenitor cells or adventitial 
application of VEGF, results in enhanced atherosclerosis and less stable 
lesions.33-36 These data show that our observed effects on plaque formation 
may be attributed to decreased adventitial angiogenesis. 
Furthermore, angiopoietins, the natural ligands for TIE2, have been shown to 
promote proinflammatory responses by activation of endothelial cells and 
neutrophils, leading to acute increased recruitment of leukocytes.19 Since 
inflammation is one of the driving mechanisms of atherosclerosis and 
recruitment of leukocytes into the atherosclerotic plaque is a key event in 
plaque formation, vaccination against TIE2 may result in reduced 
inflammation and leukocyte recruitment leading to attenuated atherosclerosis.  
In addition, it was indicated that TIE2 expression is not only restricted to 
endothelial cells but TIE2 is also expressed by other cells in the intima, 
illustrated by the co-expression of TIE2 and α-smooth muscle cell actin, but 
not CD31.20 A recent study confirmed the capacity of TIE2 positive cells to 
differentiate into smooth muscle cells in vivo during vascular recovery after 
denudation.21 Expression of TIE2 in vascular smooth muscle cells was 
recently confirmed and Ang1 has been shown to promote adhesion of 
monocytes to vascular smooth muscle cells leading to enhanced plaque 
formation in apoE-/- mice.22 These results suggest a pro-atherosclerotic role 
for TIE2 positive cells in the intima.   
The stability of the atherosclerotic plaque has been considered to be clinically 
at least as important as the actual degree of stenosis. Unstable angina 
pectoris or myocardial infarction is often the consequence of rupture of an 
unstable atherosclerotic plaque. Therefore we analyzed plaque composition 
by staining for smooth muscle cells, macrophages, and collagen. Smooth 
muscle cell and collagen content are considered to contribute to more stable 
plaques, whereas macrophages contribute to plaques that are more prone to 
rupture. Collagen content was significantly increased in the atherosclerotic 
plaque upon vaccination against TIE2, whereas macrophage and smooth 
muscle cell content did not significantly change upon vaccination against 
TIE2. Therefore, evaluation of the composition of the atherosclerotic plaque 
revealed a more stable phenotype upon vaccination against TIE2.  
In summary, our study demonstrates that vaccination against TIE2 induces 
cellular immunity against cells that overexpress TIE2 and leads to smaller 
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atherosclerotic lesions with a more stable phenotype. Therefore, vaccination 
strategies that target cells that contribute to atherosclerosis, may be of 
potential use in the development of novel therapies against atherosclerosis.  
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Introduction 
Despite extensive attempts to prevent or treat atherosclerosis by lipid 
lowering or anti-thrombotic drugs in combination with life style instructions, 
atherosclerosis remains the major underlying cause of death world-wide, 
indicating the need for the development of novel strategies that attenuate 
atherosclerosis and its consequences.1 Both further unraveling of the 
mechanisms that are involved in the pathogenesis of atherosclerosis and 
perpetual search for innovative methods to interfere in these mechanisms will 
contribute to the development of an effective therapy for atherosclerosis. This 
thesis payed attention to both of these aspects. In chapter 2 and 3, the 
potential role of C. pneumoniae in the pathogenesis of atherosclerosis was 
studied. In chapter 4 to 7, several vaccination strategies were evaluated as 
potential novel methods of interference in mechanisms involved in lesion 
formation, which may contribute to new therapies for atherosclerosis. 
 
C. pneumoniae in atherosclerosis 
Since atherosclerosis has been considered as an inflammatory response to 
injury many studies have focused on the role of infectious agents in 
atherosclerosis.2-4 Identification of  pathogens that stimulate the inflammatory 
response and hereby promote atherosclerosis may lead to novel ways of 
inhibiting atherosclerosis, such as the use of specific antibiotics or vaccines 
that protect against these pathogens. Although many infectious agents have 
been implicated to contribute to atherosclerotic lesion formation, most 
evidence has accumulated for a role of C. pneumoniae in atherosclerosis. 
Epidemiological studies showed associations between serum anti-C. 
pneumoniae antibobies and cardiovascular disease.5 Furthermore, C. 
pneumoniae was detected in half of the atherosclerotic lesions.6 These data 
linked C. pneumoniae to atherosclerotic disease, but were not suitable to 
show a contributary role for C. pneumoniae in this disease. Therefore, animal 
studies were performed to indicate a potential contributory role for these 
bacteria in atherosclerosis. In several murine models for atherosclerosis lung 
infection with C. pneumoniae did enhance lesion formation.7 In vitro studies 
further elaborated on the potential mechanisms through which C. 
pneumoniae might promote atherosclerosis by showing atherogenic effects 
on atheroma-associated cell types, such as increased expression of  pro-
inflammatory cytokines or adhesion molecules by endothelial cells, or 
accelerated foam cell formation by macrophages.8-15 Use of antibiotics 
against C. pneumoniae as a treatment for atherosclerosis was evaluated in 
both animals and humans and resulted in several studies in reduced 
atherosclerosis or its clinical consequences.16-19 
However, except for the in vitro studies, all lines of research led to conflicting 
results, which can at least partly be explained by the different experimental 
conditions.7,20 For example, in the animal experiments different animal 
strains, Chlamydia strains, or high fat diets were used leading to different 
results. Recently, the initial promising results with antibiotics were 
contradicted by two large clinical trials, in which the anti-C. pneumoniae 
antibiotics gatifloxacin or azithromycin were used for secondary prevention of 
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coronary events, but did not result in clinical benefits.21,22 Initial data, in which 
antibiotics did affect atherosclerosis in rabbits, were attributed to the fact that 
protection against C. pneumoniae only leads to reduced levels of 
atherosclerosis when interference takes place at an early stage of 
atherosclerosis.20 At the other hand, due to the persistent state, in which 
these bacteria can reside in cells, C. pneumoniae can escape from antibiotic 
treatment, leading to no benefit of this treatment.23 Therefore, the lack of 
clinical benefits from these antibiotic treatments does not exclude a 
contributary role for C. pneumoniae in atherosclerosis. These examples of 
contradictory results in animal and antibiotic studies illustrate the need for 
further evaluation of the role of C. pneumoniae in atherosclerosis.  
In this thesis we hypothesized in chapter 2 that one of the crucial conditions 
that caused the different results in animal studies, may be the time point of 
infection in relation to the onset of atherosclerosis. Therefore, we performed 
a variety of experiments in LDL receptor deficient mice, in which the time 
point of induction of a lung infection with C. pneumoniae in relation to the 
induction of atherosclerosis by perivascular collar placement was varied. 
Interestingly, only if mice were infected by C. pneumoniae simultaneously 
with the induction of atherosclerosis by collar placement, infection did 
promote atherosclerosis, whereas no effect on carotid atherosclerosis was 
observed after infection on other time points. From these observations we 
concluded that the time point of infection with C. pneumoniae in relation to 
the onset of atherosclerosis is crucial for the exerted effect on lesion 
formation. These results suggest that some of the conflicting results, obtained 
in the past with animal studies, may be based on the different time points of 
infection in relation to the onset of atherosclerosis. Furthermore, this study 
suggests that potential anti-C. pneumoniae treatments, for example by 
antibiotics or vaccination, will only be useful in a selection of patients in which 
atherosclerosis is present in a specific stage. Although further research has 
to be performed to substantiate the underlying mechanisms that cause the 
different results at different time points, one of the explanations is based on 
the fact that the time point of infection may be crucial for the amount of C. 
pneumoniae that enters the vascular wall or atherosclerotic plaque.  
Therefore, in chapter 3 we focused on the effect of the presence of C. 
pneumoniae in the vascular wall on atherosclerotic lesion formation. In this 
study, a novel model was established in which C. pneumoniae was locally 
delivered from the luminal site to the arterial wall of the carotid artery. 
Positive infection of the arterial wall was confirmed by detecting C. 
pneumoniae specific DNA (the OMP A gene) 7 days after local incubation 
with these bacteria. We also observed an inflammatory response against 
these bacteria, reflected by increased chemokine and adhesion molecule 
expression. Combined with collar induced atherosclerosis, the presence of C. 
pneumoniae promoted the development of lesion formation in the carotid 
artery. Since C. pneumoniae DNA was not detected in other organs we 
concluded that the presence of C. pneumoniae in the atherosclerotic lesion is 
sufficient for the exerted effect on atherosclerosis and that a lung infection 
with C. pneumoniae or systemic inflammation is not a necessary stimulus for 
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the exerted effect of these bacteria on atherosclerosis. The fact that a lung 
infection with C. pneumoniae does not per se lead to positive infection of the 
vessel wall may explain some of the conflicting effects of C. pneumoniae in 
atherosclerosis prone mice. In addition, this novel model can be used to 
further disect the mechanisms through which the presence of C. pneumoniae 
in the vascular wall enhances atherosclerosis. 
The data obtained in chapter 2 and 3 support the hypothesis that C. 
pneumoniae is able to play a contributory role in atherosclerosis, and that C. 
pneumoniae is often not just an innocent by-stander. However, the exerted 
effects of C. pneumoniae on atherosclerosis is dependent on the conditions, 
under which the infection takes place. Chapter 3 suggests that if a lung 
infection leads to positive infection of the vascular wall atherosclerosis is 
enhanced. 
 
Vaccination against atherosclerosis 
A variety of  vaccination techniques is available, which makes it possible to 
block the function of proteins or remove specific cells. These vaccination 
methods are therefore suitable to study the contribution of certain proteins or 
cell types in atherosclerosis. In addition, vaccination may be used as a 
potential therapy for atherosclerosis. In chapter 4-7, we used several 
vaccination methods to determine the involvement of two interleukins (IL-17 
and IL-12) and two specific cell types (highly expressing VEGFR2 or TIE2) in 
atherosclerosis. Furthermore, we aimed to evaluate vaccination as a useful 
strategy to therapeutically interfere in the development of atherosclerosis. By 
inducing humoral immunity we aimed to block interleukin  IL-17 and IL-12, 
whereas removal of VEGFR2 or TIE2 overexpressing cells was established 
by induction of a cellular immune response against these cells.  
 
Vaccination against IL-17 or IL-12 
Although the role of IL-17 in atherosclerosis has not been elucidated yet, this 
cytokine has several characteristics that make it a potential pro-atherogenic 
candidate. Exposure of macrophages, which play a central role in 
atherosclerosis, to IL-17 induces the expression of several proinflammatory 
cytokines, that have been shown to promote atherosclerosis, such as IL-1, IL-
6, and TNF-α.24,25 Furthermore binding of IL-17 to its receptor activates NF-
κB, which is a nuclear factor that regulates the expression of many 
interleukins (IL-1, IL-2, IL-3, IL-6, IL-8, and IL-12), enzymes (inducible nitric 
oxide synthase and cyclooxygenase-2), and adhesion molecules involved in 
chronic inflammation and atherosclerosis.26-28  Due to these potential pro-
atherogenic properties we aimed in chapter 4 to clarify the role of IL-17 in 
atherosclerosis by blocking the function of this cytokine with two vaccination 
techniques. Both oral delivery of the vaccine, which comprised Salmonella 
typhimurium containing pcDNA3.1 that encoded IL-17 and HEL (T cel 
epitope), as well as intramuscular injection of naked pcDNA3.1 encoding IL-
17 and HEL dramatically reduced atherosclerosis in LDL receptor deficient 
mice. These results indicate that vaccination against pro-inflammatory 
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cytokines may be of potential use in the development of novel therapies 
against atherosclerosis. 
The role of IL-12 in atherosclerosis has already been implicated by several 
studies. By immunohistochemistry an increased presence of IL-12 was 
shown in human atherosclerotic plaques as compared to normal arteries.29 In 
aortas of apoE deficient mice, IL-12 appears to be upregulated in an early 
stage of atherosclerosis at mRNA and protein level, which was accompanied 
by increased IFN-γ expression.30 IFN-γ is a pro-inflammatory cytokine, which 
has been shown to promote atherosclerosis in a variety of studies.31,32 
Furthermore, two experiments were performed that indicated the contributory 
role of IL-12 in the development of atherosclerosis. ApoE/IL-12 double 
knockout mice develop less atherosclerosis in the aortic root as compared to 
mice that are only deficient in apoE.33 In addition, daily administration of IL-12 
promotes atherosclerosis in young apoE deficient mice.29 These observations 
nicely fit with the major action of IL-12, which comprises the induction of 
inflammation by stimulating the differentiation of T helper 1 cells, which 
produce pro-inflammatory cytokines that stimulate atheroma-associated cell 
types atherosclerosis.34-36,20 In the present study we aimed to confirm the 
involvement of IL-12 in atherosclerosis by blocking the function of IL-12 by 
vaccination, but more importantly we aimed to establish a novel strategy to 
inhibit the inflammatory response and to diminish atherosclerosis.  
In this study we used a protein vaccination technique which was developed 
by the group of van Snick.37 They showed that this vaccine blocked the 
function of IL-12 and used this vaccine to attenuate experimental 
autoimmune encephalomyelitis in mice. The vaccine comprises the mouse 
IL-12 peptide sequence coupled to a highly immunogenic T cell epitope 
peptide sequence (PADRE), which induces the necessary T cell help for the 
B cells to produce antibodies against IL-12. In our study, which is described 
in chapter 5, we confirmed that this vaccine, when injected in combination 
with an adjuvant, induces high levels of antibodies, which blocked the 
function of IL-12 in LDL receptor deficient mice. This blockade of IL-12 
function resulted in a 68% reduction in atherosclerosis and induced a more 
stable phenotype of the atherosclerotic plaque, reflected by increased 
smooth muscle cell and collagen content after vaccination against IL-12. 
Furthermore, immunohistochemical analysis revealed reduced IFN-γ levels 
within the atherosclerotic plaques upon vaccination against IL-12, suggesting 
a reduction in inflammatory response. Several factors make this vaccination 
strategy potentially useful in the development of novel treatments against 
atherosclerosis. Apart from the reduction in plaque size and risk of rupture, 
this vaccination strategy induces long-standing protection (antibodies are 
elevated at least 24 weeks in mice), avoids the potential immune response 
against non-self antibodies, as can be the case with passive immunization, 
and furthermore this approach is relatively cheap. The possible disadvantage 
of this technique is based on the potential increased sensitivity against 
certain infections upon blocking IL-12. Initial studies on 3 IL-12Rβ1-deficient 
patients showed an increased risk of idiopathic Mycobacteria and Salmonella 
infections.38 However, a larger, more recent study on 41 IL-12Rβ1 deficient 
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adult individuals showed a relative resistance to infection, suggesting that 
human IL-12 is redundant in the protective immunity against most micro-
organisms other than Mycobacteria and Salmonella. IL-12 is also redundant 
for primary immunity to Mycobacteria and Salmonella in many individuals and 
for secondary immunity to Mycobacteria but not to Salmonella in most 
individuals.39 In addition, a recent study, in which IL-12 function was blocked 
by administration of anti-IL-12 antibodies to treat active Crohn’s disease in 
humans, did not reveal an increased incidence of infections.40 However, the 
effects of long-term blockade of IL-12 function by vaccination on the 
incidence of specific infections deserves further investigation, as blocking IL-
12 function forms an attractive strategy for the treatment of atherosclerosis. 
 
Vaccination against VEGFR2 or TIE2 
Induction of cellular immunity against self cells that have changed their 
characteristics and are involved in disease processes has been extensively 
studied in relation to cancer.41,42 These studies generally aimed to induce an 
immune response against tumor cells by a variety of vaccination techniques. 
Although none of these vaccination strategies has been licensed yet, there 
are about a dozen cancer vaccines in advanced clinical trials.43-45 However, 
apart from targeting tumor cells, other cell types that contribute to processes 
involved in tumor growth can be the target, such as cells that contribute to 
tumor angiogenesis. Recently, the group of Reisfeld elegantly showed in 
mice how tumor growth can be inhibited by inducing cellular immunity against 
endothelial cells that overexpress VEGFR2 and are involved in tumor 
angiogenesis.46 In order to establish cellular immunity, they used a novel oral 
DNA vaccination strategy, in which plasmids (pcDNA3.1), encoding the 
murine VEGFR2 are carried by the live attenuated bacterium Salmonella  
typhimurium. Upon administration of the vaccine specific cytotoxicity against 
VEGFR2 overexpressing cells was shown, indicating the successful induction 
of cell-mediated immunity. Since VEGFR2 overexpressing cells are also 
involved in processes that potentially contribute to the development of 
atherosclerosis, such as angiogenesis, we hypothesized in chapter 6 that this 
vaccination strategy may also interfere in the development of 
atherosclerosis.47-50 Vaccination of hypercholesterolemic mice against 
VEGFR2 resulted in cytotoxic CD8+ T cells that specifically killed cells that 
overexpressed VEGFR2. In chapter 6 we showed that vaccination indeed 
inhibited angiogenesis in a hind limb ischemia model. Furthermore, 
vaccination against VEGFR2 resulted in a reduction of both the initiation and 
the progression of atherosclerosis, indicating the involvement of VEGFR2 
overexpressing cells in atherosclerosis. However, induction of cell-mediated 
immunity against these cells led to increased post-interventional neointima 
formation, which was most likely caused by delayed reendothelialization after 
denudation of the endothelium. Although further studies are needed to 
determine the exact mechanisms, we can conclude that cells that 
overexpress VEGFR2 contribute to atherosclerosis. The fact that post-
interventional neointima formation was enhanced by vaccination indicates 
that potential use of this vaccine in future therapies for atherosclerosis may 
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be limited to a selection of patients that does not qualify for percutaneous 
transluminal angioplasty.  
In chapter 7, we used a similar approach to induce cellular immunity against 
cells that overexpress TIE2, which are also involved in angiogenesis, a 
process that potentially contributes to atherogenesis.51 Vaccination against 
TIE2 also resulted in specific killing of cells that overexpress TIE2, indicated 
by the reduced amount of TIE2 positive cells that were present in the 
circulation after vaccination. Furthermore, vaccination against TIE2 resulted 
in reduced collar induced carotid atherosclerosis, but also inhibited the 
degree of plaque formation in the aortic root. In addition, plaques developed 
after vaccination against TIE2 contained relatively more collagen, suggesting 
a more stable plaque phenotype. In conclusion, the observed effects of 
vaccination against TIE2 confirm the hypothesis that induction of cellular 
immunity against self cells can reduce atherosclerosis.  
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Inleiding 
Aderverkalking (atherosclerose) is een ziekte waarbij gedurende vele jaren 
verdikking van de vaatwand optreedt door de vorming van atherosclerotische 
plaques welke tot vernauwing van slagaderen (arteriën) kunnen leiden. Dit 
kan als gevolg hebben dat de aangedane arterie die een orgaan van 
voedingsstoffen en zuurstof zou moeten voorzien tekort schiet, waardoor er 
een infarct kan optreden. Zo kan een atherosclerotische plaque in een 
kransslagader van het hart leiden tot een myocardinfarct, dat niet zelden de 
dood tot gevolg heeft. Atherosclerose in de hals- of been arteriën kan 
resulteren in respectievelijk een herseninfarct of etalagebenen.  
Het belang van de ontwikkeling van een adequate therapie voor deze ziekte 
wordt onder andere geïllustreerd door het feit dat hart- en vaatziekten 
wereldwijd de belangrijkste doodsoorzaak vormen (11.8 miljoen gevallen per 
jaar), waarbij men zich dient te realiseren dat atherosclerose ten grondslag 
ligt aan het overgrote merendeel van deze hart- en vaatziekten. 
Verscheidene risicofactoren voor het onstaan van atherosclerose en haar 
gevolgen zijn reeds helder in kaart gebracht, zoals hypercholesterolaemie, 
hoge bloeddruk, roken, hoge leeftijd, weinig lichaamsbeweging, en hart- en 
vaatziekten in de familie. De huidige therapie is er dan ook op gericht om het 
cholesterol in het bloed te verlagen, de bloeddruk in toom te houden en 
eventuele verhoogde stollingsneiging tegen te gaan met medicatie. Deze 
medicamenteuze behandeling wordt altijd gecombineerd met leefstijl 
adviezen, zoals voldoende lichaamsbeweging en stoppen met roken. Echter, 
ondanks deze therapie blijft atherosclerose de belangrijkste doodsoorzaak, 
wat de behoefte aan nieuwe therapeutische strategieën benadrukt.      
Recentelijk is gebleken dat bij de vorming van een atherosclerotische plaque 
niet alleen vetstapeling in de vaatwand van belang is, maar dat vele, dikwijls 
complexe, mechanismen betrokken zijn bij de lokale vaatvernauwing. 
Tegenwoordig wordt wereldwijd aangenomen dat deze mechanismen 
optreden als een “response to injury”. Ook wordt steeds duidelijker dat vele 
van deze mechanismen gelijkenissen vertonen met een ontstekingsreactie. 
Zo worden leukocyten uit het bloed aangetrokken, zoals dat ook gebeurt bij 
een klassieke ontstekingsreactie, en worden vervolgens vele 
ontstekingsmediatoren uitgescheiden die verdere escalatie van de 
ontstekingsreactie tot gevolg hebben. Beschadiging van het endotheel, het 
binnenste laagje van de vaatwand, vormt meestal de prikkel voor de initiatie 
van de ontstekingsreactie die leidt tot plaquevorming. Zo kunnen een 
verhoogde bloeddruk, hypercholesterolaemie en shear stress leiden tot 
endotheeldysfunctie die vervolgens de ontstekingsreactie in gang zet. Er 
wordt veel onderzoek gedaan naar factoren die de ontstekingsreactie tijdens 
atherosclerose kunnen stimuleren, zoals bacteriën of virussen, maar ook 
lichaamseigen stoffen worden hierbij onderzocht.  
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In dit proefschrift is onderzocht of Chlamydia pneumoniae een rol speelt bij 
de ontwikkeling van atherosclerose. Wegname van deze prikkel, met 
bijvoorbeeld antibiotica, zou kunnen leiden tot minder plaquevorming. Ook is 
in dit proefschrift onderzocht of de ontstekingsreactie tijdens atherosclerose 
zou kunnen worden beïnvloed door bepaalde ontstekingsmediatoren, die 
betrokken zijn bij atherosclerose, uit te schakelen. We hebben een nieuwe 
vaccinatietechniek gebruikt om de functie van de pro-inflammatoire 
cytokines, interleukine 17 en interleukine 12, op te heffen om zo de 
ontstekingsreactie af te remmen en daardoor de atherosclerose ontwikkeling 
stil te leggen. In het laatste deel van dit proefschrift is onderzocht of het 
wegnemen van bepaalde celtypen die een rol spelen bij atherosclerose met 
een nieuwe vaccinatietechniek de vorming van atherosclerose zou kunnen 
remmen. In dit proefschrift wordt duidelijk dat vaccinatie tegen eiwitten of 
cellen een veelbelovende techniek zou kunnen zijn bij de ontwikkeling van 
nieuwe therapieën tegen atherosclerose. 
 
De rol van Chlamydia pneumoniae in atherosclerose 
Het inzicht dat atherosclerose een vorm van ontsteking is heeft veel 
onderzoekers aangezet tot de bestudering van de rol van infecties in 
atherosclerose. De potentieel pro-atherogene werking van vele micro-
organismen werd onderzocht. Echter, de meeste aanwijzingen werden 
gevonden voor Chlamydia pneumoniae als ontstekingsstimulus tijdens 
atherosclerose. Deze bacterie is een veel voorkomend pathogeen dat milde 
luchtweginfecties kan veroorzaken. De hoge prevalentie wordt geïllustreerd 
door het feit dat op 65-jarige leeftijd ongeveer 75% van de bevolking 
antilichamen tegen C. pneumoniae heeft. Aangenomen wordt dat de meeste 
mensen meerdere infecties gedurende hun leven doormaken. De relatie met 
atherosclerose werd gelegd door de observatie van een correlatie van anti-C. 
pneumoniae antilichamen met hart- en vaatziekten. Ook werd in de helft van 
alle atherosclerotische lesies post mortem C. pneumoniae aangetroffen. 
Deze studies laten een associatie van deze bacterie met atherosclerose zien, 
maar geven niet aan of C. pneumoniae ook daadwerkelijk bijdraagt aan de 
ontwikkeling van atherosclerose. Daarom werd onderzoek met proefdieren 
uitgevoerd om een mogelijke causale relatie aan te tonen. Vele van deze 
studies gaven aan dat een infectie met C. pneumoniae inderdaad zorgt voor 
meer atherosclerose. Echter, enkele andere studies konden deze causale 
relatie niet bevestigen. Antibiotica, die specifiek gericht zijn tegen C. 
pneumoniae bleken niet eenduidig hart- en vaatziekten terug te dringen, wat 
er voor heeft gezorgd dat de rol van C. pneumoniae in atherosclerose nog 
altijd niet duidelijk is. De tegenstrijdige resultaten die werden gevonden 
kunnen deels verklaard worden door de verschillende condities waaronder de 
experimenten werden uitgevoerd. Het moment van infectie ten opzichte van 
de initiatie van atherosclerose zou bijvoorbeeld cruciaal kunnen zijn voor een 
effect op plaquevorming. Hiermee samenhangend zou het zo kunnen zijn dat 
alleen een effect gezien wordt op het moment dat de bacterie ook 
daadwerkelijk de atherosclerotische lesie infiltreert.  
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In dit proefschrift hebben we nader onderzoek gedaan naar het belang van 
het moment van infectie met C. pneumoniae op atherosclerose. Hierbij werd 
gebruik gemaakt van een muizenmodel, waarin zich binnen 8 weken 
atherosclerotische lesies ontwikkelen. De vorming van atherosclerotische 
lesies kan met dit model goed geprogrammeerd worden door muizen op een 
westers vetrijk dieet te zetten en vervolgens collars te plaatsen rond de 
halsslagaders. Verschillende experimenten werden uitgevoerd waarbij het 
moment van infectie ten opzichte van het moment van initiatie van 
atherosclerose werd gevarieerd. Hierbij bleek er maar één moment te zijn 
waarop C. pneumoniae de vorming van atherosclerotische lesies kan 
stimuleren, wat aangeeft dat het moment van infectie met deze bacterie 
cruciaal is voor het effect op atherosclerose. Dit zou een van de verklaringen 
kunnen zijn voor het feit dat er in het verleden zo veel verschillende 
resultaten zijn verkregen na infectie met C. pneumoniae. Ook geven deze 
proeven aan dat eliminatie van C. pneumoniae bij patiënten met hart- en 
vaatziekten maar voor een deel van de patiënten van voordeel zou kunnen 
zijn. 
In een tweede studie werd onderzocht of de aanwezigheid van C. 
pneumoniae in de vaatwand de ontwikkeling van atherosclerose in muizen 
zou kunnen verergeren. Hiervoor werd een nieuw model gebruikt waarbij 
infectie van de vaatwand met C. pneumoniae lokaal vanuit het lumen tot 
stand werd gebracht. Direct hierop volgend werd atherosclerose geinduceerd 
door het plaatsen van collars om het geïnfecteerde vat. Na analyse van de 
ontstane atherosclerotische plaques werd bijna twee keer zo veel 
atherosclerose gevonden in het met C. pneumoniae geïnfecteerde vat als in 
het controle vat. Ook bleken de plaques na infectie minder stabiel te zijn, wat 
de kans op scheuren vergroot en kan leiden tot plotselinge stolselvorming 
met occlusie van het vat als gevolg. Verdere studies konden ook enig inzicht 
geven in de wijze waarop deze bacteriën atherosclerose versnelden. 
Moleculen die betrokken zijn bij de hechting en migratie van leukocyten, en 
zo leiden tot meer ontsteking, bleken na infectie verhoogd aanwezig te zijn. 
Deze studie geeft aan dat wanneer een infectie met C. pneumoniae leidt tot 
aanwezigheid van deze bacteriën in de vaatwand het proces van 
atherosclerose versneld kan optreden. Ook deze observaties kunnen een 
deel van de discrepantie in de resultaten uit de literatuur verklaren. Een 
luchtweginfectie met C. pneumoniae leidt namelijk niet altijd tot een positieve 
infectie van de vaatwand, waardoor een luchtweginfectie met C. pneumoniae 
dus niet altijd hoeft te leiden tot meer atherosclerose. Met dit proefdiermodel 
wordt dit verschil in aanwezigheid van C. pneumoniae in de vaatwand 
omzeild. Elke lokale incubatie met bacteriën resulteert immers in een 
positieve infectie van de vaatwand.  
Wanneer men beide studies in ogenschouw neemt kan men concluderen dat 
C. pneumoniae wel degelijk de vorming van atherosclerotische lesies kan 
stimuleren, maar dat deze effecten afhankelijk zijn van de omstandigheden 
waaronder infectie heeft plaatsgevonden. Daarom kan het zinvol zijn om 
eliminatie van C. pneumoniae bij patiënten met hart- en vaatziekten te 
bewerkstelligen. 
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Vaccinatie tegen interleukinen 
Naast eliminatie van de stimulus van de ontstekingsreactie kan ook 
ingegrepen worden op de ontsteking zelf. Interleukinen vormen een groep 
eiwitten die in sterke mate het ontstekingsproces reguleren door als 
communicatiemoleculen  tussen ontstekingscellen op te treden. Zo blijkt 
interleukine 12 (IL-12) een belangrijke rol te spelen bij de differentiatie van 
naïeve CD4+ T cellen tot T helper 1 cellen, die ook aangetroffen worden in 
atherosclerotische plaques. Deze T helper 1 cellen scheiden vele pro-
inflammatoire eiwitten uit, die het atherosclerotische proces verder 
aanwakkeren. Blokkade van de functie van IL-12 zou daarom kunnen leiden 
tot minder pro-atherogene T helper 1 cellen en zo zou atherosclerose 
afgeremd kunnen worden. De rol van IL-12 in atherosclerose werd reeds 
eerder onderzocht. Dagelijkse toediening van IL-12 aan atherosclerose 
gevoelige muizen leidde tot een toename in plaquegrootte vergeleken met 
controle muizen. Ook bleek genetische uitschakeling van IL-12 te resulteren 
in minder atherosclerose.  
In dit proefschrift werd een nieuwe vaccinatietechniek gebruikt om 
antilichamen tegen lichaamseigen IL-12 op te wekken. Er werd gebruik 
gemaakt van een vaccin dat bestond uit het eiwit IL-12 met hieraan 
vastgekoppeld een peptide sequentie (PADRE) dat in staat is een sterke T 
helper cel reactie uit te lokken, waardoor B cellen worden geactiveerd en 
starten met antilichaam productie tegen lichaamseigen IL-12. In onze studie 
bleek 5 maal intramusculaire injectie met dit vaccin in combinatie met 
adjuvant een sterke IL-12 specifieke antilichaamrespons op te wekken in 
atherosclerose gevoelige muizen. Eerdere studies lieten zien dat deze 
antilichamen ten minste 24 weken bleven circuleren na de laatste injectie van 
het vaccin. Verdere analyse wees uit dat deze antilichamen in staat waren de 
functie van IL-12 volledig te blokkeren. Na inductie van atherosclerose door 
de combinatie van een vetrijk dieet en collarplaatsing rond de halsslagaders 
bleek vaccinatie tegen IL-12 te leiden tot een 70% reductie in plaque 
vorming. Ook resulteerde vaccinatie tegen IL-12 in stabielere plaques, 
weergegeven door een hoger collageen- en gladde spiercelgehalte. Hierdoor 
scheuren atherosclerotische lesies minder snel en leiden ze minder snel tot 
stolselvorming. Bij verdere analyse bleek de ontsteking in de plaque ook 
afgenomen te zijn na vaccinatie tegen IL-12, wat werd geïllustreerd door de 
verminderde aanwezigheid van het pro-inflammatoire interferon gamma in de 
lesies.  
De aanzienlijke reductie in atherosclerose, de verhoogde stabiliteit van de 
lesies, de lange therapeutische werking en relatief lage productiekosten van 
dit vaccin maken deze vaccinatiestrategie tot een veelbelovende methode in 
de ontwikkeling van nieuwe therapieën tegen atherosclerose. 
 
Vaccinatie tegen pro-atherogene celtypen 
Afhankelijk van het vaccin en de toedieningsweg kan er na vaccinatie ófwel 
een antilichaamrepons optreden, zoals bij blokkade van interleukinen, ófwel 
inductie van cellulaire immuniteit plaatsvinden, waarbij hele cellen worden 
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aangevallen door cytotoxische CD8+ T cellen, waarna de target cellen 
worden opgeruimd. Van inductie van cellulaire immuniteit door middel van 
vaccinatie kan gebruik worden gemaakt om specifiek cellen op te ruimen die 
een rol spelen bij een bepaalde ziekte. Zo werd tumorgroei sterk geremd 
door een cellulaire immuunrespons op te wekken tegen vascular endothelial 
growth factor receptor (VEGFR2) positieve prolifererende endotheelcellen, 
die bijdragen aan tumorangiogenese. Van deze vaccinatiemethode werd in 
dit proefschrift ook gebruik gemaakt om atherosclerose te remmen. VEGFR2 
positieve cellen spelen een rol in processen die mogelijk een rol spelen in 
atherosclerose, zoals angiogenese.  
In deze studie werd cellulaire immuniteit tegen VEGFR2 positieve cellen 
geïnduceerd door te vaccineren met een oraal vaccin, bestaande uit de 
bacterie Salmonella thyphimurium die een plasmide bevat dat codeert voor 
VEGFR2. Drie maal orale toediening van dit vaccin induceerde een 
cytotoxische T cel respons tegen VEGFR2 positieve cellen. Eerder is 
gebleken dat deze respons tot ten minste 10 maanden na de laatste 
vaccinatie blijft bestaan. Verder bleek in onze studie vaccinatie tegen 
VEGFR2 te leiden tot verminderde angiogenese. Vervolgens bleek in twee 
verschillende muismodellen voor atherosclerose dat zowel de progressie als 
de initiatie van atherosclerose sterk geremd werden door deze vaccinatie. 
Echter, vaccinatie tegen VEGFR2 veroorzaakte ook een vertraagde 
endotheel vervanging na kunstmatige beschadiging van het endotheel dat 
vervolgens leidde tot toegenomen neointima vorming. Deze neointima 
vorming wordt ook wel restenose genoemd; het opnieuw vernauwen van een 
bloedvat nadat het door een interventie (Dotter behandeling of stent 
plaatsing) is geopend. Bij deze ingrepen wordt het endotheel dikwijls 
beschadigd, wat nagebootst werd in dit muizenmodel. Met deze 
vaccinatietechniek is het daarom mogelijk gebleken om atherosclerose te 
remmen, maar dit gaat ten koste van het langdurig open blijven van een 
bloedvat na interventie. 
Op een zelfde manier werd cellulaire immuniteit opgewekt tegen TIE2, een 
eiwit dat evenals VEGFR2 tot expressie komt op cellen die betrokken zijn bij 
atherosclerose. Ook in deze studie lukte het om cellulaire immuniteit op te 
wekken, wat bleek uit het verlaagde aantal TIE2 positieve cellen dat 
circuleerde in het bloed na vaccinatie. Vervolgens bleek vaccinatie tegen 
TIE2 ook te leiden tot verminderde atherosclerose. De plaques die 
ontstonden na vaccinatie tegen TIE2 bleken stabieler. Stabielere plaques 
vertonen minder neiging tot scheuren door een hogere hoeveelheid 
collageen in de plaques.   
Concluderend kan inductie van cellulaire immuniteit tegen pro-atherogene 
celtypen bijdragen aan de ontwikkeling van nieuwe therapieën tegen 
atherosclerose, waarbij geldt dat vaccinatie relatief goedkoop is en lang 
effectief blijft. 
 
Samenvattend laat het onderzoek dat beschreven staat in dit proefschrift zien 
dat C. pneumoniae een rol kan spelen bij de vorming van atherosclerotische 
lesies. Inductie van specifieke antilichamen of cytotoxische T cellen door 
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middel van vaccinatie blijkt een zeer effectieve methode te zijn om pro-
atherogene eiwitten of cellen lange tijd respectievelijk te blokkeren of op te 
ruimen, waardoor de ontwikkeling van atherosclerose geremd kan worden. 
De beschreven resultaten kunnen daarom bijdragen aan de ontwikkeling van 
nieuwe therapieën tegen atherosclerose in mensen. 
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Nawoord 
 
Wetenschap wordt zelden nog in isolement bedreven. Ook bij de tot 
standkoming van dit proefschrift waren vele personen betrokken, die ieder op 
hun eigen manier een waardevolle bijdrage leverden. 
Met veel genoegen en ook enige weemoed denk ik terug aan de zeven jaar 
durende periode die ik zowel als student maar ook als AIO op de afdeling 
Biofarmacie heb doorgebracht. Ik beschouw het als een voorrecht om als 
Geneeskunde en Biomedische Wetenschappen student een belangrijk deel 
van mijn wetenschappelijke opleiding bij deze fundamentele onderzoeks-
groep te hebben mogen volgen. Prof. van der Laarse ben ik daarom zeer 
dankbaar voor feit dat hij mij heeft laten kennismaken met Theo van Berkel 
en Johan Kuiper van de afdeling Biofarmacie, maar ook voor het feit dat hij 
mij altijd de mogelijkheid heeft geboden studie en onderzoek op een 
efficiënte manier met elkaar te combineren.  
Als student bij Jan von der Thüsen heb ik mijn eerste stappen gezet in een 
laboratorium en werd het nu nog altijd aanwezige enthousiasme voor de 
microchirurgie gewekt. In mijn tweede stage op Biofarmacie onder 
begeleiding van Ingrid Michon werden deze chirurgische technieken 
toegepast en heb ik kennisgemaakt met de techniek van phage display. Deze 
eerste fase met Jan en Ingrid, maar ook de functie van paranimf bij hun 
promotie vormen een dierbare herinnering voor mij.  
Met de komst van Louis Penning werden mijn eerste moleculair biologische 
experimenten in gang gezet. De toen verworven kennis werd nog veel 
gebruikt gedurende mijn promotieonderzoek en werd dikwijls aangevuld met 
nuttige instructies van Peter van Santbrink. Ook Niels Peterse heeft een 
belangrijke rol gespeeld bij het opzetten en uitvoeren van menig moleculair 
biologische handeling, wat duidelijk meer waarde heeft gegeven aan het 
Chlamydia onderzoek, maar ook het begin vormde van de ontwikkeling van 
vaccins tegen atherosclerose. 
Een zeer bijzondere plaats gedurende mijn jaren op de afdeling Biofarmacie 
wordt ingenomen door Paula de Vos. Vanaf het allereerste begin vormden wij 
een goed op elkaar inspeeld (operatie)team, waarbij lange dagen opereren 
door Paula’s altijd vrolijke invloed werden tot een gezelllig dagje bijpraten. 
Vele experimenten zouden jammerlijk zijn mislukt als Paula er niet bij 
betrokken zou zijn geweest.       
Kamer 839 ben ik ook veel dank verschuldigd voor nuttige aanwijzingen en 
het meedenken over mijn onderzoek. Ruud Out heeft ons Nederlands altijd 
op peil gehouden, van Eva van Wanrooij heb ik geleerd wat efficiëntie 
betekent en van Gijs van Puijvelde leerde ik hoe je een racefiets dient te 
gebruiken. Zijn aanmoedigingen op moeilijke momenten, niet alleen op de 
fiets maar ook gedurende zenuwslopende congresactiviteiten staan mij nog 
vers in het geheugen en vormen een belangrijke eigenschap van een 
geschikte paranimf. Van de nieuwe Belgische aanwinsten, Kim Habets en 
Filip Segers, leerde ik wat beleefdheid precies inhoudt en Illiana Meurs legde 
me uit hoe je snel kunt publiceren. 
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Graag bedank ik Thomas van Es voor zijn inzet de afgelopen maanden voor 
de afronding van dit proefschrift. 
De samenwerking met prof. dr. J. Van Snick en dr. C. van Uyttenhove is niet 
alleen prettig maar ook erg vruchtbaar gebleken, waarvoor ik hen zeer 
erkentelijk ben. The collaboration with prof. dr. R.A. Reisfeld offered a variety 
of promising opportunities to develop novel vaccination strategies against 
atherosclerosis. Ook met dr. P.H.A. Quax en Vincent van Weel heb ik altijd 
plezierig kunnen samenwerken. Dr. F.R. Stassen bedank ik graag voor de 
levering van de in dit proefschrift gebruikte Chlamydia pneumoniae en 
methoden om deze bacterie aan te tonen. Tevens heb ik aan de stollings- en 
diabetesproeven met Dirkje Sommeijer goede herinneringen. 
Ook noem ik hier Erik Biessen wegens het hardop meedenken over mijn 
onderzoek gedurende mijn periode als student en als AIO op de afdeling 
Biofarmacie. 
Kar Kruijt zou ik graag bedanken voor alle hulp en zijn inzet om het gehele 
lab draaiende te houden. 
De vele studenten die op de afdeling Biofarmacie actief zijn geweest en in 
het bijzonder Karin ben ik veel dank verschuldigd voor de wetenschappelijke 
en ook sociale bijdragen aan het lab. 
Johan Pragt en Fred Kokkedee waardeer ik voor hun inzet het leven van de 
muizen zo prettig mogelijk te maken.   
De Leden van jaarclub “Krypton” en mijn huisgenoten van “Louter Kerst” en 
“Trump Plaza” zou ik graag bedanken voor hun begrip voor mijn toenemende 
afwezigheid wegens promotiebezigheden.      
Mijn broer Robert ben ik zeer dankbaar voor het als paranimf samen met mij 
toeleven naar deze mooie dag en mijn broer Herbert voor het vervullen van 
een voorbeeldfunctie als reeds gepromoveerde arts en zijn tip om “toch maar 
snel te beginnen met schrijven”. 
Mijn ouders zou ik in het bijzonder willen bedanken voor hun steun bij de 
totstandkoming van dit proefschrift, maar ook voor het feit dat ze mijn 
alternatieve en langere opleiding na uitloting altijd hebben ondersteund.  
Tenslotte prijs ik mij zeer gelukkig met mijn vriendin Liesbeth met wie ik de 
muziek, bergsport, geneeskunde en de wetenschap naar harte lust deel. 
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